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Abstract 
  
 Senescence is a state of permanent proliferation arrest that normal cells 
undergo in response to shortened telomeres, oncogenic activation and other sources 
of cellular stress, thus restricting the replicative capacity of impaired or damaged 
cells. As such, senescence provides a potent mechanism of tumor suppression, but 
has also been implicated in organismal aging. Senescence is accompanied by 
profound chromatin remodeling, which reinforces several important features of the 
senescence program. Consequently, there is considerable interest in elucidating 
precisely how chromatin structure influences senescence.  
 In the present work, I set out to investigate the role of the H4K20me3 histone 
modification in senescence, as the mark has been implicated in aging and is 
commonly lost in human cancers. I first showed that although senescent cells 
undergo a progressive loss of bulk histone content, the H4K20me3 modification is 
selectively retained during senescence. I next demonstrated that while the net 
abundance of H4K20me3 remains unaltered, senescent cells display a nuclear 
redistribution of the mark that coincides with SAHF. Utilizing ChIP coupled with 
next-generation sequencing, I mapped the genome-wide distribution of H4K20me3 
in proliferating and senescent cells and found that H4K20me3 is highly enriched at 
several classes of DNA repeats and ZNF genes in senescent cells. Although 
H4K20me3 is associated with transcriptional repression, presence of the mark did 
not correlate with gene expression changes in senescence.  
 In order to investigate the mark functionally, I established cells overexpressing 
SUV420H2, a histone methyltransferase that catalyzes trimethylation of H4K20. 
Ectopic expression of SUV420H2 increased levels of the mark robustly, but 
produced no overt phenotype. When subjected to long-term culturing, SUV420H2 
overexpression produced a moderate acceleration of senescence compared to control 
cells. Following infection with oncogenic H-RASG12V, SUV420H2 cells displayed 
an enhanced degree of senescence compared to H-RASG12V-infected control cells, 
based on multiple molecular readouts. Most remarkably, SUV420H2 overexpression 
blocked senescence escape following H-RASG12V infection, which occurred at a 
much higher frequency in H-RASG12V-infected control cells. Therefore, the data 
suggest that high levels of SUV420H2 and the H4K20me3 mark are beneficial to the 
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senescence program and serve to reinforce the permanent proliferation arrest. 
Although the molecular basis for this effect is presently unclear, the findings provide 
convincing evidence that chromatin structure is indeed an important contributor to 
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Chapter 1. Introduction 
 
1.1 Cell Senescence 
 
1.1.1 Overview of Cell Senescence 
 Cell senescence is a state of permanent proliferation arrest that normal cells 
can undergo in response to a variety of detrimental stimuli. In this manner, 
senescence restricts the proliferative capacity of impaired or damaged cells. Several 
well-characterized triggers of senescence have been identified including short 
telomeres, oncogenic signalling, loss of tumor suppressors and general cell stress. 
Upon exposure to these triggers, cells exhibit a characteristic set of morphological, 
transcriptional and biochemical changes, the culmination of which is a permanent 
proliferation arrest. In order to establish senescence, cells engage a coordinated 
network of effector pathways. The p53 and pRB pathways are the master regulators 
of senescence and interact extensively with additional effector processes including 
DNA damage signalling, altered secretion and autophagy. Importantly, senescence is 
accompanied by profound changes to chromatin structure, which is thought to 
reinforce aspects of the senescence program. Functionally, senescence serves as a 
potent tumor suppression mechanism and facilitates wound healing. However, 
senescence has also been implicated in aging and tumorigenesis. Thus, senescence is 
a complex but important biological process that undoubtedly requires further study 
(Figure 1.1). 
 
1.1.2 Triggers of Senescence 
 
1.1.2.1 Telomere Shortening 
 In 1961, Leonard Hayflick and Paul Moorhead described a phenomenon that 
they termed “Phase III,” in which primary human diploid cell strains exhibited a 
reduced proliferative capacity and underwent striking morphological changes 
following extended periods in culture (Hayflick & Moorhead, 1961). Four years 
later, Hayflick reported the seminal finding that primary human diploid cells indeed 
have a finite lifespan in culture and described the Phase III phenomenon as a form of 
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“senescence” at the cellular level (Hayflick, 1965). As a result, the point at which 
normal cells cease to proliferate is commonly referred to as the “Hayflick limit.” 
 It is now recognized that after an extended period in culture, primary cells 
undergo a form of senescence called replicative senescence (RS) that results from the 
shortening of telomeres. Telomeres are the regions of repetitive DNA sequence (5’-
TTAGGG-3’) and associated proteins that protect the linear ends of chromosomes 
(Shay & Wright, 2005). However, due to the properties of DNA polymerase, a short 
50-200 base pair segment of the lagging strand is lost with each sequential round of 
DNA replication, which is referred to as the end-replication problem (Harley et al., 
1990). Thus, following repeated rounds of replication, telomeres become critically 
short and dysfunctional, which activates the DNA damage response (DDR) and 
initiates senescence (d'Adda di Fagagna et al., 2003; Herbig et al., 2004). Precisely 
how the DDR engages senescence will be discussed in detail in a subsequent section. 
 Because the rate of telomere loss is not identical for every chromosome in the 
cell, some chromosomes develop critically short telomeres faster than others. 
Consequently, the presence of only a few short telomeres is capable of inducing 
senescence (Martens et al., 2000). Remarkably, ectopic expression of telomerase, a 
ribonucleoprotein enzyme that can synthesize telomeric DNA but is not ordinarily 
expressed sufficiently in human somatic cells, is sufficient to extend lifespan and 
delay senescence in primary human cells (Bodnar et al., 1998). Importantly, this 
confirmed that telomere attrition is a molecular trigger of senescence. 
 
1.1.2.2 Activated Oncogenes  
Subsequent to the discovery that telomere shortening limits the replicative 
lifespan of normal cells, it was reported that activated oncogenes are also sufficient 
to induce senescence in primary cells. Previous studies had established that 
expression of oncogenic H-RAS is capable of transforming most immortal rodent 
cell lines (Newbold & Overell, 1983). In contrast, Scott Lowe and colleagues noted 
that introduction of an oncogenic form of H-RAS into primary human and rodent 
cells resulted in a stable G1 cell cycle arrest and the acquisition of morphological 
features reminiscent of replicative senescent cells (Serrano et al., 1997). Lowe and 
colleagues further confirmed senescence in the mutant H-RAS-expressing cells by 
showing induction of the tumor suppressors p53 and p16INK4a and pH-dependent 
senescence-associated β-galactosidase activity. Importantly, co-expression of viral 
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E1A, a protein that binds and inactivates pRB, prevented H-RAS-induced senescence 
in the human cells. These data convincingly established that oncogene activation is 
indeed capable of inducing premature senescence in primary cells.  
 Since the time of these initial findings, numerous oncogenes have been 
reported to induce senescence in vitro. For example, the activation of additional 
members of the RAS-RAF-MEK signaling pathway, including RAF, BRAF, MEK 
and MOS, has been shown to drive senescence (Zhu et al., 1998; Michaloglou et al., 
2005; Narita et al., 2003; Lin et al., 1998; Bartkova et al., 2006). Likewise, countless 
other oncogenic proteins (e.g., MYC, TGFβ, RUNX1) have also been implicated in 
the induction of senescence (Grandori et al., 2003; Katakura et al., 1999; Wolyniec et 
al., 2009). Importantly, oncogene-induced senescence (OIS) is not strictly an in vitro 
phenomenon and has been described in variety of in vivo contexts. In fact, various 
oncogenic mutations have been associated with the accumulation of senescent cells 
in premalignant lesions (Collado et al., 2005). To this end, oncogenic forms of 
BRAF, KRAS and NRAS appear to induce senescence in the contexts of benign 
melanocytic nevi, lung adenomas and lymphoproliferative disorders, respectively 
(Michaloglou et al., 2005; Collado et al., 2005; Braig et al., 2005). 
 Although oncogene-induced senescent cells resemble replicative senescent 
cells phenotypically, oncogenic activity appears to drive senescence independently of 
telomere shortening. As such, expression of telomerase, which is sufficient to delay 
replicative senescence, does not prevent OIS, indicating that oncogenes do not 
induce senescence via telomere shortening (Wei et al., 1999). Instead, oncogenic 
activation is thought to induce senescence by driving hyper-replication, resulting in 
stalled replication forks and DNA double-strand breaks, which in turn activates the 
DDR (Di Micco et al., 2006). Thus, oncogene activation represents a distinct trigger 
of cell senescence. 
 
1.1.2.3 Loss of Tumor Suppressors 
The loss or inactivation of tumor suppressor proteins is also capable of 
inducing cell senescence in vitro and in vivo. Illustrating this, Pier Paolo Pandolfi 
and colleagues reported that while targeted deletion of both alleles of the tumor 
suppressor Pten in mouse embryonic fibroblasts (MEFs) induces senescence, 
Pten/Trp53 double-null MEFs continue to proliferate (Chen et al., 2005). 
Intriguingly, MEFs in which only a single Pten allele is deleted fail to senesce and 
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proliferate more than wild-type cells. In the same study, the authors investigated the 
effect of tumor suppressor loss in vivo and found that prostate-specific deletion of 
both Pten alleles in mouse results in the initial development of pre-malignant 
prostatic intraepithelial neoplasia and senescence. 
 In a separate study, Karen Cichowski and colleagues demonstrated that 
depletion of the neurofibromin (NF1) tumor suppressor from primary human 
fibroblasts results in p53/pRB-mediated senescence (Courtois-Cox et al., 2006). The 
authors also showed that knockdown of NF1 results in a transient activation of the 
RAS pathway that is quickly attenuated. Importantly, inactivation of the RAS 
pathway after NF1 knockdown precedes senescence, suggesting that a negative 
feedback loop might be responsible for triggering senescence upon loss of NF1. 
Finally, Cichowski and colleagues showed that dermal neurofibromas, small benign 
tumors that arise from somatic mutation of NF1, contain SA β-gal and p16INK4a-
positive senescent cells. 
 In addition, William Kaelin, Jr and colleagues reported that targeted deletion 
of the von Hippel–Lindau tumor suppressor gene Vhl in MEFs results in a p53-
independent senescence proliferation arrest (Young et al., 2008). Specifically, Vhl 
deletion results in loss of the SWI2/SNF2 complex member p400, which leads to 
elevated p27 levels and subsequent activation of pRB. The authors also reported high 
levels of SA β-gal in the kidneys of Vhlfl/fl mice, indicating that loss of Vhl is also 
sufficient to induce senescence in vivo. Therefore, collective these studies provide 
compelling evidence that loss of tumor suppressors can trigger cell senescence. 
 
1.1.2.4 Cellular Stress 
It has also been noted that in culture, cells can undergo senescence in 
response to various forms of stress. To this end, suboptimal culturing conditions and 
the stress incurred by maintaining cells in an artificial environment can undoubtedly 
contribute to premature senescence in vitro (Sherr & DePinho, 2000). In addition to 
the inevitable detriments of growing cells in culture, several other factors have been 
reported to induce a form of senescence that is occasionally referred to as stress-
induced senescence (SIPS) (Toussaint et al., 2000). 
 As discussed in the sections on telomere shortening and oncogene activation, 
DNA damage appears to be a common molecular driver of cell senescence. 
Consequently, other sources of DNA damage are equally effective at inducing 
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senescence. For example, exposure to ultraviolet (UV) light has been reported to 
produce stable proliferation arrest and senescence in primary human melanocytes 
and fibroblasts (Medrano et al., 1995; Helenius et al., 1999). In a similar manner, 
ionizing radiation has been used extensively to induce senescence in human and 
mouse fibroblasts (Di Leonardo et al., 1994; Coppé et al., 2008; Rodier et al., 2009). 
Drug treatment is widely acknowledged as another source of cellular stress 
capable of inducing senescence. DNA damaging agents including hydroxyurea, 
etoposide and doxorubicin are routinely used to trigger senescence in primary cells 
(Yeo et al., 2000; Kosar et al., 2011). Likewise, treatment of cells with the histone 
deacetylase (HDAC) inhibitors sodium butyrate and trichostatin A (TSA) has been 
shown to confer senescence in primary human fibroblasts (Ogryzko et al., 1996; 
Place et al., 2005). Remarkably, treatment with chemotherapeutic agents has even 
been reported to induce senescence in certain tumor cells in vitro and in vivo (te 
Poele et al., 2002; Zheng et al., 2004; Roberson et al., 2005). 
 Finally, oxidative stress also limits cellular lifespan in culture through the 
induction of senescence. First, exposure of primary human fibroblasts to sub-lethal 
concentrations of H2O2 has been shown to promote proliferation arrest and 
senescence (Chen et al., 1998a; Dumont et al., 2000). Likewise, culturing cells under 
hyperoxic conditions accelerates the onset of senescence (von Zglinicki et al., 1995; 
Klimova et al., 2009). In contrast, maintaining primary human cells under low 
oxygen conditions extends lifespan in culture (Parker et al., 1977; Saito et al., 1995). 
Intriguingly, oxidative stress even promotes senescence in response to other triggers, 
as elevated RAS expression increases intracellular levels of reactive oxygen species 
(ROS) (Lee et al., 1999). High levels of ROS have also been reported in replicative 
senescent cells (Furumoto et al., 1998). Thus, it is evident that various sources of 
cellular stress can serve as triggers of senescence. 
 
1.1.3 Effectors of Senescence 
 
1.1.3.1 The p53 and pRB Pathways 
The establishment and reinforcement of a stable proliferation arrest is one of 
the defining features of cell senescence. In order to facilitate this critical process, 
stressed cells engage a coordinated network of effector pathways. To this end, the 
establishment of senescence is primarily contingent upon the activities of the p53 and 
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pRB tumor suppressor pathways. Underscoring the significance of p53 and pRB to 
senescence induction, the simultaneous inactivation of both pathways is required in 
order to abolish senescence in primary human cells (Shay et al., 1991; Bond et al., 
1999; Hahn et al., 2002). However, in mice, individual inactivation of either the p53 
pathway or pRB (plus p107 and p130) is sufficient to prevent senescence (Harvey et 
al., 1993; Dannenberg et al., 2000; Sage et al., 2000). Regardless, the p53 and pRB 
pathways both serve as the master regulators of the senescence program (Figure 1.2). 
 The p53 pathway is ordinarily activated upon exposure to a variety of cellular 
stressors, including DNA damage. DNA damage results in the activation of ATM 
and ATR, which subsequently phosphorylate and activate the CHK2 and CHK1 
kinases, respectively (Kurz & Lees-Miller, 2004). Upon activation, CHK2/CHK1 
phosphorylate and stabilize p53, which enables the transcriptional activation of 
specific p53 target genes (He et al., 2005). One critical p53 target gene is the cyclin-
dependent kinase inhibitor p21CIP1 (CDKN1A). Once expressed, p21CIP1 binds 
and inhibits cyclin-CDK2 complexes, thus blocking cell cycle progression and 
arresting cells in G1 phase (Sherr & Roberts, 1999). In this manner, activation of the 
p53 pathway blocks proliferation. 
 The pRB pathway is a second critical effector mechanism through which 
senescence is established. In the unphosphorylated state, pRB restricts cell cycle 
progression by binding to and inhibiting the E2F family of transcription factors. As 
the cell approaches S phase, pRB is phosphorylated by cyclin D/CDK4/CDK6, 
which releases E2F and frees the transcription factor to activate a series of target 
genes required for progression through S phase (Nevins, 2001). Cellular stress, 
including oncogenic activation, induces the expression of the cyclin-dependent 
kinase inhibitor p16INK4a (CDKN2A) (Ohtani et al., 2001). Upon induction, 
p16INK4a inhibits the activity of cyclin D/CDK4/CDK6 complexes, which in turn 
prevents the phosphorylation of pRB. Dephosphorylation of pRB restores binding 
with E2F, prevents the transcription of proliferation genes and blocks cell cycle 
progression (Lowe & Sherr, 2003). Thus, induction of the p16INK4a-pRB pathway 
provides another important mechanism of restricting proliferation following 
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1.1.3.2 DNA Damage Response 
Given the ability of DNA damage to engage the p53 and pRB pathways, it is 
not surprising that the DNA damage response (DDR) is another important effector 
pathway through which senescence is established. Although senescence can occur 
independently of DNA damage, many of the aforementioned triggers of senescence 
elicit the DDR. In fact, telomere shortening, activated oncogenes, ionizing radiation 
and genotoxic agents all induce senescence through activation of the DDR (d’Adda 
di Fagagna et al., 2003; Di Micco et al., 2006; Fumagalli et al., 2012; Ben-Porath & 
Weinberg, 2005). 
 The progressive telomere shortening that results from repeated rounds of 
DNA replication is a well-documented trigger of the DNA damage response. In one 
of the first demonstrations that telomere attrition could produce a DNA damage 
signal, Stephen Jackson and colleagues reported that replicative senescent cells 
accumulate several markers of DNA damage including phosphorylated γ-H2AX, 
SMC1, RAD17, CHK1 and CHK2 (d’Adda di Fagagna et al., 2003). The study 
further revealed that γ-H2AX was enriched at subset of subtelomeric regions of 
chromosomes that have been shown to have particularly short telomeres. 
Intriguingly, inactivation of the DNA response through expression of dominant 
negative forms of ATM, ATR, CHK1 and CHK2 enabled replicative senescent cells 
to resume DNA replication. Expanding on this work, Fabrizio d’Adda di Fagagna 
and colleagues showed that DNA damage occurring at telomeres cannot be 
effectively repaired, which results in the presence of chronic DNA damage foci, a 
persistent DDR and establishment of senescence (Fumagalli et al., 2012).  
 Activated oncogenes have also been reported to induce senescence through 
engagement of the DDR. Work from the laboratories of Jiri Bartek and Fabrizio 
d’Adda di Fagagna demonstrated that oncogenic activation indeed produces a DDR 
by causing hyper-replication that results in DNA double-strand breaks and 
improperly terminated replication forks (Bartkova et al., 2006; Di Micco et al., 
2006). Significantly, inactivation of CHK2 not only abolishes H-RAS-induced 
senescence but also results in cell transformation, highlighting the importance of an 
intact DDR for establishment of OIS (Di Micco et al., 2006).  
Finally, the DDR is not only important for the induction of a permanent 
proliferation arrest, but is also critically important to the generation of the SASP. To 
this end, Judith Campisi and colleagues reported that inactivation of critical DDR 
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mediators including NBS1, ATM and CHK2 prevents the SASP in response to 
radiation-induced senescence (Rodier et al., 2009). In addition, SASP factors 
including the chemokine IL8 and ligands of CXCR2 provide a feedback loop that 
enhances the DDR (Acosta et al., 2008). Therefore, the DDR is not an independent 
process, but rather a fully integrated branch of the other effector pathways that 
establish senescence. 
 
1.1.3.3 Senescence-Associated Secretory Phenotype 
Several early transcriptional profiling studies of senescence revealed that 
compared to proliferating cells, senescent cells exhibit a discrete pattern of altered 
gene expression (Shelton et al., 1999; Zhang et al., 2003; Yoon et al., 2004). As 
anticipated, these studies invariably revealed a significant downregulation of 
proliferation and cell cycle genes in senescent cells. Unexpectedly, the profiling 
studies also indicated that numerous genes encoding pro-inflammatory cytokines, 
chemokines, growth factors and extracellular matrix remodeling enzymes are 
consistently upregulated in senescent cells. Remarkably, many of these proteins are 
actively secreted into the extracellular environment (Campisi, 2005). Thus, while 
initially surprising, it is now evident that these secreted proteins, collectively termed 
the senescence-associated secretory phenotype (SASP), comprise an important 
feature of the senescence program (Coppé et al., 2008; Rodier et al., 2009). 
Although considered a phenotypic hallmark of cell senescence, the SASP 
also represents an important effector mechanism involved in the establishment of 
senescence. To this end, some of the components of SASP have been reported to 
reinforce the senescence proliferation arrest through an autocrine feedback 
mechanism. Work by Jinsong Liu and colleagues revealed that ectopic expression of 
RAS in ovarian epithelial cells induces the expression and secretion of GRO-1, 
which when applied to stromal fibroblasts in conditioned medium, induces 
senescence (Yang et al., 2006). Similarly, René Bernards and colleagues determined 
that expression of the SASP factor PAI-1 is both necessary and sufficient to induce 
senescence in human BJ fibroblasts and MEFs (Kortlever et al., 2006). Likewise, 
expression of oncogenic BRAFV600E in primary human cells results in the 
expression and secretion of IGFB7, which subsequently induces senescence through 
inhibition of the RAF-MEK-ERK pathway (Wajapeyee et al., 2008). Finally, work 
from the laboratories of Daniel Peeper and Jesus Gil revealed that the cytokine IL6 
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and chemokine IL8 help to establish and reinforce senescence by mediating 
expression of a C/EBPβ- and NF-κB-dependent network of inflammatory factors 
(Kuilman et al., 2008; Acosta et al., 2008). 
In light of the fact that several SASP factors actively reinforce senescence, 
considerable attention has been directed toward understanding how the SASP is 
regulated. As mentioned above, the expression of several SASP factors is regulated 
through the transcription factors C/EBPβ and NF-κB. In fact, depletion of C/EBPβ 
from cells infected with oncogenic BRAFV600E not only inhibits the expression of 
IL6 and IL8, but also allows the cells to bypass senescence and continue proliferating 
(Kuilman et al., 2008). Likewise, pharmacologic inhibition of NF-κB prevents the 
expression of numerous SASP factors in primary cells overexpressing mutant MEK 
(Acosta et al., 2008). The DDR appears to play an integral role in facilitating the 
SASP, as silencing of several DDR components attenuates the expression of several 
SASP factors (Rodier et al., 2009). It is important to note that although SASP 
expression typically accompanies several forms of senescence induction (e.g., RS, 
OIS, stress), senescence and SASP expression are separable processes. For example, 
ectopic expression of p16INK4a induces senescence in primary cells without 
eliciting the DDR or the SASP (Coppé et al., 2011). There is also evidence to support 
roles for p38MAPK signalling and microRNAs in the regulation of the SASP 
(Freund et al., 2011; Bhaumik et al., 2009). Thus, SASP regulation is undoubtedly a 
complex process that warrants additional investigation.  
While the SASP is certainly a critical effector of the senescence program, it is 
also a downstream phenotype of senescence. In this capacity, the SASP likely helps 
to facilitate the physiological function(s) of senescence in vivo. Alternatively, the 
SASP might also contribute to some potentially detrimental aspects of senescence. 
Indeed, both of these topics will be addressed in a subsequent discussion of the 
functional relevance of senescence. 
 
1.1.3.4 Autophagy 
More recently, autophagy has been identified as another key effector of the 
senescence program. Autophagy is an evolutionarily conserved process that 
facilitates the sequestration, degradation and turnover of intracellular proteins and 
organelles (Mizushima, 2007; Yang & Klionsky, 2010). It has been reported that as 
cells age they accumulate oxidatively damaged and misfolded proteins that cannot 
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undergo efficient degradation and turnover (Ryazanov & Nefsky, 2002; Breusing & 
Grune, 2008). Indeed, the accumulation of oxidized protein with age has been shown 
to impair various aspects of cellular function (Squier, 2001). Consequently, 
autophagy has been proposed as a potential mechanism for limiting the amount of 
damage protein that increases with age (Levine & Kroemer, 2008). 
In view of the concept that replicative senescence represents a form of aging 
at the cellular level, an interest in investigating the link between senescence and 
autophagy has emerged. To this end, Christian Behl and colleagues reported that 
autophagy increases in late passage, replicative senescent IMR90 cells (Gamerdinger 
et al., 2009). The study further revealed that induction of autophagy in replicatively 
aged cells occurs through a switch in the ratio of BAG3 to BAG1, two members of 
the BCL-2-associated athanogene protein family, and involves the LC3-binding 
protein SQSTM1. Thus, the authors suggested that autophagy induction in aged cells 
might mitigate the accumulation of damaged proteins. 
Work from Masashi Narita’s laboratory revealed that in human diploid 
fibroblasts, autophagic activity increases during the transition phase of OIS (Young 
et al., 2009). Activation of autophagy during the transition phase also correlates with 
the concurrent suppression of mTORC1 and mTORC2 activities. In the same study, 
shRNA-mediated depletion of ATG5 or ATG7, two genes required for autophagy, 
attenuated SA β-galactosidase activity and delayed the production of IL6 and IL8, 
two cytokines that contribute functionally to the senescence program. Importantly, 
reduction of ATG5 or ATG7 also resulted in a bypass of H-RAS-induced 
proliferation arrest suggesting that autophagy is an important effector mechanism in 
the establishment of OIS. 
Senescent cells often undergo a significant increase in size and contain more 
protein per cell than proliferating cells (Young et al., 2009). In order to accommodate 
this considerable energetic demand, senescent cells must maintain effective protein 
turnover and synthesis. Another recent study from Masashi Narita’s group revealed 
that protein turnover during OIS is mediated through the co-localization of 
autophagic and protein synthesis machinery to a sub-cellular space termed the TOR-
autophagy spatial coupling compartment (TASCC) (Narita et al., 2011). The authors 
demonstrated that recruitment of the mTOR complex to the TASCC is dependent on 
amino acids and Rag GTPase function. Likewise, expression of a Rag GTPase 
dominant negative disrupts mTOR recruitment to the TASCC and restricts the 
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expression of IL6 and IL8 during OIS. This indicated that the production of some 
SASP proteins during senescence is dependent upon the spatial overlap of mTOR-
autophagy and protein synthesis organelles. Importantly, all three of these studies 
support the concept that autophagy is an integral effector pathway of the senescence 
program.  
 
1.1.4 Functions and Consequences of Senescence 
 
1.1.4.1 Tumor Suppression 
It has been widely proposed that the primary physiological function of 
senescence is to suppress tumorigenesis. Indeed, there are several lines of evidence 
that strongly support a prominent role for senescence in preventing cancer. As 
addressed in the discussion of OIS, oncogenic activation is one of the key triggers of 
senescence in a variety of cell types. To this end, well-characterized oncogenic 
proteins including H-RASG12V and B-RAFV600E are potent inducers of cell 
senescence in vitro and in vivo (Serrano et al., 1997; Michaloglou et al., 2005; 
Sarkisian et al., 2007). In addition, senescent cells are frequently present in various 
premalignant neoplastic lesions. Senescent cells have been reported in benign 
melanocytic nevi, early-stage lymphomas, prostate intraepithelial neoplasia, dermal 
neurofibroma, colon adenoma, pancreatic intraepithelial neoplasia and early-stage 
thyroid tumors (Michaloglou et al., 2005; Gray-Schopfer et al., 2006; Braig et al., 
2005; Collado et al., 2005; Chen et al., 2005; Courtois-Cox et al., 2006; Bartkova et 
al., 2006; Kuilman et al., 2008; Acosta et al., 2008; Fujita et al., 2009; Morton et al., 
2010; Caldwell et al., 2012; Vizioli et al., 2011).  
 Further supporting a role for senescence in tumor suppression, inactivation of 
key pathways that drive the senescence program enables the progression from early-
stage pre-malignant lesions to more advanced tumors. In fact, targeted disruption of 
p53 and Ink4a/Arf has been reported to accelerate tumorigenesis in multiple murine 
models of cancer (Chin et al., 1997; Bardeesy et al., 2002; Chen et al., 2005; Braig et 
al., 2005). Additionally, reactivation of p53 within tumors results in regression of the 
tumor and is associated with senescence induction. Tyler Jacks and colleagues 
reported that reactivation of p53 within established sarcomas in mice results in 
profound tumor regression and the presence of senescence markers (Ventura et al., 
2007). Similarly, Scott Lowe and colleagues elegantly showed that reactivation of 
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p53 within Hras-induced hepatocarcinomas in mice causes senescence, tumor 
regression and immune-mediated clearance of the tumors (Xue et al., 2007).  
 Although these findings provide compelling evidence that senescence 
provides a barrier to tumorigenesis, it is also important to examine how senescence 
might accomplish this. Undoubtedly, the anti-proliferative property of senescence 
restricts damaged cells from expanding clonally, thus preventing tumor formation. 
For example, benign melanocytic nevi are comprised of non-proliferating senescent 
melanocytes, and despite frequently harboring oncogenic BRAF mutations, rarely 
progress to melanoma (Michaloglou et al., 2005; Pollock et al., 2003; Gray-Schopfer 
et al., 2007). In addition, because senescent cells cease proliferation and DNA 
replication, there is a reduced likelihood of the cells acquiring additional mutations 
that might enable bypass of senescence and promote tumorigenesis. 
 Finally, there is data emerging to suggest that senescence suppresses tumor 
formation by promoting immune-mediated clearance of damaged cells. As 
mentioned above, Scott Lowe’s laboratory first reported that senescent cells are 
subject to immune clearance in vivo (Xue et al., 2007). In the study, Lowe and 
colleagues demonstrated that reactivation of p53 in mouse liver tumors induces 
senescence and causes tumor regression. Remarkably, the authors showed tumor 
regression was facilitated by the active clearance of senescent cells by natural killer 
(NK) cells, as antibody depletion of NK cells prevented regression. Subsequent work 
from Lowe and colleagues revealed that NK cells preferentially kill senescent cells in 
vitro (Krizhanovsky et al., 2008). 
 Expanding on this concept, recent work from Lars Zender’s laboratory 
showed that in mice, RAS-induced senescent hepatocytes are cleared from the liver 
through a CD4+ T-cell-mediated adaptive immune response (Kang et al., 2011). 
Clearance of senescent hepatocytes also requires an intact monocyte/macrophage 
response. Importantly, the authors proposed that secretion of cytokines and 
chemokines by senescent cells mediates recruitment of innate and adaptive immune 
cells. Likewise, work by Lowe and colleagues revealed that factors secreted by 
senescent cells are important for attracting NK and other immune cells (Xue et al., 
2007). Senescent cells indeed secrete a wide array of chemokines, cytokines and 
other immune modulating factors as part of the SASP (Kuilman et al., 2008; Acosta 
et al., 2008). It is now evident that the SASP can promote immune-mediated 
clearance of senescent cells in vivo. Thus, two important features of senescence, 
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permanent proliferation arrest and the SASP, likely collaborate to provide a barrier to 
tumorigenesis. 
 
1.1.4.2 Wound Healing 
Cell senescence also contributes functionally to the process of wound repair. 
Wound repair is the complex but coordinated process through which tissue integrity 
is restored following injury or damage. The process of wound repair involves a 
diverse array of cellular components and pathways, but typically involves sequential 
progression through three distinct phases: inflammation, proliferation/new tissue 
formation and remodelling (Gurtner et al., 2008b). In adults, the wound repair 
process inevitably produces a localized region of non-functional fibrotic tissue called 
a scar. Recent findings suggest that senescent cells accumulate at the sites of healing 
wounds and restrict the formation of fibrotic tissue through the secretion of 
extracellular matrix remodelling enzymes. 
 Utilizing a mouse model of chemical-induced liver fibrosis, Scott Lowe’s 
laboratory demonstrated that in response to carbon tetrachloride (CCl4) treatment, 
hepatic stellate cells (HSCs) undergo an initial proliferative expansion and produce 
extracellular matrix (ECM) components that comprise the fibrotic scar 
(Krizhanovsky et al., 2008). The activated HSCs subsequently senesce, downregulate 
ECM production and induce the expression of ECM degrading enzymes and immune 
modulators. Following termination of CCl4 treatment, a significant reversion of 
hepatic fibrosis accompanied by the elimination of activated HSCs was observed. In 
contrast, livers from CCl4-treated, p53-/-;INK4a/ARF-/- senescence-defective mice 
continued to display marked hepatic fibrosis and numerous activated HSCs, after 
CCl4 withdrawal. Consequently, the authors concluded that cell senescence limits the 
extent of chemical-induced hepatic fibrosis through the secretion of ECM degrading 
enzymes and by modulating the immune clearance of activated HSCs. 
 In a separate study utilizing a mouse model of cutaneous wound healing, it 
was reported that senescent fibroblasts accumulate within granulation tissue during 
the proliferative phase of the wound repair process (Jun & Lau, 2010). Through the 
use of transgenic mice, the authors showed that CCN1, a matricellular protein highly 
expressed in granulation tissue, is required for the accumulation of senescent cells 
during cutaneous wound healing. CCN1 promotes senescence in fibroblasts by 
inducing DNA damage, resulting in p53 and RAC-NOX1-dependent production of 
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reactive oxygen species (ROS) and subsequent activation of the p16INK4a/pRB 
pathway. Following CCN1-mediated induction of senescence, fibroblasts upregulate 
the expression of the ECM-degrading enzymes MMP1 and MMP3, and 
downregulate type I collagen, a component of the ECM. Thus, senescent cells restrict 
the formation of fibrotic tissue during cutaneous wound healing. Together, these 
studies both demonstrate a role for cell senescence in the process of normal wound 
repair. 
 
1.1.4.3 Aging and Cancer 
Despite the proposed beneficial roles of senescence to tumor suppression and 
wound healing, there is evidence to suggest that senescence might also facilitate 
some pathophysiological processes. This has led some researchers in the field to 
view senescence as a form of antagonistic pleiotropy, in which features of 
senescence might be beneficial early in life, but detrimental to the aged organism 
(Campisi & d’Adda di Fagagna, 2007). To this end, cell senescence has been 
implicated as a contributor to both organismal aging and cancer. 
Organismal aging is associated with a variety of pathologies that are 
collectively characterized by a decline of normal tissue function. Indeed, there are 
several lines of evidence that suggest cell senescence contributes to age-associated 
tissue dysfunction. First, it has been reported that senescent cells accumulate with 
age in various tissues in humans, baboons and rodents (Dimri et al., 1995; Paradis et 
al., 2001; Herbig et al, 2006; Jeyapalan et al., 2007; Wang et al., 2009). To this end, 
many of the molecular markers of cell senescence increase with age, including SA β-
galactosidase activity, p16INK4a induction, the presence of shortened telomeres and 
DNA damage signals (Dimri et al., 1995; Krishnamurthy et al., 2004; Hastie et al., 
1990; Sedelnikova et al., 2004). 
Several key functional studies also strongly suggest that senescence 
contributes to aging. Most somatic mouse tissues express sufficient levels of 
telomerase to maintain telomere length (Kipling, 1997). Consequently, genetic 
disruption of the telomerase holoenzyme (mTR-/-) in mouse accelerates various aging 
phenotypes, impairs wound healing and shortens lifespan (Rudolph et al., 1999). 
Inactivation of p16INK4a, a key regulator of senescence, abrogates senescence, 
prevents loss of tissue integrity and extends lifespan in a mouse model of premature 
aging (Baker et al., 2008). Utilizing the same prematurely aged mouse model, van 
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Deursen and colleagues subsequently generated a transgenic strain that enables drug-
inducible clearance of p16INK4a-positive cells (Baker et al., 2011). Remarkably, the 
authors showed that drug-induced clearance of p16INK4a-positive senescent cells 
delays the premature adipose tissue, skeletal muscle and eye degeneration typically 
observed in these mice. Moreover, the clearance of p16INK4a-positive cells from 
tissues in which degeneration is already initiated, blocks further progression. Thus, 
these data confirm that senescence can promote organismal aging. 
Mechanistically, senescence might promote aged-associated tissue 
degeneration several ways. First, senescence might restrict normal tissue 
regeneration by blocking the proliferative capacity of progenitor cells. To this end, 
several groups have reported that the abundance and proliferative capacity of 
progenitor cells decreases with age in a variety of tissues (Nishimura et al., 2005; 
Krishnamurthy et al., 2006). Second, because senescent cells secrete an array of 
chemokines and cytokines as part of the SASP, senescence might promote a state of 
chronic inflammation. In fact, chronic inflammation is a common hallmark of and 
contributor to numerous age-associated pathologies (Chung et al., 2009). Senescent 
cells also secrete a variety of extracellular matrix remodeling enzymes (e.g., MMPs) 
that can modify the tissue stroma (Page-McCaw et al., 2007). Thus, elevated 
expression of MMPs and other proteases might irrevocably alter the extracellular 
environment and potentiate tissue dysfunction (Burrage et al., 2006). 
In addition, there is evidence that in certain contexts senescence can actually 
promote another age-associated disease: cancer. Work by Judith Campisi and 
colleagues revealed that senescent fibroblasts stimulate the proliferation of 
premalignant and malignant epithelial cells in culture, but have no effect on normal 
epithelial cells (Krtolica et al., 2001). Likewise, the authors reported that co-injection 
of senescent fibroblasts with pre-malignant or malignant epithelial cells into mice 
promotes tumorigenesis, whereas co-injection with pre-senescent fibroblasts has no 
effect. Campisi and colleagues subsequently demonstrated that the SASP produced 
by senescent fibroblasts promotes epithelial–mesenchymal transition (EMT) and 
enhances the invasiveness of epithelial cells in vitro (Coppé et al., 2008). 
Significantly, both EMT and invasiveness are defining characteristics of malignancy. 
Finally, cells depleted of IL-1a, an upstream regulator of IL6 and IL8, inhibits 
secretion of IL6 and IL8 by senescent cells and reduces the pro-malignant properties 
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of the SASP (Orjalo et al., 2009). Thus, senescent cells, and specifically the SASP, 
have the ability to promote cancer through a paracrine mechanism. 
In light of this, it is reasonable to view senescence as an antagonistically 
pleiotropic response. To this end, permanent proliferation arrest and SASP are 
important features of senescence that undoubtedly promote tumor suppression and 




1.2.1 Chromatin Structure and Organization 
Each human cell contains approximately two meters of genetic information in 
the form of DNA that must be effectively packaged and organized within the 
nucleus. To accomplish this, DNA is subjected to a series of folds and protein 
interactions, forming a higher-order structure called chromatin. The basic structural 
unit of chromatin is the nucleosome, an octameric core of highly conserved proteins 
called histones, around which approximately 147 basepairs of DNA is wrapped 
(Richmond et al., 1984). Structural studies have revealed that the nucleosome core 
consists of a tripartite structure that features one tetramer comprised of two copies 
each of histones H3 and H4 and two histone H2A/H2B dimers (Arents et al., 1991). 
Each of the core histones contains two distinct structural domains, a central globular 
fold domain through which the histone-histone and histone-DNA interactions occur 
and an unstructured amino-terminal tail domain that extends from the nucleosome 
core (Luger et al., 1997). In addition to the histone octamer and 1.75 turns of folded 
DNA, each complete nucleosome contains linker DNA, which connects one 
nucleosome to the next (Simpson, 1978). 
Based on this nucleosome/DNA interaction, if a single chromosome were to 
be stretched out into a linear arrangement, it would likely assume a “beads-on-a-
string” conformation (Hansen, 2002). However, chromatin inevitably forms several 
additional higher-order structures that exhibit increasing levels of compaction 
culminating in the mitotic chromosome. Consequently, this raises important 
questions as to how this is accomplished. To this end, several in vitro studies 
demonstrated that under optimal conditions, the 10-nm “beads-on-a-string” 
conformation assembles into a densely packed 30-nm chromatin fiber (Gall, 1966). 
Since this finding, numerous attempts have been made to visualize the 30-nm fiber in 
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situ utilizing a variety of sensitive microscopic techniques, but have largely ended 
unsuccessfully (Grigoryev & Woodcock, 2012).  
In recent years, several experimental models have succeeded in producing 
chromatin fibers approaching the 30-nm structure utilizing folded and zig-zag 
oriented arrays of reconstituted nucleosomes (Routh et al., 2008). However, an even 
more recent finding, calls into question whether the assumed 30-nm fiber really even 
exists as the fundamental unit of higher-order chromatin structure. Using cryo-
electron microscopy and synchrotron X-ray scattering, Kazuhiro Maeshima and 
colleagues demonstrated that mitotic chromosomes from HeLa cells are devoid of 
30-nm sized structures, but are actually comprised of approximately 11-nm fibers 
that are folded in an irregular fashion (Nishino et al., 2012). Thus, it is formally 
possible that chromosomes and other intermediate chromatin structures arise from 
the ~11-nm “beads-on-a-string” unit of chromatin. 
Despite these unresolved controversies, what is evident is that chromatin 
exists in the cell in two distinct forms: gene-rich, transcriptionally active 
euchromatin and gene-poor, transcriptionally silent heterochromatin (Huisinga et al., 
2006). This fascinating dichotomy is predominantly mediated through specific 
epigenetic modifications and associated proteins and dictates much of the nuclear 
function of the cell. Therefore, it is worth considering each of these structural and 
regulatory components of chromatin in greater detail. 
 
1.2.2 Histone Variants 
An additional level of chromatin regulation is provided by the nucleosome 
through the incorporation of histone variants. Whereas the expression of most 
canonical histones is coupled to DNA replication and tightly regulated through the 
cell cycle, histone variants represent a distinct set of nonallelic histone isoforms that 
are not necessarily regulated in the same manner (Malik & Henikoff, 2003). Most 
histone variants are stably incorporated into nucleosomes and impact process ranging 
from transcription to replication and DNA repair (Sarma & Reinberg, 2005). 
Numerous histone variants have been identified, including the well-documented 
histone H2A variants H2AX, H2AZ, macroH2A and H2ABBD and the H3 variants 
H3.3 and CENP-A (Paull et al., 2000, Popescu et al., 1994; Pehrson & Fried, 1992; 
Gautier et al., 2004; Ahmad & Henikoff, 2002; Palmer et al., 1987). Some histone 
variants are expressed in a cell and tissue-dependent manner, suggesting specific 
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regulatory roles for the variants (Garcia et al., 2008). For example, the histone H1, 
H2B and H3 variants, H1T, TSH2B and H3T, respectively, are expressed solely in 
the testis and likely contribute to the unique regulatory requirements of that 
chromatin environment (Sarg et al., 2009; Zalensky et al., 2002; Tachiwana et al., 
2010). 
 To date, variants of histone H3 have been investigated the most extensively. 
Several isoforms of histone H3 have been identified, including the structurally 
similar H3.1, H3.2 and H3.3 forms, the centromeric CENP-A variant and testis-
specific H3T. Expression of canonical histone H3.1 is replication-dependent and is 
restricted to S phase where it is incorporated into newly synthesized DNA (Tagami 
et al., 2004). In contrast, the H3.3 variant is expressed throughout the cell cycle and 
is deposited in both replication-dependent and independent contexts (Dunleavy et al., 
2011; Drané et al., 2010). Importantly, H3.3 deposition is associated with 
transcriptional activation, as it is typically enriched around the transcription start 
sites of active genes and frequently contains activating post-translational 
modifications (Mito et al., 2005; McKittrick et al., 2004). H3.3 is also deposited at 
centromeres during DNA replication, but is exchanged for another H3 variant, 
CENP-A, during G1 phase of the cell cycle (Dunleavy et al., 2011). Finally, 
deposition of the H3 variants is largely contingent upon the activity of specific 
histone chaperones. Whereas replication-coupled H3.1 deposition is carried out by 
CAF-1, H3.3 is deposited by the chaperones HIRA, ATRX and DAXX (Tagami et 
al., 2004; Goldberg et al., 2010). 
 Significant attention has also been directed toward understanding the histone 
H2A variants. The variant H2AX is thought to play an important role in mediating 
the DNA damage response. H2AX contains an extended C-terminal domain that 
becomes phosphorylated by ATM and DNA-PK in response to double-strand breaks, 
which in turn is required for the formation of DNA damage repair foci (Stiff et al., 
2004; Celeste et al., 2002). H2AZ is an essential gene in mammals and is reportedly 
involved in transcriptional activation (Faast et al., 2001; Santisteban et al., 2000). 
MacroH2A contains a large C-terminal domain and its incorporation into chromatin 
is enriched at heterochromatic regions including inactive X chromosomes and 
senescence-associated heterochromatic foci (SAHF) (Costanzi & Pehrson, 1998; 
Zhang et al., 2005). Less is known about the H2ABBD variant, although reports 
indicate that it is excluded from inactive X chromosomes and its incorporation into 
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nucleosomes makes them less stable (Chadwick & Willard, 2001; Gautier et al., 
2004). Little has been reported regarding histone H2A variant-specific chaperones, 
with the exception of H2AZ, which in yeast has been found in a complex that 
contains the SWI/SNF family member Swr1 (Mizuguchi et al., 2004; Kobor et al., 
2004). Thus, additional work is required in order to determine whether individual 
histone variants require unique chaperone complexes for deposition and eviction. 
 
1.2.3 Histone Posttranslational Modifications 
 Histones provide far more than just structural support for the genome and have 
been implicated in nuclear processes including transcriptional regulation, DNA 
replication and DNA repair (Bannister & Kouzarides, 2011). In order to facilitate 
these processes, histones are subject to an extensive array of post-translational 
modifications (PTMs) (Figure 1.3a). The majority of histone modifications occur at 
the N-terminal tails, which as revealed by the high-resolution crystal structure of the 
nucleosome, protrude from the nucleosome core (Luger et al., 1997). More than sixty 
individual histone PTMs have been identified, including acetylation, methylation, 
phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, deimination and 
proline isomerization modifications (Kouzarides, 2007). As proposed by Thomas 
Jenuwein and David Allis in the “histone code” hypothesis over a decade ago, 
combinations of these histone PTMs likely provide an important layer of regulation 
to the genome (Jenuwein & David Allis, 2001). 
 Although numerous histone PTMs have been reported, considerable emphasis 
has been placed on understanding one modification in particular: histone 
methylation. Histone methylation primarily occurs on lysine and arginine residues, 
but has also been reported to occur on histidine residues (Borun et al., 1972). 
Methylation of lysine residues occurs at the e-amino group and can exist in one of 
three different states: monomethylation, dimethylation or trimethylation (Murray, 
1964; Paik & Kim, 1967; Hempel et al., 1968). Arginine methylation takes place on 
the guanidinyl group of the residue and can occur in a monomethylated, 
asymmetrically dimethylated or symmetrically dimethylated state (Byvoet et al., 
1972; Borun et al., 1972). Histone histidine methylation has not been studied 
extensively. 
 Lysine methylation is one of the most abundant histone PTMs in the cell. As 
such, histone lysine methylation impacts chromatin in a variety of ways. First, 
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several methyl-lysine marks, including methylated H3K4, H3K36 and H3K79, are 
commonly found at transcriptionally active genes (Bernstein et al., 2002; Santos-
Rosa et al., 2002; Vakoc et al., 2006). In addition, it has been reported that 
methylated H3K4 and H3K36 physically interact with RNA polymerase II, 
suggesting that these marks indeed promote transcription (Ng et al., 2003; Krogan et 
al., 2003). In contrast, several well-characterized methyl-lysine marks, including 
H3K9me3, H3K27me3 and H4K20me3, are associated with transcriptional 
repression and heterochromatin (Schotta et al., 2004; Pauler et al., 2009). Further 
exemplifying the functional diversity of histone lysine methylation, both the 
H3K79me2 and H4K20me2 marks have been reported to have roles in mediating the 
DNA damage response (Wakeman et al., 2012; Sanders et al., 2010). Thus, histone 
lysine methylation is a multifaceted and critical component of the chromatin 
landscape. 
 The methylation of histone lysine residues is catalyzed by a group of enzymes 
called the histone methyltransferases (HMTs), which transfer a methyl group from S-
adenosyl methionine to the amino group of the lysine (Figure 1.3b). HMTs fall under 
one of two subcategories: SET domain-containing and non-SET domain-containing 
methyltransferases (Greer and Shi, 2012). SET domain proteins contain a conserved 
130 amino acid catalytic domain that was first identified in the Drosophila 
melanogaster proteins suppressor of variegation 3-9, enhancer of zeste and trithorax 
(Dillon et al., 2005). Well-characterized SET domain-containing HMTs include 
MLL, SUV39H1, EZH2 and SUV420H2, which catalyze H3K4, H3K9, H3K27 and 
H4K20 methylation, respectively (Dou et al., 2006; Ait-Si-Ali et al., 2004; Pasini et 
al., 2004; Schotta et al., 2008). In addition, the non-SET domain containing 
methyltransferase DOT1L also catalyzes methylation of histone H3 lysine residues 
(Min et al., 2003). Finally, in recent years several histone lysine demethylating 
enzymes have been identified including LSD1 and the JmjC domain containing 
proteins, thus providing an additional level of regulation (Shi et al., 2004; Tsukada et 
al., 2006; Whetstine et al., 2006). 
 
1.2.4 Histone Binding Proteins 
Although the histones collectively comprise a major fraction of the total 
protein content of chromatin, additional non-histone effector proteins also physically 
associate with and modify chromatin. Importantly, many of these interactions are 
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mediated by the ability of the effectors to recognize specific chemical moieties in the 
form of histone PTMs (Taverna et al., 2007). To accomplish this, the effector 
proteins contain specialized domains or modules that bind specific motifs with high 
affinity. Although numerous histone binding proteins have been identified, they can 
be reduced to a few distinct categories based on their binding modules. To this end, 
the most prominent binding modules include bromodomains, chromodomains, Tudor 
domains and PHD fingers (Taverna et al., 2007). 
 Bromodomains (BRDs) are highly conserved 120-amino acid domains that 
recognize acetylated lysine residues with high selectivity (Filippakopoulos et al., 
2012). In humans there are over 40 BRD-containing proteins, including several 
histone acetyltransferases (HATs) and the HAT co-activator p300/CBP-associated 
factor (PCAF) (Dhalluin et al., 1999; Filippakopoulos & Knapp, 2012). Despite the 
highly conserved structure of BRDs, individual BRD-containing proteins exhibit 
selectivity for different acetylated lysines. For example, whereas the BRD-containing 
transcription factor FALZ recognizes H4K5ac, the yeast HAT Gcn5p preferentially 
binds H4K16ac (Filippakopoulos et al., 2012; Owen et al., 2000). This variable 
selectivity likely enables the effectors to modulate highly specific targets. 
 In contrast, several distinct protein interaction modules specifically bind 
methyl-lysine marks, including chromodomains, Tudor domains and PHD fingers. 
Chromodomains are 40-50-amino acid long motifs present in several chromatin 
remodelling enzymes that bind di- and trimethylated histone lysine residues (Taverna 
et al., 2007). For example, the SET domain-containing histone methyltransferase 
SUV39H1 also contains a chromodomain. Remarkably, deletion of the SUV39H1 
chromodomain impairs enzymatic activity demonstrating the interdependence of the 
binding and catalytic domains (Chin et al., 2006). The Tudor domain is another 50-
amino acid module that specifically binds histone methyl-lysines. The double Tudor 
domain-containing histone demethylase, JMJD2A, binds H4K20me2 with high 
affinity, H3K9me3 with low affinity and actively demethylates H3K9me3, revealing 
one mechanism of histone crosstalk (Ozboyaci et al., 2011). PHD domains represent 
a third class of histone methyl-lysine binding modules comprised of a Cys4-His-Cys4 
structural motif that frequently associate with H3K4me2/me3. Prominent examples 
of PHD-containing chromatin effectors include the histone methyltransferase MLL, 
the nucleosomal remodelling factor BPTF and the DNA methyltransferase accessory 
protein DNMT3L (Fair et al., 2001; Li et al., 2006; Aapola et al., 2002). Importantly, 
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the aforementioned binding modules provide important mechanistic links between 
seemingly autonomous chromatin remodelling processes including histone lysine 
methylation, demethylation and acetylation, nucleosome remodelling and 
transcription. 
 
1.2.5 Nucleosome Positioning 
Nucleosome density can profoundly affect the structure and function of 
chromatin. Consequently, nucleosome positioning reflects another important 
mechanism through which chromatin structure can contribute to the regulation of 
gene expression. Studies of nucleosome positioning in a variety of species have 
revealed that nucleosomes are not even distributed across the genome (Yuan et al., 
2005; Johnson et al., 2006; Lee et al., 2007; Dennis et al., 2007). For example, the 
transcribed regions of genes usually exhibit a higher density of nucleosomes than 
promoters or regulatory elements (Bai & Morozov, 2010). Several groups have 
reported that while nucleosomes are typically present at the transcription start sites 
(TSS) of most unexpressed genes, expressed genes and genes containing 
transcriptional pre-initiation complexes at their promoters are largely devoid of 
nucleosomes at the TSS (Ozsolak et al., 2007; Schones et al., 2008). In addition, the 
nucleosome-poor regions around the TSS of active genes also exhibited high levels 
of transcription factor and RNA polymerase II binding. Thus, nucleosome-free 
regions likely permit transcription binding and gene expression. 
 A body of data suggests that nucleosome positioning is governed in a variety 
of ways. First, the underlying DNA sequence appears to dictate nucleosome 
positioning to a certain degree. Indeed, nucleosomes have higher affinities for 
specific DNA sequences and in yeast nearly 50% of nucleosome positions are likely 
determined by the genomic sequence (Sekinger et al., 2005; Segal et al., 2006). 
Second, nucleosomes positioning is also regulated by ATP-dependent histone 
chaperones, which deposit and evict nucleosomes at promoters for the purposes of 
transcriptional repression and activation, respectively (Williams & Tyler, 2007). For 
example, in yeast, Asf1-mediated eviction of histones is required for the 
transcriptional activation of certain promoters (Korber et al., 2006). Similarly, the 
histone chaperone Spt6 is required for histone deposition and subsequent repression 
of several yeast promoters (Adkins & Tyler, 2006).  
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Finally, there is evidence emerging that insulators, including the enhancer-
blocker protein CTCF, are involved in determining nucleosome position. Integrative 
analysis of several genome-wide datasets revealed that nucleosome positioning is 
relatively variable across the genome, except at gene the TSS of genes and adjacent 
to CTCF binding sites (Fu et al., 2008). In fact, nucleosome positioning at CTCF 
sites is even less variable than that of the TSS. To this end, nucleosome positioning 
might play an important role in maintaining genomic boundaries as well. 
 
1.2.6 DNA Methylation 
DNA is also subject to chemical modification in the form of DNA 
methylation, an important structural and regulatory feature of chromatin. The process 
of DNA methylation involves the transfer of a methyl group from S-adenosyl 
methionine to the 5 position of the carbon ring of cytosine residues and typically 
occurs within the context of CpG dinucleotides (Bird, 2002). Approximately 1% of 
all nucleotides in the human genome are comprised of 5-methylcytosine (5mC) in 
somatic cells (Ehrlich et al., 1982). Likewise, approximately 70% of all CpG 
dinucleotides in the human genome contain the 5mC mark (Strichman-Almashanu et 
al., 2002). 
Short regions of high CpG dinucleotide density called CpG islands are 
present at more than 50% of all genes in the human genome (Gardiner-Garden & 
Frommer, 1987). However, individual CpGs are also dispersed throughout the 
genome and tend to account for the majority of 5mC (Gama-Sosa et al., 1983; Bird et 
al., 1995). As a result, the cytosine residues within the CpG islands of genes are 
largely unmethylated. Despite this trend, methylation of CpG islands has been 
reported in the contexts of imprinted genes and the X chromosome inactivation 
(Ferguson-Smith et al., 1993; Yen et al., 1984). 
The process of DNA methylation is catalyzed by the enzymatic activities of a 
family of enzymes called the DNA methyltransferases (DNMTs). To date, three 
DNMT family members have been identified: DNMT1, DNMT3a and DNMT3b. 
DNMT1, functioning as the maintenance DNA methyltransferase, preferentially 
catalyzes the methylation of hemimethylated CpGs during DNA replication and 
repair, likely through interactions with PCNA and Np95/Uhrf1, respectively (Chuang 
et al., 1997; Sharif et al., 2007; Arita et al., 2008; Avvakumov et al., 2008). In 
contrast, the de novo DNA methyltransferases DNMT3a and DNMT3b are capable 
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of methylating CpG DNA irrespective of the initial methylation status (Hsieh, 1999; 
Gowher et al., 2005). Although no bona fide DNA demethylase has been confirmed, 
several demethylase candidates and mechanisms are currently being investigated 
(Cortázar et al., 2011; Iqbal et al., 2011; Cortellino et al., 2011). 
Functionally, DNA methylation has been implicated in a variety of processes 
including gene regulation, X chromosome inactivation, genomic imprinting and 
development. DNA methylation is present infrequently at the CpG islands of genes, 
and targeted methylation is not thought to contribute causally to gene silencing. 
However, data indicate that some genes indeed gain DNA methylation, but that gene 
silencing precedes acquisition of the 5mC mark, suggesting that methylation might 
serve to reinforce long-term gene inactivation (Ohm et al., 2007; Schlesinger et al., 
2007). In a similar manner, DNA methylation contributes to long-term gene 
silencing in the context of X chromosome inactivation (Panning & Jaenisch, 1998; 
Sharp et al., 2011). An important role for DNA methylation in the control of 
genomic imprinting, in which genes are either expressed or silenced in a parent-of-
origin-specific manner, has also been demonstrated (Li et al., 1993; Ferguson-Smith 
& Surani, 2001). Finally, DNA methylation is critically important to normal 
development, as targeted disruption of Dnmt1 causes a global reduction of 5mC that 
is embryonically lethal in mice (Li et al., 1992). Thus, DNA methylation is an 
important epigenetic contributor to diverse aspects of chromatin regulation and 
function. 
 
1.2.7 Non-Coding RNA 
In addition to DNA and protein, recent studies reveal a critical role for RNA 
as both a structural and regulatory component of eukaryotic chromatin. A 
considerable fraction of chromatin is comprised of RNA. For example, analysis of 
chromatin purified from chicken liver revealed RNA to constitute approximately 2-
5% of the total nucleic acid content (Rodriguez-Campos & Azorin, 2007). Not 
surprisingly, as many as 93% of all nucleotides in the human genome have been 
identified as being present in primary transcripts (Birney et al., 2007). Although the 
genome is highly transcribed, approximately only 1.5% of the genome is comprised 
of protein coding genes (Venter et al., 2001; International Human Genome 
Sequencing Consortium, 2004). Consequently, a large proportion of transcripts 
represent non-coding RNA (ncRNA). 
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In humans, ncRNA constitutes a considerable fraction of total chromatin-
associated RNA (CAR). One study characterizing the RNA content of chromatin in 
human fibroblasts indicated that 71% of total CAR was derived from intergenic and 
intronic regions, whereas only 29% corresponded to exons (Mondal et al, 2010). 
Given the sheer abundance of ncRNAs, considerable effort is now being directed 
toward deciphering the functional significance of these transcripts. Indeed, a growing 
body of data now supports a role for long ncRNA (lncRNA) in the regulation of 
chromatin structure and gene expression (Saxena & Carninci, 2011). In particular, 
significant regulatory roles have been revealed for four of the best-characterized 
lncRNAs: Kcnq1ot1, Airn, Xist and HOTAIR. 
Kcnq1ot1 is a 91 kilobase-long lncRNA that is involved in the lineage-
specific transcriptional silencing of multiple genes within the imprinted Kcnq1 
domain (Pandey et al., 2008). Specifically, Kcnq1ot1 promotes the formation of long 
stretches of H3K9me3 and H3K27me3 enriched silent chromatin, by recruiting the 
histone methyltransferases G9a and PRC2, respectively. Targeted disruption of the 
Kcnq1ot1 transcript in mice restores expression of multiple genes within the Kcnq1 
locus that are ordinarily paternally repressed (Mancini-Dinardo et al., 2006). 
Similarly, Airn, an ncRNA expressed in human and mouse, regulates the imprinted 
expression of the Slc22a3, Slc22a2 and Igf2r genes (Sleutels et al., 2002; Yotova et 
al., 2008). Airn recruits G9a to the promoters of these genes, resulting in H3K9me3-
mediated silencing (Nagano et al., 2008). Thus, Kcnq1ot1 and Airn actively mediate 
epigenetic imprinting control. 
In female mammals, epigenetic inactivation of a single X chromosome occurs 
during embryonic development and differentiation as a form of dosage 
compensation, and is regulated in part by the ncRNA Xist (Brown et al., 1991; Penny 
et al., 1996). Encoded within the 1 megabase-long chromosome X inactivation 
center, Xist determines which X chromosome will become inactive and facilitates the 
spreading of epigenetic silencing marks across the chromosome (Marks et al., 2009). 
Importantly, Xist is negatively regulated by another ncRNA, Tsix, which is 
concomitantly repressed during X-inactivation (Marks et al., 2009). This illustrates 
an important role for ncRNAs in wide-scale chromatin regulation. 
Finally, there is also evidence that lncRNAs can mediate long-range 
regulation of defined genomic loci. The lncRNA HOTAIR, encoded within the 
HOXC locus of human chromosome 12, represses the transcription of a 40 kilobase-
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long domain of the HOXD locus of chromosome 2 (Rinn et al., 2007). 
Mechanistically, HOTAIR silences the HOXD locus through the recruitment of the 
Polycomb Repressive Complex 2 (PRC2) and the LSD1/CoREST/REST complex, 
thus facilitating methylation of histone H3K27 and demethylation of H3K4 (Tsai et 
al., 2010). Remarkably, lncRNAs can serve as structural scaffolds capable of 
targeting chromatin modifiers to distant genomic loci. Collectively, these data 
illustrate the varied functions that ncRNAs serve in the regulation of chromatin. 
 
1.2.8 Lamins 
The nuclear lamina is a dense meshwork of filamentous structural proteins 
that lines the inner surface of the nuclear envelope (Bridger et al., 2007). As such, 
the nuclear lamina plays a crucial role in maintaining the size, shape and integrity 
and the nucleus. Structurally, the lamina is comprised of the A- and B-type nuclear 
lamins, which include lamin A, lamin C, lamin B1 and lamin B2 (Dechat et al., 
2008). Lamins A and C are both encoded by the LMNA gene and result from 
alternative splicing (Lin & Worman, 1993). The Lamin B1 and B2 proteins are 
encoded by two separate genes: LMNB1 and LMNB2, respectively (Lin & Worman, 
1995; Höger et al., 1990; Biamonti et al, 1992). 
In addition to providing structural integrity to the nucleus, lamins contribute 
to a variety of nuclear functions including chromatin organization, gene transcription 
and DNA replication (Shimi et al., 2008). First, in flies, mice and humans, it has 
been reported that chromatin physically interacts with the nuclear lamina through a 
series of domains termed lamina-associated domains (LADs) (Pickersgill et al., 
2006; Guelen et al., 2008; Peric-Hupkes et al., 2010). Remarkably, most of the genes 
contained within LADs are transcriptionally inactive. In contrast, lamins also appear 
to play a role in promoting gene expression, as silencing or inactivation of lamins A 
and B1 impairs RNA polymerase II-dependent transcription (Spann et al., 2002; 
Tang et al., 2008; Shimi et al., 2008). Finally, lamins reportedly contribute to DNA 
replication. To this end, lamins co-localize with PCNA at replication foci as well as 
at sites of BrdU incorporation (Moir et al., 1994; Kennedy et al., 2000). In addition, 
DNA replication is blocked by the expression of lamin B dominant negative mutants 
(Spann et al., 1997; Moir et al., 2000). 
Lamin mutations are associated with numerous human diseases, including 
Hutchinson–Gilford Progeria Syndrome (HGPS) (Dittmer & Misteli, 2011). Caused 
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by mutation of the LMNA gene that results in expression of an abnormal form of 
lamin A called progerin, HGPS is characterized by an accelerating aging phenotype 
in children and premature death (Uitto, 2002). Further underscoring the role of 
lamins in maintaining genomic integrity, cells isolated from HGPS patients exhibit 
an array of chromatin abnormalities. First, it was reported that in female HGPS 
fibroblasts, the H3K27me3 histone mark is lost from the inactive X chromosome and 
is accompanied by reduced expression of the H3K27 histone methyltransferase 
EZH2 (Shumaker et al., 2006). In addition, HGPS cells contain lower levels of 
H3K9me3 and exhibit an altered pattern of localization between the mark and 
heterochromatin protein 1 (HP1) and CREST, suggesting that constitutive 
heterochromatin is disrupted in the cells. Intriguingly, levels of H4K20me3, another 
constitutive heterochromatin mark, were markedly elevated in HGPS cells. 
Collectively, the data illustrate how lamin dysfunction can influence chromatin 
structure. 
 
1.3 Chromatin Dynamics in Cell Senescence 
 
1.3.1 Senescence-Associated Heterochromatic Foci 
As cells undergo senescence, they typically exhibit profound changes to 
chromatin structure. Probably the most striking and widely documented 
manifestation of chromatin reorganization in senescent cells is the formation of 
senescence-associated heterochromatic foci (SAHF) (Figure 1.4). First reported by 
Scott Lowe’s laboratory, SAHF represent distinct structures of facultative 
heterochromatin that appear as punctate foci following staining of senescent cells 
with the DNA dye 4’,6-diamidino-2-phenylindole (DAPI) (Narita et al., 2003). The 
number of visible SAHF foci per cell varies, but typically ranges from approximately 
30-50, with each focus arising from compaction of an individual chromosome 
(Funayama et al., 2006; Zhang et al., 2007). Although SAHF is reflective of a 
heterochromatic state, domains of constitutive heterochromatin including telomeres 
and pericentromeres largely localize to the periphery of SAHF (Narita et al., 2003; 
Funayama et al., 2006; Zhang et al., 2007, Chandra et al., 2012).  
Initial molecular analysis of SAHF composition revealed that the foci contain 
the heterochromatic histone modification H3K9me, but largely exclude the 
euchromatic H3K9ac and H3K4me marks (Narita et al., 2003; Narita et al., 2006). 
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More recent work from Masashi Narita’s lab indicates that SAHF do not form 
through the spreading of repressive histone modifications, but rather through the 
spatial reorganization of existing domains of repressive marks into focal structures 
(Chandra et al., 2012). This work also elegantly showed that H3K9me3 localizes 
solely to the SAHF core and is surrounded by a ring of H3K27me3, while H3K9me2 
is present across the entire SAHF focus. Additional components of SAHF include the 
histone H2A variant, macroH2A, heterochromatin protein 1 (HP1) and the high-
mobility group A (HMGA) proteins (Narita et al., 2003; Narita et al., 2006; Zhang et 
al., 2005).  
 Some progress has been made in deciphering the molecular mechanisms by 
which SAHF is regulated. Several reports indicate that SAHF formation is at least 
partially, if not fully dependent on the activities of the p16INK4a-pRB and p53 
pathways (Narita et al., 2003; Chan et al., 2005; Ye et al., 2007a). To this end, in 
IMR90 cells, knockdown of either p16INK4a or pRB is insufficient to prevent RAS-
induced proliferation arrest but does abolish SAHF formation (Narita et al., 2003). 
Although correlative, BJ fibroblasts induced to senescence by either replicative 
exhaustion or exposure to DNA-damaging agents fail to induce p16INK4a and do 
not form SAHF, providing additional evidence of a critical role for p16INK4a in the 
formation of SAHF (Kosar et al., 2011). 
The chromatin regulators HIRA and ASF1a also appear to play an important 
role in mediating SAHF formation (Zhang et al., 2005). Upon downregulation of the 
Wnt ligand, Wnt2, in prescenescent primary human fibroblasts, GSK3β 
phosphorylates the histone chaperone HIRA, resulting in translocation of HIRA to 
promyelocytic leukemia (PML) nuclear bodies (Ye et al., 2007b). HIRA 
translocation to PML bodies subsequently promotes SAHF formation, potentially 
through an interaction with HP1 (Zhang et al., 2007). Also consistent with the 
putative role for HIRA in the formation of SAHF, in senescent mouse embryonic 
fibroblasts (MEFs), HIRA does not translocate to PML bodies and the cells fail to 
form discrete SAHF foci (Kennedy et al., 2010). Alternatively, some other difference 
between the mouse and human senescence programs might account for the inability 
of MEFs to form proper SAHF. 
Regardless of the precise mechanism, it is clear that the formation of SAHF 
in senescent cells reflects a profound reorganization of chromatin structure and likely 
mediates important functions of the senescence program. It was initially suggested 
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that SAHF might reinforce the senescence proliferation arrest, by suppressing the 
expression of proliferation genes. Supporting this concept, the cyclin A2 gene 
acquires the repressive H3K9me histone mark and co-localizes with SAHF foci in 
senescent cells (Narita et al., 2003; Zhang et al., 2007). Likewise, sites of active 
transcription are predominantly excluded from SAHF (Narita et al., 2003; Funayama 
et al., 2006). 
However, Fabrizio d’Adda di Fagagna and colleagues recently postulated a 
different functional role for SAHF, arguing that formation of SAHF serves to 
dampen the DNA damage response (DDR) following oncogene-induced replication 
stress (Di Micco et al., 2011). In the study, the authors showed that two distinct 
forms of heterochromatin exist in senescent cells, one that acts locally to suppress 
gene expression and another large-scale form, SAHF, which serves to blunt the 
DDR. The authors also demonstrated that the local heterochromatin formation is 
mediated through ATM, whereas the formation of SAHF is mediated by ATR. 
Intriguingly, inactivation of ATM or p53 in RAS-induced cells allowed cells to 
continued to proliferate, even in the presence of prominent SAHF, indicating that 
SAHF is not responsible for the silencing of proliferation genes. 
 
1.3.2 Histone Modifications and Senescence 
Posttranslational histone modifications play a critical role in the regulation of 
chromatin structure and function. As such, histone modifications can influence 
diverse processes ranging from control of gene transcription to the maintenance of 
higher order chromatin structure. Consequently, the altered pattern of gene 
expression and profound structural changes to chromatin exhibited by senescent cells 
are likely mediated at least in part by histone marks. In fact, there is considerable 
evidence accumulating to suggest this is the case. 
As discussed above, work from Scott Lowe’s laboratory provided some of the 
first data implicating histone modifications in the formation of facultative 
heterochromatin (e.g. SAHF) in senescent cells (Narita et al., 2003). As discussed 
above, Lowe and colleagues demonstrated that SAHF contain enrichment of the 
H3K9me modification, but are largely devoid of the euchromatic histone marks 
H3K9ac and H3K4me. Importantly, the authors also found that in senescent cells, 
levels of the repressive H3K9me modification increased at the promoters of CCNA2 
and PCNA, two E2F target genes that are downregulated during senescence.  
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Expanding on these earlier observations, Masashi Narita’s laboratory 
subsequently reported that SAHF reflect a spatial rearrangement of regions of 
chromatin containing pre-existing histone modifications rather than local changes to 
histone marks (Chandra et al., 2012). Using confocal microscopy, Narita and 
colleagues elegantly showed that SAHF are comprised of discrete layers of 
chromatin containing the H3K9me3, H3K9me2 and H3K27me3 modifications, 
respectively. The SAHF core primarily contains H3K9me3-enriched regions of 
chromatin and is surrounded by layers of H3K9me2 and H3K27me3. In contrast, the 
active mark H3K36me3 is largely excluded from SAHF. These findings suggest that 
histone modifications contribute to higher-order chromatin structure in senescent 
cells. 
Recently, Scott Lowe’s laboratory utilized quantitative mass spectrometry in 
order to screen for global histone modification changes during RAS-induced 
senescence (Chicas et al., 2012). Consistent with the formation of heterochromatin, 
the abundances of several repressive histone modifications increase in senescent cells 
including H3K9me3, H3K27me3 and H4K20me3. In contrast, the RAS-induced 
senescent cells exhibit a profound loss of H3K4me3, a mark that typically coincides 
with transcriptional activation. A marked reduction of H3K4me3 levels was also 
observed in senescent cells induced by either prolonged passage in culture (RS) or 
etoposide treatment. ChIP-seq of H3K4me3 in proliferating and senescent cells 
revealed that the mark is predominantly lost at E2F target genes, which are required 
for proliferation. The authors subsequently showed that pRB mediates H3K4me3 
removal at E2F target genes during senescence via recruitment of the histone 
demethylases Jarid1a and Jarid1b. Importantly, this study illustrates how specific 
histone modification changes can regulate gene expression during senescence. 
Finally, there is evidence to suggest that histone modification changes also 
contribute to another important feature of senescence: p16INK4a induction. The 
INK4a gene is located within the INK4b-ARF-INK4a locus and is controlled by 
tightly regulated epigenetic mechanisms (Gil & Peters, 2006). Work from Kristian 
Helin’s laboratory showed that in normal proliferating human fibroblasts, the 
oncoprotein BMI1 directly binds and represses INK4a through a mechanism that 
involves H3K27me3 and the EZH2 and SUZ12-containing Polycomb-Repressive 
Complex 2 (PRC2) (Bracken et al., 2007). As cells approach senescence, EZH2 
expression decreases, which results in a reduction of H3K27me3 at the INK4a 
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promoter, loss of BMI1 binding at the locus and activation of INK4a transcription. 
Similarly, depletion of EZH2 or SUZ12 is sufficient to alleviate BMI1 binding, 
activate INK4a expression and induce senescence. Thus, these data confirm that local 
histone modification changes can mediate important aspects of the senescence 
program.  
 
1.3.3 Histone Loss and Senescence 
The profound chromatin remodelling that occurs as cells undergo senescence 
is likely at least partially mediated through changes in histone dynamics. Histone 
gene expression is a tightly controlled process regulated by both transcriptional and 
post-transcriptional mechanisms (Ma et al., 2000, Zhao et al., 2000). The expression 
of most canonical histone genes is tightly coupled to DNA replication and cell cycle 
progression, culminating in a robust upregulation of histone proteins specifically 
during S phase (Osley, 1991). Consequently, the expression of replication-dependent 
histones is largely suppressed in non-proliferating cells. For example, a significant 
repression of histone gene expression has been observed in quiescent human and 
murine fibroblasts (Coppock et al., 1993, Zahradka et al., 1993). Likewise, during 
terminal differentiation, histone gene expression is inhibited at the level of 
transcription as cells differentiate and exit the cell cycle (Stein et al., 1989). Not 
surprisingly, the expression of replication-dependent histone genes is also repressed 
in senescent human diploid fibroblasts (Pang & Chen, 1994). 
Although de novo histone synthesis is attenuated in the quiescent and 
terminally differentiated states, levels of chromatin-bound histones appear to remain 
unperturbed in these cells. For example, while mRNA levels of HIST1H1D, a gene 
that encodes the linker histone H1, become undetectable in quiescent human WI-38 
fibroblasts, the chromatin-bound levels of histone H1 remain identical to that of 
proliferating WI-38 cells (Funayama et al., 2006). In contrast, evidence is emerging 
that chromatin-bound histones are actually lost from senescent cells. To this end, 
Fuyuki Ishikawa and colleagues reported that the linker histone H1 is lost in 
senescent primary human fibroblasts induced by either oncogenic activation, 
prolonged culturing or activation of stress-induced p38 MAP kinase signalling 
(Funayama et al., 2006). The authors also showed that histone H1 loss occurs 
through a post-transcriptional mechanism and contributes to the formation of SAHF. 
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Several additional groups have subsequently reported that aging yeast and 
senescent human cells contain reduced protein levels of the core histones. Work from 
Shelley Berger’s laboratory revealed that compared to young cells, old 
Saccharomyces cerevisiae exhibit profound histone loss at several subtelomeric loci 
and moderate histone loss at numerous other regions (Dang et al., 2009). Similarly, 
Jessica Tyler’s laboratory reported a marked reduction of global histone levels in 
aged Saccharomyces cerevisiae (Feser et al., 2010). Remarkably, the authors also 
found that overexpression of histones H3 and H4 significantly extended lifespan in 
wild-type yeast. Finally, Jan Karlseder and colleagues reported that core histone 
protein levels decrease in IMR90 cells during replicative aging or after bleomycin-
induced DNA damage (O’Sullivan et al., 2010). Based on their findings, the authors 
proposed that the stress of progressive telomere shortening during replicative aging 
inhibits DNA synthesis and destabilizes histone chaperones, which in turn alters the 
chromatin landscape, resulting in degradation of the core histones. Taken together, 
these studies confirm that global histone levels indeed decrease during replicative 
aging and likely during senescence. 
 
1.3.4 DNA Methylation and Senescence 
 Methylation of DNA on cytosine residues within the CpG dinucleotide context 
is an important and stable epigenetic modification that contributes to transcriptional 
repression. Consequently, DNA methylation plays an important role in maintaining 
genomic integrity and function (Lengauer et al., 1997; Chen et al., 1998b). In light of 
the profound chromatin changes that occur during senescence, it is not surprising that 
DNA methylation patterns are also altered in senescent cells. Seminal work from 
Peter Jones’ laboratory demonstrated that the aging of normal human diploid 
fibroblasts in culture is accompanied by a prominent reduction of global 5-
methylcytosine content (Wilson & Jones, 1983). While this work was not conducted 
explicitly in senescent cells, it implicated DNA methylation changes in the 
replicative aging process. 
 Subsequent studies confirmed that genome-wide 5-methylcytosine patterns are 
indeed altered in senescent cells. One group reported reductions of both 5-
methylcytosine and the expression of the DNA methyltransferase DNMT1 in 
replicative senescent and oxidative stress-induced senescent human embryonic lung 
fibroblasts (Zhang et al., 2008). Recent work from Peter Adams’ laboratory also 
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revealed that replicative senescent IMR90 cells exhibit a marked reduction of DNA 
methylation at late-replicating regions of the genome and lamina-associated domains 
and increased methylation at some CpG islands (Cruickshanks et al., submitted). 
DNA methylation profiling conducted on a panel of early passage and senescent 
mesenchymal stem cells (MSC) identified numerous CpG sites that consistently 
become either differentially hypomethylated or hypermethylated during senescence 
(Schellenberg et al., 2011). Importantly, the authors also found that CpG sites that 
become hypomethylated in senescence are associated with enrichment of the 
H3K4me3 histone mark, whereas the CpG sites that become hypermethylated are 
associated with the repressive histone marks H3K27me3 and H3K9me3. Building on 
this work, the same group recently identified a senescence DNA methylation 
signature, which based on the methylation levels of six CpG sites, can accurately 
predict the replicative age and state of senescence of cells in culture (Koch et al., 
2012). 
 Finally, there is emerging evidence that the expression of some genes and 
non-coding transcripts is regulated at least in part through changes in DNA 
methylation during replicative aging and senescence. To this end, several genes 
involved in cell cycle progression, including CDK2, CDK4 and PCNA, or DNA 
replication, including POLD4, POLE and RFC2, become differentially 
hypermethylated in late passage MSCs relative to early passage cells, and possibly 
contribute to the onset of senescence (Choi et al., 2011).  Methylation changes have 
also been described at non-genic loci in senescent cells. Demethylation of the 
pericentromeric human satellite 3 (HS3) repeats of chromosome 1 has been reported 
in replicative senescent MRC5 cells, and is associated within increased transcription 
of the locus (Enukashvily et al., 2007). These data collectively support a functional 
role for DNA methylation in transcriptional regulation during senescence. It is 
important to note that to date, the majority of work focused on defining the senescent 
DNA methylome has been conducted in replicative senescent cells, and altered 
patterns of DNA methylation have not yet been described for oncogene-induced 
senescent cells. 
 
1.3.5 Lamins and Senescence 
Given the important contribution of the nuclear lamins to the regulation of 
chromatin structure and function, it is important to consider how dysregulation of 
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lamins might influence the chromatin state of senescent cells. To this end, a 
considerable body of data has accumulated implicating lamin dysregulation as a 
driver of premature senescence in a variety of cellular contexts. First, it has been 
widely reported that primary cells isolated from Hutchinson-Gilford Progeria 
Syndrome (HGPS) patients harboring variety of lamin A defects, undergo 
accelerated senescence in culture (McClintock et al. 2006; Taimen et al. 2009). 
Importantly, various lamin A mutations have been shown to promote an accelerated 
senescence phenotype in non-HGPS contexts as well. For example, primary 
myoblasts isolated from a patient with a lamin A arginine 545 to cysteine point 
mutation displayed an abnormal nuclear morphology, nuclear accumulation of p21 
and a higher percentage of SA β-gal-positive cells, when compared to myoblasts 
expressing WT lamin A (Kandert et al., 2009). Similarly, the overexpression of 
lamin A mutants in 82-6pBlox human diploid fibroblasts resulted in abnormal 
nuclear morphology, accelerated rates of telomere loss and the premature onset of 
senescence (Huang et al., 2008). 
Premature senescence has also been reported in cells lacking sufficient levels 
of the mature processed forms of lamin A/C. Depletion of lamin A/C from IMR90 
cells results in conversion to a large flattened cellular morphology, induction of a 
p53-mediated cell cycle arrest and concomitant expression of multiple senescence 
markers (Moiseeva et al., 2011). Similarly, compared to normal human dermal 
fibroblasts, fibroblasts null for lamin A/C expression accumulate excessive ROS and 
undergo accelerated senescence following exposure to mild oxidative stress (Pekovic 
et al., 2011). Finally, accumulation of unprocessed pre-lamin A, either through direct 
overexpression or through knockdown of the pre-lamin A processing enzyme 
Zmpste24/FACE1, results in mitotic defects, impaired nuclear integrity and 
accelerated senescence in vascular smooth muscle cells (Ragnauth et al., 2010). 
In addition to the role that dysregulation of the nuclear lamina plays in 
initiating the onset of senescence, lamin perturbations also occur as a downstream 
consequence of senescence. Recent work from Robert Goldman’s laboratory 
revealed that in replicative senescent WI-38 human dermal fibroblasts, lamin B1 
protein levels decrease by 80-90%, yet remain unaffected in quiescent WI-38 cells 
(Shimi et al., 2011). The authors also observed a comparable reduction of lamin B1 
in senescent WI-38 cells resulting from expression of oncogenic H-RASG12V.  
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Research conducted by Judith Campisi’s laboratory similarly demonstrated 
that lamin B1 levels decrease in multiple human diploid fibroblast cell lines 
following induction of senescence by exposure to ionizing radiation, repeated 
passage in culture, expression of H-RASG12V or continuous p38 MAP kinase 
activity (Freund et al., 2012). The authors also showed that lamin B1 loss during 
senescence occurs after activation of either the pRB or p53 pathways, but is 
independent of the NF-κB, p38 MAPK, ATM and ROS signalling pathways. 
Importantly, both of these studies suggest that lamin B1 loss is a novel marker of 
senescence. 
 
1.4 Aim of the Study 
Chromatin structure undoubtedly plays an integral part in the establishment 
and reinforcement of cell senescence. As discussed above, chromatin undergoes 
extensive remodeling upon induction of senescence and contributes functionally to 
important processes including the maintenance of a permanent proliferation arrest 
and dampening of the DDR. Indeed, the formation of facultative heterochromatin 
domains, either locally or in the form of SAHF, appears to contribute significantly to 
both of these processes. Thus, chromatin structure has the potential to influence 
essential biological processes ranging from tumor suppression to wound healing. 
 Since the histone code was first proposed, considerable effort has been 
directed toward understanding how specific histone modifications impact various 
aspects of chromatin including gene regulation and higher-order chromatin structure. 
In light of the overt chromatin changes that accompany senescence, several 
laboratories have investigated the relationship between histone marks and chromatin 
structure in senescent cells. To this end, elegant work from the laboratories of Scott 
Lowe, Masashi Narita and others has provided critical insight into the epigenetic 
underpinnings of senescence-specific chromatin changes. 
 Despite the current progress, there is much to learn with regards to how 
individual histone marks might influence the chromatin landscape of senescent cells. 
More specifically, are specific histone modifications individually capable of 
regulating features of the senescence program such as gene expression or 
proliferation arrest? In order to address this question, I first wanted to identify a 
histone mark that might be of relevance to cell senescence. Therefore, after a 
thorough review of the literature and given the putative importance of 
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heterochromatin to senescence, I selected the histone H4 lysine 20 trimethyl 
(H4K20me3) modification for further investigation. 
 Histone H4 lysine 20 trimethylation is an evolutionarily conserved histone 
modification that is found in S. pombe, D. melanogaster and mammals (Schotta et 
al., 2004; Sanders et al., 2004). The H4K20me3 mark is typically present at a 
relatively low abundance in the cell and occupies only 5% of all histone H4 
molecules in HeLa S3 cells (Pesavento et al., 2008). Unlike numerous other histone 
modifications, H4K20me3 levels remain stable and fluctuate very little throughout 
the cell cycle (Pesavento et al., 2008). In humans, the SET domain-containing HMTs 
SUV420H1 and SUV420H2 are both capable of methylating histone H4 at lysine 20, 
although SUV420H2 preferentially deposits the H4K20me3 mark (Schotta et al., 
2004; Yang et al., 2008). Subsequent loss-of-function studies confirmed that Suv4-
20h2 is indeed responsible for the majority of H4K20me3 deposition in mice, while 
SUV420H2 confers the mark in human cells (Schotta et al., 2008; Kapoor-Vazirani 
et al., 2011). 
 An increasing body of literature indicates that H4K20me3 localizes to 
domains of constitutive heterochromatin and likely contributes to the transcriptional 
silencing of these regions. As reported by Thomas Jenuwein and colleagues, the 
H4K20me3 modification is highly enriched at pericentric heterochromatin in 
Drosophila, mouse embryonic fibroblasts (MEFs) and HeLa cells (Schotta et al., 
2004). This study additionally revealed that in MEFs, deposition of the H4K20me3 
mark at pericentric heterochromatin is dependent on the H3K9 methyltransferase 
Suv39h1/2 and the H3K9me3 binding protein HP1. A subsequent study from Maria 
Blasco’s laboratory demonstrated that in MEFs, the RB1 family proteins are required 
for proper heterochromatin formation and facilitate H4K20 trimethylation at 
pericentric and telomeric chromatin through recruitment of the HMTs Suv4-20h1 
and Suv4-20h2 (Gonzalo et al., 2005). 
 H4K20me3 enrichment has also been reported at other domains of 
transcriptionally silent chromatin, including imprinted regions and several classes of 
repetitive DNA. A study by Denise Barlow and colleagues found that in MEFs, 
H4K20me3 is present along with H3K9me3 and HP1α, -β and -γ at the silent 
maternal promoter of the Air ncRNA, within the Igf2r imprinted cluster (Regha et al., 
2007). A separate report showed that H4K20me3, H3K4me3 and H3K9me3 together 
comprise an epigenetic signature that is present at all imprinting control regions in 
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mice and humans (McEwen & Ferguson-Smith, 2010). Utilizing next-generation 
sequencing, several groups have observed marked enrichment of H4K20me3 at 
multiple classes of repetitive elements including satellite repeats, simple repeats and 
ERVL repeats, as well as at ZNF genes in human CD4+ T cells (Barski et al., 2007; 
Ernst & Kellis, 2010). Several lines of evidence support a functional role for 
H4K20me3 in the maintenance of transcriptional silencing and genomic integrity at 
regions of repetitive DNA. For example, in Drosophila H4K20me3 cooperates with 
DNMT2 to reinforce the silencing of retrotransposons (Phalke et al., 2009). In 
addition, H4K20me3 protects against telomere elongation and prevents telomeric 
recombination in MEFs (Benetti et al., 2007). Collectively, these data demonstrate 
that H4K20me3 is enriched at domains of constitutive heterochromatin and repetitive 
DNA and plays a critical role in the maintenance of these genomic regions. 
Several key findings from the literature suggest that H4K20me3 might be 
relevant to senescence. First, as discussed above, H4K20me3 is a marker of 
heterochromatin and is highly enriched at transcriptionally silent domains including 
telomeres, pericentromeres, imprinted regions and the inactive X chromosome 
(Schotta et al., 2004; Henckel et al., 2009; McEwen & Ferguson-Smith, 2010; 
Chadwick & Willard, 2004). This is potentially significant as senescent cells undergo 
extensive chromatin changes that ultimately manifest in the formation senescence-
associated heterochromatic foci (SAHF). Second, elevated levels of the H4K20me3 
mark have been reported in the livers of aged rats and in cells isolated from 
Hutchinson–Gilford Progeria Syndrome (HGPS) patients (Sarg et al., 2002; 
Shumaker et al., 2006). Intriguingly, these data suggested a potential link between 
H4K20me3, aging and senescence. Senescent cells have been reported to accumulate 
with age in various tissues, including rodent liver (Wang et al., 2009). Likewise, 
HGPS is premature-aging syndrome and primary cells isolated from HGPS patients 
senesce at an accelerated rate in culture (McClintock et al., 2006). 
Finally, H4K20me3 is frequently lost from human cancers (Fraga et al., 
2005). Because senescence provides a barrier to tumorigenesis, I wanted to 
investigate whether H4K20me3 contributes to the tumor suppressive properties of 
senescence. Therefore, in the present study I set out to address the following critical 
questions. (1) What happens to the H4K20me3 modification in senescent cells? (2) Is 
H4K20me3 required for senescence? (3) What is the function of H4K20me3 in 
senescent cells? 
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Chapter 2. Materials and Methods 
  
2.1 Expression and shRNA Vectors 
 
2.1.1 Expression Vectors 
The pBABE-puro and pBABE-puro-H-RAS-V12 (H-RASG12V) retroviral 
expression vectors were obtained as gifts from Robert Weinberg (Massachusetts 
Institute of Technology). pC1-HA-SUV420H1_i1 and pC1-HA-SUV420H2 were 
obtained as gifts from D. Alan Underhill (University of Alberta). pCMV-VSVG was 
purchased from Clontech Laboratories. psPAX2 was obtained from Addgene 
(plasmid 12260). 
 
2.1.2 Generation of SUV420H1 and SUV420H2 Vectors 
The pBABE-puro-MYC-SUV420H1 and pBABE-puro-MYC-SUV420H2 
vectors were generated using conventional molecular biology methods as follows. 
The full length SUV420H1 ORF was PCR amplified from pC1-HA-SUV420H1_i1 
using the following primers: Forward: 5’-GCG CGG ATC CGC CAC CAT GAA 
GTG GTT GGG AGA ATC C-3’; Reverse: 5’-GCG CGT CGA CTT AGG CAT 
TAA GCC TTA AAG A-3’. The PCR product was digested with BamHI and SalI 
and ligated into pBABE-puro-MYC digested with the same enzymes. The full length 
SUV420H2 ORF was PCR amplified from pC1-HA-SUV420H2 using the following 
primers: Forward: 5’-GCG CGG ATC CGC CAC CAT GGG GCC CGA CAG AGT 
GAC A-3’; Reverse: 5’-GCG CGT CGA CTC ACA GCT CTT CAC CGC CGA C-
3’. The PCR product was digested with BamHI and SalI and ligated into pBABE-
puro-MYC digested with the same enzymes. 
The pBABE-puro-MYC-SUV420H2-281-462 vector was generated using 
conventional molecular biology methods as follows. A fragment of SUV420H2 
corresponding to amino acid residues 281-462 was PCR amplified from pBABE-
puro-MYC-SUV420H2 using the following primers: Forward 5’-GCG CGG ATC 
CCT GGG CCC TCG GGC CTG CGT G-3’; Reverse: 5’-GCG CGT CGA CTC 
ACA GCT CTT CAC CGC CGA C-3’. The PCR product was digested with BamHI 
and SalI and ligated into pBABE-puro-MYC digested with the same enzymes. All of 
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the expression vectors were verified through restriction digestion and direct 
sequencing. 
 
2.1.3 Short Hairpin RNA (shRNA) Vectors 
A set of five human SUV420H2 lentiviral shRNA constructs was purchased 
from Open Biosystems (RHS4533). The set contains five unique short hairpins 
(TRCN0000142036, TRCN0000141493, TRCN0000141258, TRCN0000143766, 
TRCN0000141926) targeted against human SUV420H2, contained within the 
pLKO.1 lentiviral vector. An additional set of four human SUV420H2 retroviral 
shRNA constructs was purchased from OriGene Technologies (TR307397). The 
constructs feature four unique 29-mer hairpins targeted against human SUV420H2, 
contained within the pRS retroviral vector. 
 
2.2 Cell Culture 
 
2.2.1 IMR90 Cells 
IMR90 primary human diploid fibroblasts were obtained from the Coriell 
Institute (Camden, New Jersey, USA). The cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 20% fetal bovine serum, 2 
mM L-glutamine, 25 U/ml penicillin and 25 µg/ml streptomycin. Cells were 
maintained in a humidified incubator under the following conditions: 37° C, 5% CO2 
and 3% O2. The IMR90 cells were subjected to serial passage approximately every 
two to three days.   
 
2.2.2 Phoenix-Ampho Cells 
Phoenix–Ampho embryonic kidney cells (SD-3443) were obtained from the 
American Type Culture Collection (Manassas, Virginia, USA). The cells were 
cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 25 U/ml penicillin and 25 µg/ml 
streptomycin. Cells were maintained in a humidified incubator under the following 
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2.2.3 HEK-293T Cells 
HEK 293T/17 embryonic kidney cells (CRL-11268) were obtained from the 
American Type Culture Collection (Manassas, Virginia, USA). The cells were 
cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 25 U/ml penicillin and 25 µg/ml 
streptomycin. Cells were maintained in a humidified incubator under the following 
conditions: 37° C and 5% CO2. 
 
2.2.4 Transfection of Phoenix-Ampho Retroviral Packaging Cells 
Working with 70% confluent 100 mm dishes of Phoenix-Ampho cells, the 
growth medium was removed, replaced with 9 ml of fresh medium and returned to 
the incubator four hours prior to transfection. 2.5 M CaCl2 was diluted to a final 
concentration of 250 mM with Milli-Q dH2O and 0.5 ml of the diluted CaCl2 was 
aliquotted into one sterile 15 ml centrifuge tube per transfection. Twenty-five µg of 
purified plasmid DNA was added to each tube of CaCl2 and mixed by flicking 
gently. To each tube of CaCl2/DNA, 0.5 ml 2X BBS (50 mM BES, 280 mM NaCl, 
1.5 mM Na2HPO4, pH 6.95) was added slowly, drop-wise. The tubes were incubated 
for 15 minutes at room temperature, mixed by gently bubbling air through the 
mixture and distributed drop-wise to the plates of Phoenix-Ampho cells. The plates 
were rocked gently and placed into a humidified 37° C, 5% CO2 incubator overnight. 
  
2.2.5 Retroviral Production and Infection 
Approximately 12-16 hours after transfection, the medium was removed from 
the Phoenix-Ampho cells, replaced with 6 ml of complete growth medium and the 
plates returned to a 32° C, 5% CO2 incubator for 24 hours. Twenty-four hours after 
the medium change, viral supernatants were collected from the transfected Phoenix-
Ampho cells and passed through 0.45 mm syringe filters. Fresh growth medium was 
again applied to the plates of Phoenix-Ampho cells and the plates were returned to 
the 32° C, 5% CO2 incubator for an additional 24 hours. 
Working with 100 mm dishes of target IMR90 cells, the growth medium was 
removed and replaced with 3 ml of fresh growth medium supplemented with 8 µg/ml 
polybrene. The target cells were then pre-incubated for 2 hours in a 32° C, 5% CO2 
incubator. After 2 hours, 3 ml of the filtered viral supernatant was applied to the pre-
incubated IMR90 cells. The IMR90 cells were returned to the incubator for 24 hours. 
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After 24 hours, the viral supernatant was removed from the IMR90 cells and 
replaced with 3 ml fresh viral supernatant and 3 ml growth medium supplemented 
with 8 µg/ml polybrene. The IMR90 cells were again returned to the 37° C, 5% CO2, 
3% O2 incubator for an additional 24 hours. Following the second 24-hour 
incubation, the viral supernatant was removed from the IMR90 cells and replaced 
with growth medium containing an appropriate selection drug. Infected IMR90 cells 
were typically selected as appropriate with either 1 µg/ml puromycin or 500 µg/ml 
neomycin (G418).  
 
2.2.6 Transfection of HEK-293T Lentiviral Packaging Cells 
 Working with HEK-293T cells, 11-12 million cells in 15 ml of normal 
growth medium were seeded onto T175 flasks and allowed to adhere for 24 hours. 
Approximately 24 hours after seeding, the transfection reactions were prepared. The 
following plasmids were added to sterile 15 ml centrifuge tubes containing 1.5 ml 
DMEM: 5 µg pCMV-VSVG, 14 µg psPAX2, 19 µg shRNA-containing plasmid.  In 
a separate set of sterile 15 ml centrifuge tubes, 100 µl Lipofectamine 2000 (Life 
Technologies) was mixed with 1.5 ml DMEM and incubated for 5 minutes at room 
temperature. The contents of the DMEM/DNA and DMEM/Lipofectamine 2000 
tubes were then combined, mixed gently and incubated for 20 minutes at room 
temperature. After 20 minutes, the DNA/Lipofectamine 2000 solutions were mixed 
by gentle bubbling with a pipette and distributed evenly to the flasks of HEK-293T 
cells. The HEK-293T flasks were then placed into a 37° C, 5% CO2 incubator. Six 
hours later, the transfection medium was carefully removed from each flask, replaced 
with 15 ml of normal growth medium and the flasks returned to the incubator. 
 
2.2.7 Lentiviral Production and Infection 
Approximately 12-16 hours after transfection, the medium was removed from 
the HEK-293T cells, replaced with 15 ml of normal growth medium and the flasks 
returned to a 37° C, 5% CO2 incubator for 24 hours. Twenty-four hours after the 
medium change, the lentiviral supernatants were collected from the HEK-293T cells, 
placed into sterile 50 ml centrifuge tubes and stored at 4° C overnight. The HEK-
293T cells were then covered with a fresh 15 ml of normal growth medium and the 
flasks were returned to a 37° C, 5% CO2 incubator for an additional 24 hours. After 
24 hours, the second 15 ml batches of lentiviral supernatant were collected and 
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pooled with the first batches for a total volume of 30 ml. In order to clear cellular 
debris, the lentiviral supernatants were then subjected to centrifugation for 10 
minutes at 3000 rpm. The supernatants were passed through 0.45 µm PVDF low 
protein-binding filters and transferred to sterile 25 x 89 mm polyallomer centrifuge 
tubes (Beckman, 326823). The tubes were weighed in a sterile laminar flow hood 
and balanced by the precise addition of sterile PBS. The tubes were then placed into 
an SW-28 rotor and subjected to centrifugation for 2 hours at 47,000 x g (23,000 
rpm) and 10° C in a Beckman-Coulter ultracentrifuge. Upon completion of the spin, 
the supernatants were removed by gentle inversion and placed inside sterile 50 ml 
centrifuge tubes. One hundred µl of sterile PBS was added to each lentiviral pellet, 
the tubes were capped and incubated overnight (12-16 hours) at 4° C on an orbital 
rocking platform. The following day, the purified lentiviruses were aliquotted as 
small volumes into sterile 1.5 ml microcentrifuge tubes and stored in the -80° C 
freezer. 
Working with 6-well dishes of IMR90 cells, the growth medium was 
removed and replaced with 2 ml of fresh growth medium supplemented with 8 µg/ml 
polybrene. The IMR90 cells were then pre-incubated for 2 hours in a 37° C, 5% CO2, 
3% O2 incubator. After 2 hours, 0, 4, 8, 12 or 16 µl of purified shControl or 
shSUV420H2 lentivirus was applied to the wells of the pre-incubated IMR90 cells. 
The IMR90 cells were then returned to the incubator for 24 hours. After 24 hours, the 
infection medium was removed from each well, replaced with 2 ml of fresh growth 
medium supplemented with 1 µg/ml puromycin and cultured until all of the 
uninfected cells were dead. The minimum volume of shControl or shSUV420H2 
lentivirus that yielded 100% cell survival following puromycin selection was utilized 
for all subsequent infections. For each experiment, the lentiviral-infected IMR90 
cells were maintained under puromycin selection for the full duration of the 
experiment. 
 
2.3. Induction of Cell Senescence and Quiescence 
 
2.3.1 Induction of Replicative Senescence 
Low passage IMR90 cells were initially thawed and cultured in normal 
growth medium (DMEM + 20% fetal bovine serum, 2 mM L-glutamine, 25 U/ml 
penicillin, 25 µg/ml streptomycin) under standard conditions (37° C, 5% CO2, 3% 
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O2). The cells were subjected to prolonged serial passage in culture under these 
conditions and counted at every split. Cumulative population doublings were 
calculated using the following equation ([log(number of cells counted) − log(number 
of cells plated)] / log(2)) and the resulting growth curves were plotted graphically. 
Once the growth curves began to exhibit a plateau, the cells were assayed routinely 
for markers of senescence (e.g., SA β-gal activity, decreased BrdU incorporation, 
p16INK4a induction, SAHF formation). The cells were considered replicative 
senescent when no proliferation was observed for a two week period following the 
final passage and the cells displayed the senescence hallmarks listed above. 
 
2.3.2 Induction of Oncogene-Induced Senescence 
Low passage IMR90 cells were initially thawed and cultured in normal 
growth medium (DMEM + 20% fetal bovine serum, 2 mM L-glutamine, 25 U/ml 
penicillin, 25 µg/ml streptomycin) under standard conditions (37° C, 5% CO2, 3% 
O2). Control (pBABE-puro) or H-RASG12V (pBABE-puro-H-RASG12V) 
retroviruses were produced following transfection of Phoenix-Ampho cells by 
standard procedures. IMR90 cells were subsequently infected with either control or 
H-RASG12V retroviruses and subjected to drug selection in normal growth medium 
supplemented with 1 µg/ml puromycin. The cells were maintained in culture under 
puromycin selection for the remainder of each experiment and passaged as 
necessary. Control and H-RASG12V-infected cells were typically harvested 12-14 
days after infection. The H-RASG12V-infected cells were considered senescent 
when no proliferation was observed and the cells displayed the senescence hallmarks 
(e.g., SA β-gal activity, decreased BrdU incorporation, p16INK4a induction, SAHF 
formation). 
 
2.3.3 Induction of Quiescence 
 Low passage IMR90 cells were initially thawed and cultured in normal 
growth medium (DMEM + 20% fetal bovine serum, 2 mM L-glutamine, 25 U/ml 
penicillin, 25 µg/ml streptomycin) under standard conditions (37° C, 5% CO2, 3% 
O2). Once the cells reached confluence, they were subjected to a 1:2 split in growth 
medium containing reduced serum (DMEM + 0.1% fetal bovine serum, 2 mM L-
glutamine, 25 U/ml penicillin, 25 µg/ml streptomycin). Seventy-two hours after 
splitting, the cells were harvested and assayed for hallmarks of proliferation arrest 
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and senescence. The cells were considered quiescent if they no longer proliferated, 
but also did not exhibit markers of senescence (e.g., SA β-gal activity, p16INK4a 
induction). 
 
2.4 Senescence Assays 
 
2.4.1 Senescence-Associated β-Galactosidase Assay 
Prior to the onset of senescence, cells were seeded onto sterile glass 
coverslips, allowed to adhere and transferred to 6-well tissue culture dishes. At the 
time of harvest, cells were rinsed once briefly with 1X PBS. The PBS was aspirated 
and the cells were covered with 2 ml of freshly prepared fixative solution (1X PBS 
containing 2% formaldehyde, 0.2% glutaraldehyde) and subjected to fixation for 5 
minutes at room temperature. The cells were washed twice with 1X PBS. After the 
second wash, the PBS was aspirated and cells were covered with 2 ml of freshly 
prepared staining solution (40mM Na2HPO4 pH 6, 150mM NaCl, 2mM MgCl2, 5mM 
K3Fe(CN)6, 5mM K4Fe(CN)6, 1mg/mL X-gal (in DMSO)) and incubated 12-16 
hours at 37° C in a non-CO2 incubator. Following incubation, the cells were washed 
twice with 1X PBS and twice with dH2O to remove residual salt. The coverslips 
were allowed to air dry at room temperature, mounted on glass microscope slides and 
visualized using conventional bright field microscopy. 
 
2.5 Gene Expression Analysis 
 
2.5.1 RNA Isolation 
Isolation of total RNA was performed using the RNeasy Mini Kit (Qiagen, 
74104). Working with 1-5 million IMR90 cells per 100 mm dish, the dishes were 
immediately transferred from the incubator to an ice tray. The growth medium was 
removed by aspiration and replaced with 10 ml of ice cold 1X PBS. The 1X PBS was 
removed and the cells were scraped into 350 µl Buffer RLT + 1% 2-mercaptoethanol 
and collected in 1.5 ml microcentrifuge tubes on ice. Now working at room 
temperature, the RLT lysates were sheared repeatedly with a pipette tip and 
transferred to QIAshredder spin columns (Qiagen, 79654). The columns were 
subjected to centrifugation for 2 minutes at 16,000 x g and room temperature. The 
QIAshredder columns were discarded, and 350 µl of 70% ethanol was added to each 
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lysate, mixed by pipetting and transferred to RNeasy spin columns. The columns 
were subjected to centrifugation for 15 seconds at 8,000 x g and room temperature. 
The flow-through was discarded, 350 µl of Buffer RW1 was added to each column 
and the columns were again subjected to centrifugation for 15 seconds at 8,000 x g. 
The flow-through was discarded, 80 µl of DNAse I mix (70 µl Buffer RDD + 10 µl 
DNAse I) was added to each column and the columns were incubated for 15 minutes 
at room temperature. After the incubation, 350 µl of Buffer RW1 was added to each 
column and the columns were subjected to centrifugation for 15 seconds at 8,000 x g. 
The flow-through was discarded and 500 µl of Buffer RPE was added to each 
column. The columns were subjected to centrifugation for 15 seconds at 8,000 x g, 
the flow-through was discarded and another 500 µl of Buffer RPE was added to each 
column. The columns were centrifuged for 2 minutes at 8,000 x g and then 
transferred into new 2 ml collection tubes. The columns were subjected to 
centrifugation for 1 minute at 16,000 x g and the columns were transferred into 1.5 
ml microcentrifuge tubes. Twenty-five µl RNAse-free dH2O was added to each 
column, incubated for 1 minute at room temperature and subjected to centrifugation 
for 1 minute at 8,000 x g in order to elute the RNA. RNA concentrations were 
determined for each sample using the NanoVue Plus spectrophotometer (GE 
Healthcare) and the RNA samples were stored in the -80° C freezer. 
 
2.5.2 Qualitative Assessment of RNA 
RNA integrity was evaluated using the RNA 6000 Nano Kit (Agilent) and the 
2100 Bioanalyzer (Agilent). First, the gel matrix was prepared by aliquotting 550 µl 
of the matrix into a supplied spin filter and centrifuging the filter for 10 minutes at 
1,500 x g and room temperature. Subsequently, the gel-dye mix was prepared by 
aliquotting 65 µl of the filtered gel matrix into a 1.5 ml microcentrifuge tube and 
mixing it with 1 µl of the RNA 6000 Nano dye concentrate. The gel-dye mix was 
vortexed thoroughly and subjected to centrifugation for 10 minutes at 13,000 x g and 
room temperature. 
To prepare the RNA samples, 1 µl of each sample was aliquotted into RNase-
free 0.2 ml PCR tubes, mixed with 9 µl RNase-free dH2O and kept on ice. The tubes 
were then placed into a thermal cycler and denatured for 2 minutes at 70° C to 
prevent the formation of secondary structure. The denatured RNA samples were then 
immediately placed on ice. 
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An RNA 6000 Nano chip was placed into the priming station and 9 µl of gel-
dye mix was dispensed into the appropriately marked well. The priming station 
syringe was then depressed, held in place for 30 seconds and released. Next, 9 µl of 
gel-dye mix was dispensed into the two additional appropriately marked wells. Five 
µl of the RNA 6000 Nano marker reagent was dispensed into the ladder well and 
each of the 12 sample wells. One µl of the supplied RNA 6000 Nano ladder was 
added to the indicated ladder well. For the denatured RNA samples, 1 µl of each 
sample was added to the indicated sample wells. The RNA 6000 Nano chip was 
placed into the foam adapter and vortexed for 1 minute on the 2400 rpm setting and 
then immediately run on the Agilent 2100 Bioanalyzer. Upon completion of the run, 
an RNA integrity number (RIN) was generated for each RNA sample and used to 
evaluate the quality of the samples.  
 
2.5.3 Affymetrix Microarray Analysis 
The Paterson Institute for Cancer Research Microarray Facility (Manchester, 
UK) conducted gene expression analysis of RS and OIS cells using Affymetrix 
Human Genome U133 Plus 2.0 GeneChIPs. Using 50 ng total RNA, the first and 
second strand cDNA synthesis steps were performed sequentially using the Ovation 
Pico WTA System (NuGEN Technologies, #3300). The resulting double-stranded 
cDNA was purified using Agencourt RNAClean beads (Beckman Coulter) and 
subjected to SPIA amplification to produce single-stranded cDNA complementary to 
the original RNA template. The resulting single-stranded cDNA was again purified 
using the Agencourt RNAClean beads. For each sample, 5 µg of purified, SPIA-
amplified, single-stranded cDNA was subjected to fragmentation and subsequent 
biotin labelling using the Encore Biotin Module kit (NuGEN Technologies, #4200). 
Hybridization cocktails were prepared by mixing 50 µl of biotin-labelled, 
single-stranded cDNA with a buffer containing 50 pM control oligonucleotide B2, 
1.5 pM bioB, 5 pM bioC, 25 pM bioD and 100 pM cre eukaryotic hybridization 
controls, 0.1 mg/ml herring sperm DNA, 0.5 mg/ml acetylated BSA, 1X 
hybridization buffer (100 mM MES, 1 M [Na+], 20 mM EDTA, 0.01% Tween-20) 
and 10% DMSO in a final volume of 220 µl. The hybridization cocktails were then 
heat denatured for 2 minutes at 99° C, incubated for 5 minutes at 45° C on a heat 
block and subjected to centrifugation for 5 minutes at 16,000 x g. 
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Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were filled with 
1X hybridization buffer and pre-incubated for 10 minutes in a 45° C rotating 
hybridization oven. The pre-hybridization buffer was removed from the arrays, 
replaced with 200 µl of the denatured cDNA hybridization cocktails and hybridized 
for 16 hours at 45° C in the hybridization oven. The arrays were then washed and 
stained with streptavidin phycoerythrin (SAPE) and a biotinylated anti-streptavidin 
antibody on the Affymetrix GeneChip Fluidics Station. After an additional washing 
procedure, the hybridized and stained arrays were scanned with the Affymetrix 
GeneChip Scanner 3000 and the images managed with the GeneChip Operating 
Software (GCOS). 
 
2.5.4 Microarray Data Analysis  
Tony McBryan, our laboratory computational biologist, performed the 
microarray data processing and analysis. The raw data files (.CEL files) for each 
Affymetrix GeneChip were imported into the R software application and analyzed 
using the Bioconductor packages (http://www.bioconductor.org). All samples were 
subjected to background correction and normalization using the GC Robust Multi-
array Average (GCRMA) method. Differential expression was determined by 
performing T-tests based on the log-normalized values produced by the GCRMA 
method. Genes were considered differentially expressed if the fold difference 
between the control (i.e., proliferating) and experimental (i.e., senescent) groups 
exceeded 1.5 fold (or less than -1.5 fold) and exhibited a Benjamini–Hochberg false 
discovery rate (BH-FDR) adjusted p-value less than 0.05. BH-FDR is an error 
control method for multiple testing procedures first proposed by Benjamini and 
Hochberg that involves the ordered ranking of each comparison in a dataset by its 
unadjusted p-value in order to calculate the likelihood of any statistically significant 
change being a false positive (i.e., the false discovery rate) (Benjamini & Hochberg, 
1995). In this manner, the BH-FDR method provides a more statistically stringent 
and conservative method for evaluating differential gene expression data. 
Gene Set Enrichment Analysis (GSEA; www.broad.mit.edu\gsea) was 
applied to the microarray datasets in order to identify altered pathways and functions. 
Probes from the Affymetrix microarrays were collated into individual gene features 
and arranged by signal to noise ratios into a rank-ordered list (L). For each gene set 
(S), an enrichment score (ES) derived from the Kolmogorov-Smirnov statistic and 
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reflecting the degree to which the gene set was overrepresented at either the top or 
bottom of the entire ranked list (L) and was calculated. The statistical significance 
(nominal p-value) of the ES was determined by empirical phenotype-based 
permutation analysis. Significance levels of the ES were subsequently adjusted to 
account for multiple hypotheses testing, initially by normalizing the ES for each gene 
set to account for the size of the set (NES) and then by controlling the proportion of 
false positives by calculating the FDR for each NES. The respective gene sets were 
obtained from the Broad Institute Molecular Signatures Database. 
The microarray data were also evaluated to identify affected pathways and 
functions using Ingenuity Pathway Analysis (IPA, www.ingenuity.com). Previously 
determined lists of differentially expressed genes were compiled in a standard (.txt) 
file format and uploaded to the IPA application using the Core Analysis feature. 
Based on the input datasets, IPA subsequently generated lists of biological functions 
and canonical pathways that were affected in a statistically significant manner. 
Statistical significance was calculated for each function/pathway using the right-
tailed Fisher‘s Exact Test, by considering the following parameters: the number of 
genes included in the specific IPA function/pathway, the total number of 
function/pathway eligible genes annotated in IPA and the total number of genes in 
the input dataset. 
 
2.6 Protein Analysis 
 
2.6.1 Protein Isolation 
Working with 100 mm tissue culture dishes of adherent cells, the growth 
medium was aspirated and the cells were washed once with 10 ml of 1X PBS at 
room temperature. The PBS was aspirated completely and 300-500 µl of freshly 
boiled 1X sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.1 M 
DTT, 0.01% bromophenol blue) was added to each plate. Using a plastic cell scraper, 
the cells were collected in the 1X sample buffer and the contents of the plate 
transferred to 1.5 ml microcentrifuge tubes. The lysates were boiled for 4 minutes 
and homogenized by vigorous vortexing. Lysates were subjected to centrifugation 
for 5 minutes at 12,000 x g and room temperature, transferred to new 1.5 ml 
microcentrifuge tubes and snap frozen in a dry ice/ethanol bath. The lysates were 
transferred to the -80° C freezer for long-term storage. 
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2.6.2 Protein Quantification 
The protein concentrations of lysates prepared in 1X sample buffer were 
determined using the Bradford method. To each of three 1.5 ml microcentrifuge 
tubes 0, 5 or 10 µl of 1 mg/ml BSA was aliquotted and mixed with 1 µl 1X sample 
buffer. In a separate set of 1.5 ml microcentrifuge tubes, 1 µl of each lysate was 
aliquotted. To each BSA standard and lysate sample, 700 µl 1X Bradford reagent 
(BioRad) was added and mixed by pipetting. Each sample was transferred to a 
disposable plastic cuvette and the absorbance at 595 nm was determined using a 
spectrophotometer. The values for the BSA standards were utilized to construct a 
standard curve and the protein concentrations of the respective lysates determined by 
extrapolating from the curve. 
 
2.6.3 Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Glass electrophoresis plates were washed thoroughly with water, rinsed with 
100% ethanol and allowed to dry. The glass plates were then assembled and placed 
into the gel casting apparatus. Separating gels of appropriate acrylamide composition 
were prepared according to the recipes contained in Table 2.1. The separating gels 
were poured into the assembled plates and a layer of water-saturated butanol was 
applied to the top of the gel. Following gel polymerization, the butanol layer was 
decanted and the top of the gel washed repeatedly with water to remove residual 
butanol and unpolymerized acrylamide. Stacking gels were prepared according to the 
following recipe: 6.34 ml H2O, 2.5 ml 4X Upper Tris pH 6.8, 1.3 ml 30% 
Acryl/0.8% MBA, 100 µl 10% APS, 10 µl TEMED. The stacking gels were poured 
above the separating gels, gel combs were inserted and the gels were allowed to 
polymerize. Prepared gels were then placed into the electrophoresis apparatus and 
the tanks were filled with 1X SDS-PAGE running buffer (25 mM Tris, 192 mM 
glycine, 0.1% SDS, pH 8.3). The gel combs were carefully removed and each well 
flushed repeatedly with running buffer in order to remove unpolymerized 
acrylamide. 
 When the gels were ready, protein lysates previously prepared in 1X sample 
buffer were subjected to boiling for 4 minutes and collected by brief centrifugation. 
The boiled protein lysates were loaded into the gels and separated by the application 
of a constant electric current. Total electrophoresis time varied according to the 
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acrylamide composition of the gels and the molecular weights of the intended protein 
targets. 
 
2.6.4 Immobilization of Protein 
Following the completion of SDS-PAGE, the fractionated proteins were 
immobilized to polyvinylidene fluoride (PVDF) membranes. To prepare the PVDF 
for electrophoretic transfer, the membranes were placed into 100% ethanol for 
approximately 30 seconds, rinsed with dH2O and equilibrated in cold 1X SDS-PAGE 
transfer buffer (25 mM Tris, 192 mM Glycine, 0.01% SDS, 20% methanol). The 
SDS-PAGE electrophoresis apparatus was disassembled and transfer cassettes were 
assembled in the following order: (1) foam pad, (2) Whatman paper equilibrated in 
transfer buffer, (3) SDS-PAGE gel, (4) PVDF equilibrated in transfer buffer, (5) 
Whatman paper equilibrated in transfer buffer, (6) foam pad. The assembled 
cassettes were placed into the transfer apparatus containing 1X SDS-PAGE transfer 
buffer and immobilized to PVDF through the application of constant electric current. 
After the transfer was complete, the cassettes were disassembled and the PVDF 
membranes were allowed to dry at room temperature. 
 
2.6.5 Western Blotting 
Following protein fractionation by SDS-PAGE and immobilization to PVDF, 
the membranes were immersed in 100% ethanol and subjected to gentle agitation for 
30 seconds. The ethanol was removed and the membranes were washed several times 
in TBS with gentle agitation. The membranes were blocked with TBS + 5% non-fat 
dry milk for 1 hour at room temperature and then washed briefly in TBS + 4% BSA 
+ 0.02% NaN3. Membranes were then incubated with primary antibodies typically 
diluted to 0.1-1 µg/ml in TBS + 4% BSA + 0.02% NaN3 for either 1 hour at room 
temperature or overnight at 4° C, depending on the manufacturer’s instructions. A 
list of the antibodies used in this study is included in Table 2.2. The membranes were 
washed three times for 15 minutes each in TBS + 0.05% Tween 20. Membranes were 
incubated with horseradish peroxidase-coupled secondary antibodies diluted in TBS 
+ 4% BSA + 0.02% NaN3 according to the manufacturer’s instructions for 1 hour at 
room temperature. The membranes were washed three times for 15 minutes each in 
TBS + 0.05% Tween 20. Membranes were transferred to a 1:1 solution of ECL Plus 
Western blotting substrate (Pierce), developed for 1 minute with gentle agitation and 
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dried quickly between blotting paper. The membranes were covered with plastic 
wrap, exposed to film for appropriate time intervals and the films developed. 
 
2.7 Chromatin Analysis 
 
2.7.1 Chromatin Immunoprecipitation 
Proliferating and replicative senescent IMR90 cells were cultured as 
described previously. For chromatin immunoprecipitation, cells were cultured to 
approximately 95% confluence in 100 mm cell culture dishes containing 10 ml 
growth medium. This corresponds to approximately 4-5 million proliferating cells or 
1-2 x million senescent cells per 100 mm culture dish. Cells were subjected to cross-
linking in the presence of 1% formaldehyde by the addition of 271 µl of 37% 
formaldehyde (Sigma) to 10 ml of growth medium. Cross-linking was conducted for 
10 minutes at room temperature, with gentle agitation on a rocking platform. The 
cross-linking reaction was quenched for 5 minutes at room temperature by the 
addition of 500 µl 2.5 M glycine to a final concentration of 125 mM. Cells were 
detached from the culture dishes using plastic cell scrapers and collected in 50 ml 
centrifuge tubes kept on ice. Cells were subjected to centrifugation for 5 minutes at 
200 x g and 4° C. The supernatant was removed by aspiration, the cell pellets were 
washed with cold 1X PBS and subjected to centrifugation for an additional 5 minutes 
at 200 x g and 4° C. The supernatant was removed by aspiration, cell pellets were 
snap frozen with dry ice and ethanol and stored at -80° C.  
Frozen pellets comprised of approximately 10 million cross-linked 
proliferating or senescent IMR90 cells were resuspended with 1 ml cold (1:1) 
modified nuclear lysis buffer (mNLB):IP dilution buffer (IPDB) (35 mM Tris-HCl 
pH 8.0, 75 mM NaCl, 5.5 mM EDTA pH 8.0, 3 mM EGTA pH 8.0, 0.5% SDS, 0.5% 
Triton X-100) supplemented with inhibitors (10 µg/ml aprotinin, 5 µg/ml leupeptin 
and 50 µg/ml PMSF) and incubated on ice for 10 minutes. The cells were subjected 
to centrifugation for 5 minutes at 200 x g and 4° C. The supernatant was removed by 
careful aspiration and the cell pellets were resuspended with 0.5 ml cold (1:1) 
mNLB:IPD and inhibitors. Cell suspensions were transferred to 2 ml centrifuge tubes 
(Eppendorf) on ice and subjected to sonication in a Bioruptor XL water bath 
sonicator (Diagenode). Cells were sonicated at the highest amplitude setting for 22.5 
minutes, with cycles of 24 seconds on/24 seconds off. 
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Each 2 ml tube of sonicated chromatin was subjected to centrifugation for 5 
minutes at 12,000 x g and 4° C. The supernatants were collected, transferred to fresh 
1.5 ml microcentrifuge tubes and subjected an additional round of centrifugation for 
5 minutes at 12,000 x g and 4° C. The supernatants were collected, identical 
chromatin samples pooled in 15 ml centrifuge tubes and stored on ice. Aliquots were 
taken from the chromatin samples and used to determine the protein and DNA 
concentrations, respectively. Protein concentrations were determined using the 
Bradford assay, while DNA concentrations were determined using the Qubit dsDNA 
HS Assay Kit and a Qubit fluorometer (Life Technologies). Depending on the 
experiment, the respective chromatin solutions were diluted to either equal protein 
concentrations or equal DNA concentrations with (1:1) mNLB:IPDB + inhibitors. 
The chromatin solutions were then diluted with IPDB to a final mNLB:IPDB ratio of 
1:10 and kept on ice.  
The appropriate ChIP antibodies were pre-bound to Dynabeads M-280 Sheep 
anti-Rabbit IgG magnetic beads (Life Technologies) as follows. For each ChIP 
reaction, 100 µl of Dynabeads was aliquotted into a 1.5 ml microcentrifuge tube. The 
beads were washed 3 times with 1X PBS + 0.5% BSA using a magnetic rack. After 
the final wash, the beads were resuspended with 0.5 ml 1X PBS + 0.5% BSA. In 
order to facilitate the formation of antibody-bead complexes, 6 µg of primary 
antibody was added to each tube of Dynabeads and the tubes were incubated for 6 
hours at 4° C, on a rotating wheel. Following the incubation, the antibody-bead 
complexes were washed 3X with ice-cold IPDB using the magnetic rack. During the 
final wash, the IPDB was aspirated completely and the antibody-bead complexes 
were combined with the appropriate diluted chromatin solutions. After combining 
the chromatin and antibody-bead complexes, the reactions were incubated overnight 
(12-16 hours) at 4° C, on a rotating wheel.  
Following the overnight incubation, the beads were kept on ice and washed 
with the following ice-cold buffers: 2X with IPDB, 1X with High Salt Wash Buffer 
(20 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-
100), 1X with LiCl Wash Buffer (10 mM Tris-HCl pH 8.1, 250 mM LiCl, 1 mM 
EDTA, 1% NP-40, 1% deoxycholic acid) and 2X with TE (10 mM Tris-HCl pH 8.0, 
1 mM EDTA). After the last wash, the beads were aspirated to dryness, resuspended 
in 500 µl IP Elution Buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM EDTA 
pH 8.0, 1% SDS) and added 0.5 µl 100 mg/ml RNase A and incubated at 65° C for 
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4-6 hours. To each tube, 6 µl 20 mg/ml proteinase K was added and the tubes were 
incubated at 45° C for 12 hours. The ChIP DNA was subsequently purified by 
phenol/chloroform extraction followed by ethanol precipitation, resuspended with 20 
µl nuclease-free dH2O and quantified using the Qubit dsDNA HS Assay Kit and a 
Qubit fluorometer (Life Technologies). 
 
2.7.2 Preparation of ChIP-Seq Libraries 
ChIP-Seq libraries were generated using the NEBNext® ChIP-Seq Sample 
Prep Master Mix Set 1 (New England Biolabs, E6240S) as follows. End Repair: 10 
ng ChIP or input DNA (in a 44 µl volume) was mixed the DNA with 5 µl NEBNext 
End Repair Reaction Buffer and 1 µl NEBNext End Repair Enzyme Mix in a PCR 
tube and incubated for 30 minutes at 20° C in a thermal cycler. The end-repaired 
DNA was purified using the QIAquick PCR Purification Kit (Qiagen, 28104) and 
eluted in 44 µl dH2O. dA-Tailing of End-Repaired DNA: 44 µl end-repaired DNA 
was mixed with 5 µl NEBNext dA-Tailing Reaction Buffer (10X) and 1 µl Klenow 
Fragment in a PCR tube and incubated at 37° C for 30 minutes in a thermal cycler. 
The dA-tailed DNA was purified using the MinElute PCR Purification Kit (Qiagen, 
28004) and eluted in 20 µl dH2O. Adaptor Ligation of dA-Tailed DNA: 19 µl dA-
tailed DNA was mixed with 6 µl Quick Ligation Reaction Buffer (5X), 1 µl 1.5 µM 
DNA Adaptors and 4 µl Quick T4 DNA Ligase in a PCR tube and incubated at 20° C 
for 15 minutes in a thermal cycler. The adaptor-ligated DNA was purified using the 
MinElute PCR Purification Kit (Qiagen, 28004) and eluted in 10 µl dH2O. 
 The purified adaptor-ligated DNA samples were subsequently fractionated on 
2% regular melting point agarose TAE gels containing 1 µg/ml ethidium bromide. 
The samples were oriented with empty wells between them so as to avoid cross-
contamination between wells. The gels were subjected to electrophoresis for 1 hour 
45 minutes at 60 volts, constant voltage. Using fresh scalpels for each sample, bands 
corresponding to 225 to 275 base pairs were excised and placed into sterile 1.5 ml 
microcentrifuge tubes. The gels were photographed before and after excision, to 
ensure uniform size selection occurred for all of the samples. The excised gel 
fragments were weighed, purified using the QIAquick Gel Extraction Kit (Qiagen, 
28704) and eluted in 37 µl dH2O. It is important to note that the gel digestion step of 
the gel extraction protocol was performed at room temperature as opposed to the 
recommended 65° C. 
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The purified size-selected, adaptor-ligated DNA was then subjected to PCR 
amplification: 36 µl size selected, adaptor-ligated was mixed with 10 µl 5X Phusion 
HF Buffer, 1.5 µl dNTP Mix, 0.9 µl Primer 1 (25 µM stock), 0.9 µl Primer 2 (25 µM 
stock), 0.5 µl Phusion High-Fidelity DNA Polymerase and 0.1 µl nuclease-free 
dH2O in a PCR tube. The samples were PCR amplified using the following cycling 
parameters: initial denaturation at 98° C for 30 seconds; 18 cycles of denaturation at 
98° C for 10 seconds, annealing at 65° C for 30 seconds, extension at 72° C for 30 
seconds; and final extension at 72° C for 5 minutes. The PCR-amplified, size-
selected, adaptor ligated DNA was then purified using the MinElute PCR 
Purification Kit (Qiagen, 28004) and eluted in 16 µl dH2O. The ChIP-Seq libraries 
were quantified using the Qubit dsDNA HS Assay Kit and a Qubit fluorometer (Life 
Technologies). 
 
2.7.3 Qualitative Assessment of ChIP-Seq Libraries 
The ChIP-Seq libraries were evaluated using the DNA 1000 Assay (Agilent) 
and the 2100 Bioanalyzer (Agilent). The gel-dye mix was prepared by combining 25 
µl of DNA dye concentrate with an entire DNA gel matrix vial. The gel-dye mix was 
vortexed, transferred to a supplied spin filter and subjected to centrifugation for 15 
minutes at 2240 x g. A DNA 1000 Assay chip was placed into the priming station 
and 9 µl of gel-dye mix was dispensed into the appropriately marked well. The 
priming station syringe was depressed, held in place for 60 seconds and then 
released. Nine µl of gel-dye mix was dispensed into the two additional marked wells 
of the chip. Five µl of the assay marker reagent was dispensed into the ladder well 
and each of the 12 sample wells of the chip. One µl of the supplied DNA ladder was 
added to the indicated well. For the ChIP-Seq library samples, 1 µl of each library 
was added to an appropriately indicated sample well. The DNA 1000 chip was 
placed into the foam adapter and vortexed for 1 minute on the 2400 rpm setting and 
then immediately run on the Agilent 2100 Bioanalyzer. The resulting 




Billy Clark, from the Beatson Institute for Cancer Research Molecular 
Technology Services department, performed the sequencing. The ChIP libraries were 
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diluted to 2 nM stocks with nuclease-free dH2O. The libraries were then denatured 
with 0.1 N NaOH and diluted to 5 pM stocks. The denatured and diluted libraries 
were hybridized to Illumina flowcells using the TruSeq SR Cluster v2–cBot-GA kit 
(Illumina) on the Illumina cBot cluster generation instrument. Following cluster 
generation, the flowcells were inserted into the Illumina Genome Analyzer IIx 
sequencer and subjected to single-read sequencing using the TruSeq SBS Kit v5-GA 
kit (Illumina). 
 
2.7.5 ChIP-Seq Data Analysis 
Tony McBryan, our laboratory computational biologist, performed the ChIP-
Seq data processing and analysis as follows. Raw intensity files obtained from the 
Illumina GAIIx were converted into the standard textual FASTQ format using the 
Consensus Assessment of Sequence and Variation (CASAVA) version 1.8.2 
software. The default settings were used except for the FASTQ-cluster-count 
parameter, which was set to 500 million (far in excess of the GAIIx capacity) such 
that all reported clusters were retained within a single FASTQ file. The FASTQ files 
were subsequently inspected for quality using FastQC version 0.10.0 (Babraham 
Bioinformatics). FastQC provides basic statistics, per base and per sequence quality 
scores and additional metrics such as per base GC content, N counts, length 
distribution, estimated duplication levels and over-represented sequences. 
 The FASTQ files were subsequently aligned to the human genome (assembly 
hg18, NCBI Build 36) using Bowtie version 0.12.9 (Langmead et al., 2009). The 
following settings were used: chunkmbs 512 to provide additional memory for 
backtracking of difficult to map reads; m 1 to limit the reported alignments to reads 
which map uniquely to the genome; phread33-quals for input quality scores in 
FASTQ files compatible with CASAVA 1.8; p 8 to enable the processor to use 
additional CPU cores for alignment; best to guarantee that the reported reads were 
the best possible alignments in terms of the number of mismatches and quality values 
at mismatched positions. 
 For the purpose of visualization, reads were extended to account for the fact 
that the estimated ChIP DNA fragment size (150 bp) was larger than the sequenced 
reads. Duplicate reads containing identical start and end positions were removed as 
potential PCR artifacts. The genome-wide distributions of the input and ChIP reads 
were generated in bigWig format representing the number of detected fragments at a 
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given location normalized by the library size and visualized using the UCSC 
Genome Browser (Kent et al., 2002). 
 SICER version 1.1 was utilized in order to identify enriched regions within 
the H4K20me3 ChIP samples relative to the total histone H4 ChIP samples. SICER 
is particularly designed to identify enriched domains of histone modifications under 
contexts in which such domains might be diffuse (Zang et al., 2009). SICER 
specifically identifies clusters of signal unlikely to occur by chance by comparison to 
an idealized Poisson distribution. Briefly, reads were shifted by 75 bp from the 5' 
start to represent the center of the DNA fragment that was sequenced. The genome 
was then divided into non-overlapping windows of 200 bp. For each window, the 
number of reads mapped to the window was counted and a score was assigned as the 
negative log probability of detecting that number of reads within the window. 
Candidate islands were defined as a contiguous series of windows with a score 
greater than or equal to a threshold determined by the Poisson distribution. Candidate 
islands were compared to the control sample using an FDR criterion (FDR ≤ 0.01). 
 Domains of differential H4K20me3 enrichment between the proliferating 
(PD32) and senescent (PD86) samples were identified using the DiffBind (version 
1.2.0) Bioconductor package. Each SICER-identified region within each PD32 and 
PD86 sample was Trimmed Mean of M-values (TMM) normalized and scored for 
each sample as H4K20me3 ChIP read counts minus histone H4 ChIP read counts 
(after normalization) (Robinson & Oshlack, 2010). Specifically, the 
DBA_SCORE_TMM_MINUS_FULL scoring scheme was utilized. Four samples 
were used (two PD32 replicates and two PD86 replicates). Regions were only 
analyzed if they were present in at least two of the four samples, as identified by 
SICER. As with UCSC and SICER, insert lengths were again extended to 150 bp to 
account for DNA fragment size. Identified regions of differential H4K20me3 
enrichment between the PD32 and PD86 samples were extracted (FDR ≤ 0.1) and 
used in subsequent downstream analyses. Iranges (version 1.14.4) and 
GenomicRanges (version 1.8.7) were used as dependencies. 
Clustering analysis was performed using the R statistics environment (version 
2.15.1). Regions of differential H4K20me3 enrichment between the PD32 and PD86 
samples were overlapped with the coordinates of defined genomic features and 
assigned positive (1) or negative (0) values for either presence or absence of overlap. 
A matrix of the overlaps was loaded into the R environment, clustered using the 
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hclust function within the fastcluster package (version 1.1.6) and visualized using the 
heatmap.2 function from the gplots package (version 2.11.0). 
 In order to evaluate whether the PD86-specific H4K20me3 enrichment 
correlated with changes in gene expression, a scatterplot was generated to display the 
Affymetrix fold change of a gene (x-axis) plotted against the H4K20me3 ChIP 
difference (y-axis) within the promoter (5 kb upstream, 1 kb downstream) region of 
the gene. The Affymetrix NetAffx annotation (version 29) was used to annotate each 
probeset from the replicative senescence Affymetrix Human Genome U133 Plus 2.0 
array and to assign it to an Ensembl gene identifier. Any probesets targeting multiple 
Ensembl genes were discarded. Ensembl genes containing multiple probesets were 
assigned a fold change equal to the geometric average of valid probesets. H4K20me3 
ChIP signal was determined by measuring the number of reads (extended to 150 bp) 
within the promoter region of each gene normalized by the library size, with the 
histone H4 reads subtracted after similar normalization. ChIP difference was defined 
as the senescent (PD86) ChIP signal minus the proliferating (PD32) ChIP signal. 
In order to visualize H4K20me3 distribution upstream, downstream and 
within gene bodies, composite gene profiles were assembled. To generate composite 
gene profiles, the Ensembl gene annotation (version 54) was used to identify gene 
transcription start (TSS) and termination (TES) sites for each of the Ensembl genes 
in the replicative senescence microarray dataset. For each gene, the area between the 
TSS and TES was defined as the gene body and divided into forty windows of equal 
size (each corresponding to 2.5% of the total gene body). Ten additional 500 bp 
windows were added in front of the TSS or after the TES of the gene in order to 
provide genomic context. For each site within the composite gene (e.g., 0-2.5%, 2.5-
5%, etc), the H4K20me3 ChIP signal was calculated for each gene as previously 
described. The mean H4K20me3 ChIP signal was then plotted for subsets of genes 
(e.g., upregulated, downregulated or unchanged). Upregulated and downregulated 
genes were defined as genes for which at least one probeset changed 1.5-fold or 
greater in the appropriate direction and exhibited a BH-FDR value of less than or 
equal to 0.05. Unchanged genes were defined as the genes for which every probeset 
for that gene exhibited a BH-FDR greater than or equal to 0.9. ZNF genes were 
defined by their inclusion on the Zinc finger gene list available from HGNC 
(http://www.genenames.org/genefamily/znf.php), including a wildcard for ZNF* 
pattern genes. 
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Statistical analysis of the overlap between H4K20me3 ChIP enrichment (as 
defined by SICER) and defined genomic features (e.g. ZNF genes, non-ZNF genes, 
DNA repeats) was performed as follows. The genomic coordinates of H4K20me3 
ChIP enriched regions and specific genes/features were compared and the number of 
basepairs that were present in both datasets expressed as a percentage of the total 
number of gene basepairs occupied by H4K20me3. For example, for a given set of 
genes, a figure of 10% would indicate that an H4K20me3 enriched region 
overlapped 10% of all basepairs contained within that set of genes. A random 
overlap percentage was also computed, which is the result of random distribution of 
the gene set across the genome and the calculation of the overlap between this 
random gene set and the ChIP enriched signal. The random distribution was carried 
out 1000 times and the average overlap was used. P-values were also calculated by 
observing the frequency that a random overlap was greater than or equal to the true 
overlap. All p-values were below the detectable level using 1000 iterations (p < 
0.001). 
 
2.8. Immunological Methods 
 
2.8.1. Immunofluorescence  
Proliferating and presenescent IMR90 cells were seeded onto sterile glass 
coverslips, allowed to adhere and transferred to 6-well tissue culture dishes. The cells 
were washed twice with 1X PBS. The PBS was aspirated, the cells were covered 
with 2 ml freshly prepared 4% paraformaldehyde in 1X PBS and subjected to 
fixation for 10 minutes at room temperature. The coverslips were washed twice with 
1X PBS. The PBS was aspirated and the cells were permeabilized for 2 minutes by 
the addition of 2 ml of 0.2% Triton X-100 in 1X PBS to each well. The coverslips 
were washed 3 times with 1X PBS. The PBS was aspirated, the cells were covered 
with 2 ml 1X PBS with 3% BSA, 1% goat serum and incubated for 1 hour at room 
temperature to block. After blocking, the coverslips were inverted cell-containing 
side down onto 100 µl drops of primary antibody diluted in 1X PBS containing 3% 
BSA and 1% goat serum and incubated for 1 hour at room temperature. In most 
cases, the primary antibodies were used within a concentration range of 0.1-10 
µg/ml. A list of the antibodies used in this study is included in Table 2.2. Following 
the incubation, the coverslips were transferred back into 6-well plates containing 1X 
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PBS + 1% Triton X-100 and washed 3 x 5 minutes at RT. After the last wash, the 
coverslips were incubated for 1 hour at room temperature with either Alexa Fluor® 
488 F(ab')2 Fragment of Goat Anti-Mouse IgG (H+L) or Alexa Fluor® 594 Donkey 
Anti-Rabbit IgG (H+L) (Life Technologies) secondary antibodies diluted 1:5000 in 
1X PBS + 3% BSA, 1% goat serum. The coverslips were kept in the dark from this 
point. After the secondary antibody incubation, the coverslips were washed 3 x 5 
minutes with 1X PBS. The 1X PBS was aspirated and replaced with 1X PBS + 0.1 
µg/ml 4',6-diamidino-2-phenylindole (DAPI) for 5 minutes. The coverslips were then 
washed 3 x 5 minutes with 1X PBS, mounted onto glass microscope slides with 
ProLong Gold Antifade mounting medium (Life Technologies), sealed with clear 
fingernail polish and stored at 4° C, in the dark. 
 
2.8.2 Epifluorescence Microscopy and Imaging 
 Immunofluorescence slides were viewed using a Nikon Eclipse 80i 
epifluorescence microscope. Microscopic images were captured using a Hamamatsu 
ORCA-ER digital camera, controlled by the MetaMorph Microscopy Automation 
and Image Analysis Software (Molecular Devices). To enable accurate comparison 
between samples, all images from a given experiment were captured using identical 
exposure settings. 
 
2.8.3 MODified Histone Peptide Array 
 H4K20me3 antibody specificity was evaluated using the MODified Histone 
Peptide Array (Active Motif, 13005) as follows. Individual peptide arrays were 
immersed in 3 ml Blocking Solution (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 
0.05% Tween 20, 5% non-fat milk) and incubated for 1 hour at room temperature on 
a rocking platform. The Blocking Solution was removed and the arrays were rinsed 
briefly and then washed 3 x 5 minutes with TTBS Buffer (10 mM Tris-HCl pH 7.4, 
150 mM NaCl, 0.05% Tween 20) at room temperature. After the last wash, the TTBS 
was removed and each array was incubated with a different primary H4K20me3 
antibody diluted 1:2000 in Blocking Solution. The arrays were incubated with the 
H4K20me3 antibodies for 1 hour at room temperature, on a rocking platform. Each 
array was rinsed briefly and then washed 3 x 5 minutes with TTBS Buffer at room 
temperature. Following the last wash, the arrays were incubated with anti-rabbit-
HRP (Cell Signaling Technology, 7074) diluted 1:2500 in 3 ml Blocking Solution 
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for 1 hour at room temperature, on a rocking platform. Each array was rinsed briefly 
and then washed 3 x 5 minutes with TTBS Buffer at room temperature. The arrays 
were developed for 1 minute at room temperature with ECL Plus Western Blotting 
Substrate (Pierce) and exposed to film (Kodak). 
 The resulting autoradiographic films were scanned with a conventional flatbed 
scanner and saved as TIFF files. The scanned images were then aligned to a 
reference grid to identify individual peptide spots using the Array Analyse software 
(Active Motif). Spot intensities for the individual peptides were determined and used 
to generate a specificity factor for each H4K20me3 antibody. The specificity factor 
is a calculated ratio of the average intensity of all spots that contain a specific 
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Chapter 3. Establishing Model Systems of Cell Senescence 
 
3.1 Rationale 
Cell senescence provides a potent mechanism of tumor suppression and is 
mediated through a specific program that entails the establishment of a stable 
proliferation arrest and altered secretory phenotype. The induction and maintenance 
of senescence is concurrently accompanied by profound changes to chromatin 
structure and regulation. Despite considerable progress in the senescence field, it is 
not definitively known how the extensive chromatin remodeling might facilitate the 
various features of the senescence program. In order to interrogate the putative 
relationship between chromatin structure and the senescence program, it was first 
important to develop and validate relevant model systems. In this manner, I set out to 
establish multiple in vitro models of cell senescence in order to determine how 
changes in chromatin structure could promote proliferation arrest and other aspects 
of the senescence program. More specifically, I sought to define a molecular and 
transcriptional profile of cell senescence that could be used as a framework to 




3.2.1 Establishing Experimental Models of Cell Senescence 
The ability to investigate a cellular state as complex as senescence is largely 
contingent upon the successful establishment and implementation of a robust model 
system. Therefore, in order for any senescence model system to provide maximum 
insight, it must be able to withstand experimental manipulation and respond in a 
reproducible manner. In addition, because the senescence program is such a 
complicated biological phenomenon, the utilization of multiple senescence models 
can lend an added level of confidence and specificity to a given observation. For this 
reason, models of both replicative senescence and oncogene-induced senescence 
were selected for use in studies to examine the contribution of chromatin structure to 
the regulation of the senescence program. 
Primary human diploid fibroblasts (HDFs) are a commonly employed cell 
type used in the mechanistic investigation of cell senescence. More specifically, 
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IMR90 cells, a thoroughly characterized HDF strain isolated from fetal lung has been 
utilized for nearly 30 years in the study of replicative lifespan and senescence 
(Nichols et al., 1977). As such, IMR90 cells were selected as an appropriate cell line 
for use as a model of replicative senescence. To facilitate replicative senescence, 
young IMR90 cells were subjected to serial passage in culture and maintained in a 
low (3%) oxygen incubator. To minimize stress, the cells were kept between 30 and 
95% confluence at all times and removed from low oxygen conditions for only the 
minimal amount of time required for sub-culturing. At each passage the cells were 
counted, cumulative population doubling values calculated and then plotted 
graphically (Figure 3.1a). The cells were assayed for features of replicative 
senescence once the population doubling time exceeded 14 days. 
To confirm senescence, whole cell extracts were prepared from proliferating 
(PD30) and replicative senescent (PD88) IMR90 cells, fractionated by SDS-PAGE 
and transferred to PVDF membranes for subsequent Western blot analysis. The 
membranes were then blotted to assess expression of several markers of cell 
proliferation and the senescence program. While lamin A/C expression appeared 
unaffected in the PD88 cells, a marked reduction of lamin B1 levels was observed 
(Figure 3.1b). Likewise, cyclin A was largely depleted from the PD88 cells, 
indicating that the cells had undergone cell cycle exit. Consistent with the PD88 cells 
being senescent, a robust induction of p16INK4a was noted, along with induction of 
another inhibitor of cell cycle progression, p21WAF1. As a loading control, GAPDH 
levels remained relatively consistent between the PD30 and PD88 lysates. 
 Detection of increased β-galactosidase activity is commonly utilized as an 
important diagnostic assay to distinguish senescent cells from other cellular states. 
To evaluate the cells for β-galactosidase activity, PD30 and PD80 cells were 
subjected to fixation and incubated in a buffer containing the synthetic substrate 5-
bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal). Cells that contained 
lysosomal β-galactosidase activity were detected by the formation of a perinuclear 
blue precipitate. While fewer than 5% of the PD30 cells stained positively for β-
galactosidase, more than 95% of the PD88 cells exhibited visually detectable 
perinuclear β-galactosidase staining (Figure 3.1c). Bright field microscopy of the 
stained cells also revealed profound differences in cellular morphology between the 
PD30 and PD88 cells. Whereas, the PD30 cells exhibited a characteristic spindly 
fibroblast morphology, the PD88 cells had an enlarged, flattened shape, often 
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contained multiple nuclei per cell and possessed prominent vacuoles. The latter 
PD88 morphology is a commonly observed feature of replicative senescent IMR90 
cells. 
The combined growth curve data, Western blotting analyses, β-galactosidase 
staining and cellular morphology of the PD30 and PD88 IMR90 cells validated that 
the PD88 cells were truly senescent. In this manner, a seemingly uniform population 
of senescent cells was generated with relative technical ease. In fact, during multiple 
subsequent rounds of culturing IMR90 cells to replicative senescence under the same 
conditions, the cells reproducibly underwent senescence between 86 and 90 
cumulative population doublings. As such, this confirmed that the IMR90 replicative 
senescence model would provide a robust and predictable system with which to 
interrogate aspects of the senescence program. 
Constitutive oncogene activation is also capable of inducing senescence in 
normal primary human cells and can be exploited experimentally to provide an 
additional model of cell senescence. Although a variety of oncogenes can induce 
senescence, ectopic expression of a constitutively active mutant H-RAS allele (H-
RASG12V) is commonly utilized to confer senescence in HDFs (Serrano et al., 
1997). To accomplish this, early passage IMR90 cells were infected with either a 
control retrovirus or a retroviral construct directing the expression of H-RASG12V, 
subjected to drug selection and maintained in culture. Infection efficiency was 
controlled for using several approaches. First, the transfection efficiency of the 
Phoenix retroviral packaging cells was evaluated by transfecting a parallel plate with 
a GFP expression construct and scoring for GFP-positive cells. The transfection was 
considered successful as greater than 95% of the Phoenix cells exhibited GFP 
expression twenty-four hours after transfection. Second, 100% of the control and H-
RASG12V-infected IMR90 cells survived puromycin selection, whereas the drug 
killed 100% of cells from an uninfected plate of IMR90 cells. These criteria were 
applied to all subsequent retroviral infection experiments in order to confirm that a 
comparable if not identical viral multiplicity of infection (MOI) was attained for each 
experiment.  
Ten days after retroviral infection, the control and H-RASG12V-infected 
cells were harvested and assayed for key markers of cell proliferation and 
senescence. Whole cell extracts prepared from the control and H-RASG12V cells 
were fractionated by SDS-PAGE and immobilized to PVDF membranes. The PVDF 
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membranes were then Western blotted to confirm expression of ectopic H-RAS. As 
anticipated, the H-RASG12V-infected cells exhibited high levels of H-RAS (Figure 
3.2a). Western blot analysis of lamin A/C revealed a subtle decrease in the upper 
lamin A band in the H-RASG12V cells, while the lower lamin C band remained 
unaffected. Similar to replicative senescent cells, lamin B1 and cyclin A expression 
were both greatly reduced in the H-RASG12 cells. In addition, both p16INK4a and 
p21WAF1 were induced to high levels in the H-RASG12V cells but not in the 
control cells. As a control, GAPDH expression levels remained comparable in both 
the control and H-RASG12V cells. These data collectively suggested that whereas 
the control cells continued to proliferate, the H-RASG12V-infected cells had 
undergone H-RAS-induced cell cycle exit. 
Control and H-RASG12V-infected cells were also fixed and stained to detect 
β-galactosidase activity. Similar to normal early passage IMR90 cells, very few cells 
(< 5%) stained positive for β-galactosidase activity (Figure 3.2b). In contrast, the 
majority of the H-RASG12V-infected cells showed robust staining for β-
galactosidase activity. In addition, the H-RASG12V expressing cells exhibited 
several morphological hallmarks of senescent cells including a large flattened shape 
and prominent vacuole formation. Importantly, the observed change in morphology 
in the H-RASG12V cells was not simply a consequence of viral infection, as the 
majority of the control-infected cells retained a normal spindly fibroblast 
morphology. Taken together, the Western blotting data, β-galactosidase staining and 
altered morphology confirmed that the H-RASG12V-infected cells were senescent. 
The results also confirmed that retroviral mediated introduction of an activated H-
RAS allele into IMR90 cells could be utilized as a second and complimentary model 
to study senescence in vitro. 
Two defining features characterize the cell senescence program: the 
maintenance of a stable proliferation arrest and an altered secretory phenotype. 
Although these two hallmarks have been studied individually in considerable detail, 
it is important to recognize that cellular states other than senescence may often share 
either feature of the senescence program. For example, whereas both quiescent and 
terminally differentiated cells possess a phenotype defined by proliferation arrest, 
unlike senescence these cellular states typically do not involve p16INK4a induction 
and SA β-gal activity. Therefore, one of the key challenges of investigating cell 
senescence at the molecular level is to distinguish whether a given observation 
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represents a specific aspect of the senescence program, or is alternatively simply a 
consequence of cell cycle exit. In order to make this distinction, it is critical to 
determine whether a particular effect observed using models of cell senescence is 
unique to senescence, or whether it also occurs in the context of other non-
proliferative cellular states. To this end, the specificity of any putative senescence-
associated finding should first be validated using a model of quiescence. Although 
cell cycle arrest is a hallmark of both senescence and quiescence, the proliferation 
arrest associated with quiescence is by definition transient and can be reversed 
following exposure to sufficient mitogenic stimuli (Coller, Sang & Roberts, 2006). 
Experimentally, quiescent cells can be generated in culture by growing 
primary cells to high confluence in medium containing low serum content. To 
accomplish this, early passage IMR90 cells were seeded at approximately 90% 
confluence in medium containing only 0.1% FBS as opposed to the standard 20% 
FBS that is routinely used to culture IMR90 cells. Four days after seeding, whole cell 
extracts were prepared from the cells, subjected to fractionation by SDS-PAGE and 
immobilized to PVDF membranes for assessment of proliferation and senescence 
markers. Western blot analysis revealed that similar to senescent cells, quiescent 
cells maintain lamin A/C levels and exhibit a marked reduction of cyclin A 
expression (Figure 3.3a). The overall depletion of cyclin A confirmed that very few 
cells, if any within the quiescent population were actively progressing through S 
phase and therefore no longer proliferating. However, in contrast to senescent cells, 
no decrease of lamin B1 expression was observed in the quiescent cells. Also 
contrary to senescent cells, no induction of the cell cycle inhibitors p16INK4a and 
p21WAF1 was observed in the quiescent lysates. These data confirmed that although 
the quiescent cells had undergone cell cycle exit, they did not exhibit gene 
expression changes reflective of an activation of the senescence program. 
Although quiescent cells share a phenotype characterized by proliferative 
arrest with senescent cells, quiescent cells should not possess the increased 
lysosomal β-galactosidase activity that is associated with senescence. In parallel with 
the whole cell lysate preparation, proliferating and quiescent IMR90 cells were fixed 
and assayed to detect increased lysosomal β-galactosidase activity. As expected, in 
both the proliferating and quiescent IMR90, fewer than 5% of the cells stained 
positive for SA β-galactosidase activity (Figure 3.3b). Collectively, the general 
absence of β-galactosidase activity and failure to induce known molecular markers of 
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senescence, coupled with a robust reduction of cyclin A expression, indicate that 
although quiescent cells are non-proliferative, they are phenotypically distinct from 
senescent cells. As such, this confirmed that quiescent cells could provide a useful 
model for evaluating the specificity of senescence-associated findings. 
 
3.2.2 Identifying Gene Expression Changes in RS 
In order to further characterize and validate the replicative and oncogene-
induced senescence models, it was important to evaluate the respective systems on a 
more global level. To this end, transcriptional profiling provides a comprehensive 
and informative snapshot of a cell population’s state at a given time. Moreover, by 
evaluating the transcriptional status of a particular cell population, it is possible to 
gain insight into the pathways and processes that are engaged under a defined 
cellular state. Therefore, by obtaining gene expression profiles for replicative and 
oncogene-induced senescent IMR90 cells, it might be possible to identify additional 
transcriptional changes that might reveal novel aspects of the senescence program.  
To facilitate transcriptional profiling, total RNA was isolated from low 
passage, proliferating IMR90 cells (PD28) and late passage, replicative senescent 
IMR90 cells (PD90). The RNA samples were subsequently processed and hybridized 
to Affymetrix Human Genome U133 Plus 2.0 Arrays by the Cancer Research UK 
Microarray Facility (Paterson Institute for Cancer Research, Manchester, UK). The 
hybridized arrays were scanned and the resulting raw data (.CEL) files were 
imported into R and analyzed using the Bioconductor software packages. Each 
sample was subjected to background correction and normalization using the GC 
Robust Multi-array Average (GCRMA) method. Normalized intensity values for 
each probe from the PD28 and PD90 microarrays were compared and displayed as a 
scatter plot (Figure 3.4). Although the majority of probes exhibited comparable 
normalized intensity values between the PD28 and PD90 arrays, a smaller subset of 
probes contained higher intensity values on either the PD28 or PD90 arrays, 
respectively. 
  Differential expression was calculated from the log-normalized values of the 
proliferating and replicative senescent cells. T-tests were performed to determine 
statistical significance and genes were considered differentially expressed if the 
absolute fold difference between the proliferating and senescent samples exceeded 
1.5-fold and the BH-FDR adjusted p-value was lower than 0.05. For genes that were 
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represented by multiple probe sets on the microarray, the gene was only considered 
differentially expressed if all probe sets changed in the same direction and met the 
statistical criteria. Using these parameters, 5,447 differentially expressed genes were 
identified in the PD90 replicative senescent cells when compared to PD28 
proliferating cells. Of the 5,447 genes, 2,711 genes were significantly upregulated in 
the PD90 cells, while 2,736 genes were significantly downregulated.  
In order to identify biological processes that were altered in the PD90 
replicative senescent cells, the microarray intensity data were collated into individual 
gene values, ranked by signal to noise ratio and subjected to Gene Set Enrichment 
Analysis (GSEA). GSEA is a statistical method used to identify sets of genes within 
a dataset that are coordinately regulated by comparing the expression changes to 
predefined gene ontology categories (Subramanian et al., 2005). The resulting 
analyses reveal biological pathways and functions based on sets of genes that are 
either enriched in the control group (i.e., proliferating cells) or enriched in the 
experimental group (i.e., senescent cells). To this end, gene sets identified as 
enriched in replicative senescent cells predominantly contained genes that were 
upregulated in senescence, whereas gene sets enriched in proliferating cells were 
largely comprised of genes downregulated in the senescent cells. 
Based on GSEA, a number of gene sets were identified as significantly 
enriched in PD90 replicative senescent IMR90 cells (i.e., derived from genes that 
were upregulated in the PD90 cells). These gene sets represented diverse biological 
processes and functions (Table 3.1). The most significantly enriched gene set in the 
PD90 cells was the extracellular structure organization & biogenesis category. 
Remarkably, the identification of this category was seemingly influenced by the 
increased expression of numerous protocadherin genes (e.g., PCDHB2, PCDHB3, 
PCDHB6, PCDHB9, PCDHB10, PCDHB13, PCDHB14, PCDHB16) in the PD90 
cells. Elevated expression of the protocadherin genes, as well as another adhesion-
related gene, NRCAM, also contributed to high enrichment scores for additional 
gene sets (e.g., synapse organization and biogenesis, synaptogenesis). Consistent 
with the senescence-associated secretory phenotype, a category related to cytokine 
activity (hematopoietin interferon class D2000 cytokine receptor activity) was also 
highly enriched in the PD90 cells. 
In addition to the categories that were enriched in the senescent cells, GSEA 
also identified multiple significant gene sets that were enriched in the PD28 
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proliferating cells (i.e., derived from genes that were downregulated in the PD90 
senescent cells). Of the top 10 gene sets significantly enriched in proliferating cells, 
8 sets involved processes related to cell cycle progression (e.g., cell cycle process, 
cell cycle phase, mitosis), while 2 sets related specifically to chromosomes (e.g., 
chromosome, chromosomal part) (Table 3.2). The 8 cell cycle-related categories 
contained a number of overlapping genes that were robustly downregulated including 
KIF15, TTK, CDC25C, KIF2C, NCAPH, NEK2, CDKN3 and CDKN2C. The fact 
that nearly all of the most significantly enriched categories in the proliferating cells 
related to cell cycle progression, indicated that the replicative senescent cells had 
truly undergone proliferation arrest and provided additional validation of the RS 
model.   
 
3.2.3 Identifying Gene Expression Changes in OIS 
Transcriptional profiling was also performed on oncogene-induced senescent 
cells. Total RNA was isolated from proliferating control-infected and senescent H-
RASG12V-infected IMR90 cells 10 days after infection and prepared for microarray 
analysis in the same manner as for the replicative senescent cells. As before, control 
and H-RASG12V samples were hybridized to Affymetrix Human Genome U133 
Plus 2.0 Arrays, scanned to obtain raw (.CEL) files, imported into R and analyzed 
with Bioconductor. Each control and H-RASG12V replicate was subjected to 
background correction and normalization using the GC Robust Multi-array Average 
(GCRMA) method. Normalized intensity values for each probe from the control and 
H-RASG12V arrays were compared graphically as a scatter plot (Figure 3.5a). 
Similar to the RS dataset, the majority of probes displayed comparable normalized 
intensity values for both the control and H-RASG12V arrays, while a smaller subset 
of probes contained higher intensity values for either the control or H-RASG12V 
arrays.  
Gene changes exhibiting an absolute fold change greater than 1.5-fold and a 
BH-FDR adjusted p-value lower than 0.05 were considered differentially expressed. 
By these criteria, 3,189 genes were identified as being differentially expressed in the 
H-RASG12V-induced senescent IMR90 cells when compared to control-infected 
proliferating cells. Of the 3,189 genes, 1,502 genes were significantly upregulated in 
the H-RASG12V cells, while 1,687 genes were significantly downregulated. To 
evaluate the general performance of the microarray, several genes reported to 
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undergo expression changes during senescence were selected for measurement by 
quantitative real-time PCR (qPCR) (Figure 3.5b). Consistent with the microarray 
data, qPCR confirmed an upregulation of MMP1, MMP3 and IL8 and a repression of 
WNT2 in the OIS cells.  
Similar to the analyses conducted for the RS microarray data, the OIS gene 
expression data were also subjected evaluation by GSEA. Based on GSEA, multiple 
gene sets were identified as enriched in H-RASG12V-infected senescent IMR90 
cells. Assessment of the 10 most highly enriched gene sets in the H-RASG12V cells 
indicated that a variety of biological processes were affected, including cell 
differentiation, metal ion binding, metalloendopeptidase activity and the regulation 
of protein translation (Table 3.3). The identification of categories related to 
metalloendopeptidase activity was anticipated, as the matrix metalloproteinases 
(MMPs) comprise a family of genes that are induced in senescent cells as part of the 
secretory phenotype. Specifically, the metalloendopeptidase activity category 
revealed elevated expression for MMP3, MMP8, MMP9, MMP12, MMP13, MMP14 
and MMP16 in the H-RASG12V-infected senescent cells. To this end, the findings 
provided evidence that H-RASG12V infection of IMR90 cells resulted in the 
characteristic secretory phenotype and could therefore be utilized as a viable model 
of senescence. 
GSEA also identified diverse gene sets that were enriched in the control-
infected proliferating cells (i.e., comprised of genes that were downregulated in the 
H-RASG12V-infected senescent cells). As expected, several categorical gene sets 
related to cell cycle progression (e.g., spindle, cell division, cytokinesis) were 
identified as highly enriched in the control-infected proliferating cells (Table 3.4). In 
fact, the spindle and cell division gene sets exhibited the highest enrichment scores in 
the control cells, and were largely influenced by downregulation of cell cycle genes 
in the H-RASG12V-infected senescent cells. Multiple gene sets related to 
extracellular matrix composition (e.g., extracellular matrix structural constituent, 
proteinaceous extracellular matrix, extracellular matrix) were also significantly 
enriched in the control-infected cells. This revealed that genes involved in the 
structure of the extracellular matrix, including matrilin (MATN3), fibulin (FBLN1, 
FBLN2), collagen (COL4A2) and laminin (LAMA1), were downregulated in the H-
RASG12V cells. Collectively, downregulation of genes related to the cell cycle and 
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extracellular matrix are both hallmarks of senescence and further validated H-
RASG12 infection of IMR90 cells as a robust model of senescence. 
 
3.2.4 Defining a Transcriptional Profile of Cell Senescence 
Although the identification of differentially expressed genes in both 
replicative and oncogene-induced senescent cells could provide relevant biological 
insight into the respective model systems, a direct comparison of the two models 
could provide a more comprehensive understanding of the universal features of cell 
senescence. To this end, the replicative senescence and oncogene-induced 
senescence microarray datasets were queried to identify gene expression changes that 
were either common or unique between the two systems. For the respective datasets, 
a gene was considered differentially expressed if it exhibited an absolute fold change 
greater than 1.5-fold with a BH-FDR adjusted p-value lower than 0.05. According to 
these criteria, 1,770 genes were identified as being differentially expressed in both 
replicative senescent and oncogene-induced senescent IMR90 cells (Figure 3.6a).  
While the expression of 1,770 genes changed significantly in both models of 
senescence, the initial analysis did not account for the directionality of change. For 
example, some genes were identified as having met the statistical cutoff and found to 
be upregulated in one senescence model, but downregulated in the other. To address 
this discrepancy, analyses of upregulated and downregulated genes were performed 
separately. Of the 2,711 genes that were upregulated in replicative senescent cells 
and 1,502 genes that were upregulated in oncogene-induced senescent cells, 424 
genes were identified as upregulated in both senescence models (Figure 3.6b). 
Likewise, while 2,736 genes were downregulated significantly in replicative 
senescent cells and 1,687 genes downregulated in oncogene-induced senescent cells, 
584 genes were identified as downregulated in both model systems (Figure 3.6c). In 
all, the expression of 1,008 genes was altered in common between the replicative 
senescent and oncogene-induced senescent IMR90 cells. 
Based on prior investigation of cell senescence by many laboratories and the 
fact that 1,008 genes were differentially expressed in two models of senescence, it 
was reasonable to hypothesize that specific pathways and processes might be altered 
as part of the senescence program. In order to identify potentially affected biological 
processes, the genes that were differentially expressed in both the replicative 
senescent and oncogene-induced senescent IMR90 cells were evaluated using 
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Ingenuity Pathway Analysis (IPA). IPA utilizes literature-based findings to predict 
cellular phenotypes, biological interactions and physiological or disease processes 
based on user provided transcriptional profiling datasets. To help delineate between 
processes that were potentially activated or inhibited, the gene expression changes 
were queried as three distinct datasets: genes that were upregulated in common, 
genes that were downregulated in common and all genes that changed in common 
between the replicative senescent and oncogene-induced senescent cells. 
Through IPA evaluation of the 424 genes upregulated in both the RS and OIS 
models, multiple canonical signaling and metabolic pathways were identified as 
being affected in a statistically significant manner (Figure 3.7a). Several well-
characterized cancer associated pathways were identified (e.g., bladder cancer 
signaling, ErbB signaling, pancreatic adenocarcinoma signaling). In addition, 
multiple pathways related to the regulation of apoptosis and cell death were also 
significantly affected (e.g., retinoic acid mediated apoptosis signaling, death receptor 
signaling). In fact, retinoic acid mediated apoptosis signaling was identified as the 
most significantly altered pathway derived from the upregulated genes dataset. 
Specifically, key pro-apoptotic genes including TNFRSF10A, TNFRSF10D, DAP3, 
IFNA1, PARP8 and TIPARP were all induced in both RS and OIS (Figure 3.7b). 
However, it is important to recognize that regulation of signal transduction can be 
highly complex and elevated expression of pathway components may not be solely 
sufficient to activate a given pathway. To this end, the anti-apoptotic regulators 
CFLAR/FLIP and XIAP were also upregulated significantly in RS and OIS, 
suggesting that as expected, the apoptotic pathway is not fully engaged in senescent 
cells. 
Despite exhibiting some similar molecular characteristics, senescence and 
apoptosis reflect distinct cellular programs that result in separate endpoints. The 
senescence program involves the establishment of a permanent proliferation arrest 
and promotion of a proinflammatory environment through expression of the SASP 
(Coppé et al., 2010). In contrast, apoptosis is characterized by a caspase-mediated 
cell death program that involves rapid self-destruction and clearance, yet fails to 
elicit an inflammatory response (Taylor, Cullen & Martin, 2008). Thus, while 
senescence and apoptosis both restrict the proliferative capacity of damaged cells and 
suppress tumorigenesis, whether these processes cooperate at the molecular level is 
yet to be fully elucidated. 
	   101	    
	   102	  
The 584 genes downregulated in both the RS and OIS IMR90 cells were also 
subjected to evaluation with IPA, which revealed several significantly affected 
pathways (Figure 3.8a). Remarkably, 4 of the top 10 altered canonical pathways 
involved aspects of the DNA damage response (e.g., G2/M DNA damage checkpoint 
regulation, role of BRCA1 in DNA damage response, ATM signaling, GADD45 
signaling). This was a little surprising as DNA damage signaling is a known effector 
mechanism of the senescence program. Importantly, each of the DNA damage 
response related pathways also incorporate elements of cell cycle regulation. This 
was also the case for the most significantly affected canonical pathway: mitotic roles 
of polo-like kinase. This pathway summarizes several distinct stages of mitosis: 
centrosome separation and maturation, mitotic entry, metaphase to anaphase 
transition, mitotic exit and cytokinesis (Figure 3.8b). In both RS and OIS cells, the 
mitosis genes EG5 (KIF11), PLK, CDC2 (CDK1), CCNB1, CDC20, PRC1, EMI1 
(FBXO5), PTTG1, MKLP1 (KIF23) were all significantly downregulated. Although 
the reduced expression of these genes could suggest a mitotic defect in senescent 
cells, it is more likely that these genes were downregulated as a secondary 
consequence of the senescence proliferation arrest. 
In order to obtain a more comprehensive assessment of the senescence-
associated gene expression changes, both the upregulated and downregulated gene 
lists were combined into a single dataset and evaluated with IPA. Similar to the 
individual upregulated and downregulated gene analyses, analysis of the combined 
dataset revealed multiple metabolic and signaling pathways were significantly 
affected in common between the RS and OIS IMR90 cells (Figure 3.9a). Four of the 
top 10 identified pathways involved diverse processes relating to intermediary 
metabolism (e.g., nitrogen metabolism, lysine biosynthesis, nicotinate and 
nicotinamide metabolism, ascorbate and aldarate metabolism). In each case, the 
metabolic pathways included upregulated and downregulated genes, complicating 
interpretation of the status of the pathways. Comparable to analysis of the 
downregulated gene list, IPA identified the mitotic roles of polo-like kinase pathway 
as the most significantly affected process based on the combined upregulated and 
downregulated dataset. In addition, G2/M DNA damage checkpoint regulation also 
scored highly in the pathway analysis of the combined gene list. Evaluation of this 
pathway revealed that key regulators of DNA replication and cell cycle progression 
including CDC2 (CDK1), CCNB1, CNNB2, SFN (14-3-3 s), CDC25B, TPO2A and 
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SKP2 were all significantly downregulated (Figure 3.9b). Another component of the 
pathway, the tumor suppressor p19ARF, was upregulated in both RS and OIS cells. 
This was not entirely surprising as p19ARF, an alternative gene product of the 
INK4/ARF locus known to increase in senescent cells, helps stabilize p53 by binding 
and sequestering MDM2. To this end, the gene expression analyses confirmed that 
both RS and OIS IMR90 cells exhibited a transcriptional profile consistent with cell 
cycle arrest and promotion of tumor suppression. 
 
3.3 Discussion 
 Before initiating mechanistic studies of a complex biological phenomenon, it 
is first critical to identify and implement an appropriate model system. Because 
several well-documented triggers of cell senescence have been identified, I selected 
two in vitro systems that were the most relevant to cancer and ageing: replicative 
senescence and oncogene-induced senescence. Both of these models have been 
utilized extensively to study senescence in the laboratory and were therefore 
relatively simple to establish and optimize. I selected IMR90 cells as a relevant cell 
line in which to induce senescence as this HDF line is not only well-characterized, 
but has been widely used by others to investigate senescence in vitro. 
 Upon implementation, both model systems were critically assessed for 
parameters of cell senescence including proliferation arrest, the expression of key 
senescence regulatory proteins and SA β-galactosidase activity. Both the late passage 
IMR90 and H-RASG12V-infected IMR90 cells exhibited clear indicators of cell 
cycle exit and senescence onset (e.g., reduction of cyclin A and lamin B1 expression, 
induction of p16INK4a and p21WAF1), while the respective early passage and 
control-infected IMR90 cells did not. Likewise, the late passage and H-RASG12V-
infected IMR90 cells stained uniformly positive for SA β-galactosidase activity. 
These data collectively confirmed that both models were suitable to generate 
senescent cells in a robust and reproducible manner. 
 Gene expression profiles were also generated for the RS and OIS models in 
order to further verify the senescent phenotype and to provide a transcriptional 
framework that could be used to assess the impact of chromatin changes. GSEA and 
IPA were employed to identify biological processes that were significantly affected 
during senescence. As expected, genes related to cell cycle progression and 
extracellular matrix composition were primarily downregulated, whereas genes 
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associated with cell cycle inhibition and the secretory phenotype were significantly 
upregulated. The consistency of these gene expression data with earlier findings from 
other laboratories further validated the two models as appropriate tools for studying 
cell senescence (Shelton et al., 1999; Zhang et al., 2003; Krizhanovsky et al., 2008). 
Genes differentially expressed in both the RS and OIS models were also 
identified and used to define a composite transcriptional profile of cell senescence. 
Although expression changes specific to either model might have provided some 
insight, it was formally possible that any given change could reflect a nuance or 
artifact of the individual model systems. By identifying genes that were differentially 
expressed in both RS and OIS senescent cells, it increased the likelihood that the 
gene changes were specific to senescence. However, one caveat to the interpretation 
of the RS and OIS gene expression data was that the analyses failed to account for 
any transcriptional changes that might have occurred as a secondary consequence of 
the proliferation arrest. One way to address this caveat would be to compare the 
overlapping senescence datasets with a gene expression profile derived from 
quiescent IMR90 cells. Any genes that would change in union between the RS, OIS 
and quiescence datasets could be eliminated as being related to proliferation arrest 
and not specific to the senescence program. This would provide a more accurate and 
definitive transcriptional representation of the senescence program. Despite this 
caveat, the derived gene expression signature of senescence could still serve as a 
baseline to evaluate the functional consequences of specific chromatin changes 
during senescence. 
In the process of defining a common RS and OIS transcriptional profile, it 
was evident that none of the IPA canonical pathways and processes was completely 
saturated. In fact, no single pathway exhibited altered expression for every gene 
within the pathway, raising the issue of how robust the pathway changes were. 
However, it is important to consider that the activity of a given pathway can be 
affected even in the absence of expression changes for all members of the pathway. 
For some genes, regulation is mediated through mechanisms other than transcription, 
including posttranslational modification or protein stabilization. For example, altered 
transcription of a rate-limiting gene within a pathway can have a profound affect on 
the overall activity of the pathway. In this context, an upstream member of a pathway 
might be regulated at the transcriptional level and still affect the activity of 
downstream pathway members without altering their absolute expression levels. 
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Importantly, IPA was employed in the current study simply as an exploratory 
tool in order to identify pathways and gene networks that were likely to be altered in 
a statistically significant manner during cell senescence. To this end, all of the 
pathways presented in Figures 3.5, 3.6 and 3.7 were ranked on the basis of statistical 
significance and had p-values lower than 0.5 (expressed as –log[p-value]). As 
described in Chapter 2 (Materials and Methods), the p-value was calculated for each 
pathway using the right-tailed Fisher Exact Test and incorporated several parameters: 
the number of genes within the IPA pathway, number of pathway eligible genes 
annotated in IPA and the total number of genes in the input dataset. Ultimately, a 
complete biochemical validation would be required to demonstrate that a specific 
pathway was truly altered, but is beyond the scope of the present study. Instead, the 
transcriptional profiling of RS and OIS was conducted primarily to provide a context 
for evaluating the impact of chromatin changes in cell senescence. 
Having now established and validated two separate in vitro models of cell 
senescence, I was subsequently in a position to evaluate the chromatin structure of 
senescent cells. The formation of SAHF in senescent IMR90 cells represents an 
extreme remodeling of chromatin that is thought to facilitate aspects of the 
senescence program. To this end, I set out to examine how other epigenetic features 
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Chapter 4. Characterization of H4K20me3 in Senescence 
 
4.1 Rationale 
 The senescence program is characterized by an altered pattern of gene 
expression that simultaneously promotes both a permanent proliferation arrest and a 
secretory phenotype. In addition to these characteristic features, senescent cells 
concurrently undergo extensive chromatin remodeling. Although important research 
by several laboratories has already examined how changes in chromatin structure 
(e.g., SAHF formation) can promote senescence, little emphasis has been placed on 
elucidating the role of individual histone modifications in the regulation of the 
senescence program. Histone H4 lysine 20 trimethylation (H4K20me3) represents a 
key epigenetic marker of heterochromatin that is elevated in aged tissues and cells 
isolated from Hutchinson–Gilford Progeria Syndrome patients, but is lost in human 
cancers (Sarg et al., 2002; Shumaker et al., 2006; Fraga et al., 2005). Given the role 
of senescence in tumor suppression and its putative contribution to organismal aging, 
the H4K20me3 modification is of major interest in the senescence program. 
Consequently, I set out to characterize the H4K20me3 histone modification in 




4.2.1 Evaluation of H4K20me3 Antibody Specificity 
  Before attempting to investigate a particular protein or post-translation 
modification, it is important to obtain and validate the appropriate tools and reagents. 
This is particularly crucial when the experimental approach necessitates the use 
specific antibodies to detect a desired protein target. As such, possessing the ability 
to definitively confirm the specificity for a given signal in any antibody-based assay 
is fundamentally critical to the interpretation of the assay. Antibody specificity is a 
particularly important consideration in the assessment of histone modifications, as 
antibodies that exhibit some degree of cross-reactivity may not allow for 
discrimination between subtle differences in posttranslational modification. For 
example, the dimethylation or trimethylation of a particular histone residue may not 
result in discrete differences in mobility by SDS-PAGE, thus confounding the 
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interpretation of Western blotting results. As a result, it is essential to confirm that a 
given antibody detects the desired histone modification with high specificity and 
exhibits minimal cross-reactivity. 
Based on information provided in the literature, publicly accessible databases 
(http://compbio.med.harvard.edu/antibodies/) and commercial availability, several 
H4K20me3 antibodies were selected and obtained for evaluation (Egelhofer et al., 
2010). The utilization of spotted arrays comprised of diverse combinations of 
unmodified and modified histone peptides has proven to be an effective method of 
evaluating the specificity of antibodies raised against various histone modifications 
(Bock et al., 2011). To this end, the MODified Histone Peptide Array (Active Motif) 
was selected for use in assessing the binding specificities of the obtained H4K20me3 
antibodies. The array is comprised of 384 separate peptides containing various 
combinations of acetylation, methylation, phosphorylation and citrullination 
modifications of the N-terminal tails of the four core histones. The H4K20me3 
modification is represented by seven different peptides on the array, either alone or 
in combination with additional modifications. 
In order to evaluate binding specificity, three H4K20me3 antibodies 
(Millipore, 04-079; Cell Signaling Technology, 5737; Abcam, ab9053) were 
subjected to a 2000-fold dilution and incubated with separate peptide arrays. The 
arrays were subsequently incubated with species-appropriate HRP-conjugated 
secondary antibodies and developed with standard enhanced chemiluminescence 
(ECL) reagents. The arrays were then exposed to film and the resulting 
autoradiographic images captured using a conventional flatbed scanner. Each of the 
three H4K20me3 antibodies detected only a few of the 384 total peptides on the 
array (Figure 4.1a). Both the Millipore and Cell Signaling Technology antibodies 
primarily detected the seven H4K20me3-containing peptides as indicated by the red 
circles, and exhibited only minimal signal for the other peptides. Although the 
Abcam antibody also detected the seven H4K20me3-containing peptides, it 
displayed moderate signal intensity for several other peptides as well. The arrows on 
the radiographic images denote examples of antibody cross-reactivity with peptides 
lacking the H4K20me3 modification. 
To obtain a more quantitative metric of the binding specificities of the 
respective H4K20me3 antibodies, the scanned images of the arrays were analyzed 
using the Array Analyse software (Active Motif). Array Analyse generates a 
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numerical value (i.e., specificity factor) that indicates how specific a given antibody 
is for each of the histone modifications on the array. The specificity factor is 
determined by dividing the average intensity of all spots that contain a given 
modification by the average intensity of all the other spots that lack the modification. 
Consistent with the autoradiographic images, both the Millipore and Cell Signaling 
Technology antibodies displayed high specificity factors for the H4K20me3 
modification and low values for the other modifications (Figure 4.1b). Although the 
Abcam antibody had an acceptable specificity factor for the H4K20me3 
modification, it also exhibited moderate cross-reactivity with the H4K20me2 
modification. Genome wide, H4K20me2 is far more abundant than H4K20me3, 
which might interfere with the interpretation of any results obtained using the Abcam 
antibody. For this reason, the Millipore and Cell Signaling Technology antibodies 
were utilized exclusively for all subsequent immunological-based assays of 
H4K20me3.  
 
4.2.2 H4K20me3 is Selectively Retained in Senescent Cells 
Having tested and validated multiple H4K20me3 antibodies, it became 
important to characterize the H4K20me3 modification in proliferating and senescent 
cells. In order to determine the relative abundance of H4K20me3 in proliferating and 
senescent cells, whole cell extracts were prepared from low passage (PD28) 
proliferating and late passage (PD90) senescent IMR90 cells. In parallel, whole cell 
extracts were also obtained from control and H-RASG12V-infected IMR90 cells. To 
accurately determine the stoichiometry of a histone modification between samples, it 
is important to utilize volumes of extract that contain an equivalent amount of total 
histone. To determine this, the volumes of both sets of extracts were titrated, 
subjected to fractionation by SDS-PAGE and Western blotted to quantify total 
histone H4 levels (data not shown). Optimal loading volumes were determined in 
order to ensure that an equal amount of total histone H4 was loaded for each sample. 
Based on this determination, extract volumes containing equal amounts of total 
histone H4 from the PD28, PD90, control-infected and H-RASG12V-infected cells 
were fractionated by SDS-PAGE and immobilized to PVDF. The PVDF membranes 
were then subjected to Western blotting to determine abundances of total histone H4 
and the H4K20me1, H4K20me2 and H4K20me3 modifications. 
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As anticipated, the PD28 proliferating and PD90 senescent samples contained 
normalized levels of total histone H4 (Figure 4.2a). Likewise, the control-infected 
proliferating and H-RASG12V-infected senescent cells contained normalized 
amounts of total histone H4. H4K20me1 levels were lower in the PD90 cells and to a 
lesser extent in the H-RASG12V senescent cells, relative to the respective 
proliferating cell extracts. In contrast, H4K20me2 abundance was higher in the PD90 
senescent cells but remained unchanged in H-RASG12V senescent cells, when 
compared to levels in proliferating cells. Intriguingly, the level of H4K20me3 in the 
PD90 cells was markedly elevated relative to the PD28 cells. Similarly, the H-
RASG12V-infected senescent cell extracts also contained a higher level of 
H4K20me3 than extracts from the control-infected proliferating cells. To 
demonstrate the specificity of the observed differences in H4K20me3 abundance, 
Western blots were performed with two independent H4K20me3 antibodies 
(Millipore and Cell Signaling) and these yielded comparable results. 
 However, it was formally possible that H4K20me3 levels were elevated in 
RS and OIS cells simply as a consequence of either the cell cycle position or non-
proliferative state of the senescent cells. In either of these scenarios, the observed 
elevation of H4K20me3 levels might have been a secondary effect of cell cycle exit 
and not specific to senescence. To address this, whole cell extracts from 
proliferating, replicative senescent and quiescent IMR90 cells were titrated, 
fractionated by SDS-PAGE and Western blotted to assess histone H4 levels. As 
before, extract volumes that would permit loading of equal amounts of total histone 
H4 were determined for each sample (data not shown). Appropriate extract volumes 
for the samples were subsequently fractionated by SDS-PAGE and transferred to a 
PVDF membrane. The membrane was then subjected to Western blotting to detect 
histone H4 and H4K20me3 (Figure 4.2b). As expected, H4K20me3 levels were 
again markedly higher in the senescent cells when compared to the proliferating 
cells. In contrast, the quiescent cells exhibited only modestly higher levels of 
H4K20me3 than the proliferating cells, suggesting that the robust increase of the 
modification in senescent cells is not merely a consequence of proliferation arrest or 
cell cycle position. 
 Although the Western blot data demonstrated that H4K20me3 levels were 
seemingly higher in senescent cells, the analyses relied on normalization to total 
histone H4. As a result, it was only possible to conclude that the ratio of H4K20me3-
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containing histone H4 to total histone H4 was higher in senescent cells than in 
proliferating cells. It has been reported that total histone levels undergo a marked 
reduction in senescent cells, so the higher levels of H4K20me3 could have simply 
reflected an overloading of the senescent samples in order to attain equal total 
histone H4 levels. As such, the Western blot data failed to provide any information 
about the actual abundance of H4K20me3 on a per cell basis, in the respective 
proliferating and senescent populations. In order to address this caveat, low passage 
(PD33) proliferating IMR90 cells and late passage (PD87) senescent IMR90 cells 
were dislodged by treatment with trypsin, subjected to manual cell counting with a 
hemocytometer and used to generate whole cell extracts. Additional plates of PD87 
senescent cells were harvested in a similar manner 1, 2, 3 or 4 weeks after the onset 
and confirmation of senescence. For each timepoint, the amount of lysis buffer was 
varied so that the proliferating and senescent extracts contained equal numbers of 
cells per volume of buffer. 
 Whole cell extracts from the RS timecourse containing equivalent numbers of 
cells were fractionated by SDS-PAGE, immobilized to PVDF membranes and 
subjected to Western blot analysis of proliferation/senescence markers and histones 
(Figure 4.3). As expected, levels of lamin A/C remained largely unchanged for the 
duration of the timecourse. Consistent with a senescent phenotype, lamin B1 and 
cyclin A expression underwent a robust decline beginning with the PD87 cells and 
continued over the course of the experiment. Further confirming senescence, marked 
induction of p16INK4a was observed in the PD87 cells and was maintained at 
comparable levels for up to 4 weeks after the onset of senescence. Beginning with 
the PD87 senescent cells, a progressive loss of total histone H4 content occurred over 
the remainder of the timecourse. Despite the significant decrease in total histone H4 
expression, H4K20me3 levels remained unchanged between the PD33 proliferating 
cells and PD87 senescent cells. Remarkably, H4K20me3 levels also remained 
unaltered for up to 4 weeks from the onset of senescence. These data indicated that 
on a per cell basis, the total amount of H4K20me3 was unaffected as cells underwent 
RS. The data also suggested that the previously observed elevation of H4K20me3 
levels during RS was primarily a consequence of normalizing the Western blot 
samples for total histone content. In other words, the total amount of H4K20me3 per 
cell does not change, but the proportion of H4 carrying this modification is 
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increased. This in turn implies that H4K20me3 is selectively retained in senescent 
cells, relative to other forms of histone H4.  
  
4.2.3 Assessment of H4K20me3 Localization in Senescent Cells 
In addition to measuring H4K20me3 abundance in proliferating and 
senescent cells, it was important to ask whether the nuclear localization of 
H4K20me3 in senescent cells differed from that of proliferating cells. To accomplish 
this, proliferating and senescent cells were subjected to indirect immunofluorescence 
staining with H4K20me3 antibodies. Low passage proliferating (PD22) and high 
passage senescent (PD85) IMR90 cells were fixed, permeabilized and stained with 
an H4K20me3 antibody and DAPI. The stained cells were subsequently visualized 
by fluorescence microscopy. The PD22 cells exhibited even predominantly nuclear 
DAPI staining and a diffuse, granular nuclear H4K20me3 staining pattern (Figure 
4.4a). By comparison, the PD85 senescent cells displayed a DAPI staining pattern 
characteristic of SAHF and H4K20me3 staining that revealed distinct, variably sized 
nuclear foci. Control-infected proliferating and H-RASG12V-infected senescent 
IMR90 cells were also fixed, permeabilized and subjected to H4K20me3 and DAPI 
staining (Figure 4.4b). Comparable to low passage IMR90 cells, control-infected 
cells displayed an even predominantly nuclear DAPI staining pattern and diffuse, 
granular H4K20me3 staining in the nucleus. In the H-RASG12V cells, DAPI 
staining revealed prominent SAHF formation and an H4K20me3 pattern that 
exhibited defined nuclear foci of variable size.  
 Whereas proliferating cells mostly displayed a uniformly diffuse H4K20me3 
nuclear staining pattern, senescent cells contained intensely staining H4K20me3 
nuclear foci. Several distinct types of nuclear foci have been previously described in 
senescent cells. The promyelocytic leukemia (PML) protein forms punctate nuclear 
bodies that increase in number and size during RS and OIS and contribute to the 
senescence program (Ferbeyre et al., 2000; Pearson et al., 2000; Bischof et al., 2002). 
Because PML forms prominent foci that mediate aspects of cell senescence, it was 
relevant to ask whether H4K20me3 foci co-localized with PML nuclear bodies in 
senescent cells. To examine this, control-infected proliferating and H-RASG12V-
infected senescent IMR90 cells were fixed, permeabilized and co-stained with DAPI 
and antibodies against H4K20me3 and PML. The stained cells were detected by 
indirect immunofluorescence and visualized by fluorescence microscopy. While the 
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DAPI and H4K20me3 nuclear staining patterns remained diffuse and even in the 
control cells, the H-RASG12V cells again exhibited SAHF formation and the 
presence of H4K20me3 foci (Figure 4.5a). As expected, both the number and size of 
the PML nuclear bodies increased in the H-RASG12V cells compared to control 
cells. Despite the prominence of both the H4K20me3 and PML foci in the H-
RASG12V cells, no spatial co-localization was observed. In fact, the respective foci 
appeared to occupy mutually exclusive nuclear locations in the senescent H-
RASG12V cells, indicating that H4K20me3 was not present at sites of PML nuclear 
bodies.  
Given the important contribution of DNA damage signalling as an effector 
mechanism of the senescence program, several nuclear structures indicative of DNA 
damage have also been identified in senescent cells. To this end, the DNA damage 
signalling mediator 53BP1 and phosphorylated histone H2AX (γ-H2AX), which 
marks DNA double-strand breaks, both form discrete nuclear foci in senescent cells 
(d'Adda di Fagagna et al., 2003). To examine whether H4K20me3 foci were present 
at these nuclear sites of DNA damage in senescent cells, cells were subjected to co-
staining by immunofluorescence. Control-infected proliferating and H-RASG12V-
infected senescent cells were fixed, permeabilized and co-stained with DAPI, an 
H4K20me3 antibody and antibodies against either 53BP1 or γ-H2AX. Control cells 
exhibited even DAPI staining and diffuse nuclear staining patterns for both 
H4K20me3 and 53BP1 (Figure 4.5b). In contrast, H-RASG12V-infected cells 
displayed SAHF, H4K20me3 staining of greater intensity with some foci and large 
discrete 53BP1 foci. Although some foci were adjacent, no overt co-localization was 
observed between the H4K20me3 and 53BP1 foci. 
Control and H-RASG12V cells were also assayed by immunofluorescence to 
compare H4K20me3 and γ-H2AX staining patterns. As anticipated, control cells 
contained even DAPI staining, a diffuse H4K20me3 pattern and the presence of very 
few, small nuclear γ-H2AX foci (Figure 4.5c). H-RASG12V cells again contained 
distinct SAHF and prominent H4K20me3 foci, as well as an increased number of 
larger γ-H2AX puncta. No co-localization between H4K20me3 and γ-H2AX 
occurred, as the γ-H2AX foci were mostly present at H4K20me3-poor regions of the 
nucleus. Taken together, the 53BP1 and γ-H2AX immunofluorescence data indicated 
that H4K20me3 foci did not mark regions of DNA damage in senescent cells. As 
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such, the data suggested that H4K20me3 is likely not involved in mediating the DNA 
damage signalling aspect of the senescence program. 
Despite the lack of co-localization between H4K20me3 and PML, 53BP1 or 
γ-H2AX, H4K20me3 appeared as distinct nuclear foci in senescent cells, suggesting 
a possible structural role for the modification during senescence. Senescent cells 
often appeared to harbour two distinct types of H4K20me3 nuclear structures: large 
globular foci and smaller, intensely staining puncta. In terms of size, shape and 
abundance, the larger globular H4K20me3 foci resembled SAHF. Therefore, it 
became important to address whether the H4K20me3 foci co-localized with SAHF in 
senescent cells. To examine this possibility, proliferating and replicative senescent 
IMR90 cells were fixed, permeabilized and stained with DAPI and an antibody 
against H4K20me3. The stained cells were visualized by epifluorescence microscopy 
and images were captured using identical exposure settings. As before, the 
proliferating cells displayed uniform DAPI and H4K20me3 nuclear staining patterns 
(Figure 4.6a). In contrast, the senescent cells exhibited SAHF formation and the 
presence of defined H4K20me3 foci. 
 Merged images of the DAPI and H4K20me3 immunofluorescence signals 
revealed that H4K20me3 frequently co-localized with SAHF in the senescent cells 
(Figure 4.6a). In order to provide an unbiased assessment of the co-localization, line 
scans were performed on the merged DAPI/H4K20me3 images and fluorescence 
intensity values (gray level) were determined for the respective channels (Figure 
4.6b). In proliferating cells, both the DAPI and H4K20me3 signals remained 
relatively uniform across the section of the nucleus measured by the line scan. In the 
senescent cells, more uneven line scan profiles of the DAPI and H4K20me3 staining 
were revealed. Regions of the nucleus that exhibited higher DAPI signal also 
displayed higher H4K20me3 signal in a strongly correlative manner. Because the 
images were captured by standard epifluorescence microscopy and not by confocal 
sectioning, it was formally possible that the SAHF and H4K20me3 foci existed in 
different focal planes. However, despite this caveat, it was reasonable to conclude 
that the larger H4K20me3 foci were located in close spatial proximity to SAHF in 
senescent cells. As such, the data suggested that H4K20me3 might be a structural 
component of SAHF. 
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4.2.4 SUV420H2 Expression is Modestly Altered in Senescent Cells 
 Having established that levels of H4K20me3 remained stable in senescent 
cells and that the modification co-localized with SAHF, it became important to ask 
how H4K20me3 was maintained given the dramatic reduction of histone content 
during senescence. To this end, there were two plausible scenarios that could explain 
how H4K20me3 levels remained unaltered in senescent cells despite a net decrease 
in histone expression: (1) H4K20me3-containing nucleosomes were protected from 
being lost during senescence or (2) H4K20me3-containing nucleosomes were lost 
during senescence, but the modification was deposited to remaining nucleosomes 
such that the steady state level of H4K20me3 appeared unchanged. As such, the 
latter argument would presumably require the activity of an H4K20me3-depositing 
enzyme.  
The majority of H4K20me3 is catalyzed in vivo by the activity of the histone 
methyltransferase SUV420H2 (Schotta et al., 2004; Schotta et al., 2008). In order to 
determine whether SUV420H2 expression was maintained as cells underwent 
senescence, the RS and OIS microarray datasets were queried. The Affymetrix 
Human Genome U133 Plus 2.0 Array contained multiple probesets for the 
SUV420H2 gene. Therefore, data for each probeset was compiled and assessed to 
determine whether SUV420H2 expression was altered in senescent cells No 
statistical difference was observed for either of the SUV420H2 probesets from the 
RS microarray (Table 4.1). Likewise, no change in expression was observed for 
either of the SUV420H2 probesets from the OIS microarray. Based on the 
microarray data, it was reasonable to conclude that SUV420H2 mRNA expression 
was not significantly altered in senescent cells.  
Although the microarray expression data for SUV420H2 were not confirmed 
by quantitative PCR, it was reasonable to measure expression of the enzyme at the 
protein level in RS and OIS cells. Before proceeding with analysis of SUV420H2 
expression, it was first necessary to identify and obtain a suitable SUV420H2 
antibody. To this end, it was important to verify that the antibody was specific and 
could be used for Western blot detection of SUV420H2. One approach commonly 
employed to confirm antibody specificity is to demonstrate that several independent 
antibodies are capable of detecting the same protein band by Western blot. However, 
due to the limited commercial availability of SUV420H2 antibodies, only a single 
antibody was obtained and tested for specificity. 
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In order to determine whether the SUV420H2 antibody could recognize the 
specified epitope, a control plasmid (pBABE-puro) or plasmids encoding MYC-
tagged full-length SUV420H1 (pBABE-puro-MYC-SUV420H1) or SUV420H2 
(pBABE-puro-MYC-SUV420H2) were transfected into Phoenix-Ampho cells. 
Forty-eight hours after transfection, whole cell extracts were prepared, subjected to 
fractionation by SDS-PAGE and immobilized to a PVDF membrane. The PVDF was 
cut vertically into two equal halves, containing the control, MYC-SUV420H1 and 
MYC-SUV420H2 cell lysates. The two membranes were Western blotted with either 
an antibody raised against the MYC tag or the SUV420H2 antibody. As anticipated, 
the MYC antibody detected a single band that migrated just above the 52 kDa 
molecular weight marker in the MYC-SUV420H2 lane, but not in the control or 
MYC-SUV420H2 lanes (Figure 4.7a). Importantly, the band corresponded with the 
predicted molecular weight (~ 53 kDa) of MYC-SUV420H2. The other half of the 
membrane was probed with the SUV420H2 antibody, which detected a band in the 
MYC-SUV420H2 lane that migrated at the same position as the band from the MYC 
Western blot. Although the signal from the SUV420H2 Western blot was 
considerably less intense than that of the MYC tag blot, the data indicated that the 
SUV420H2 antibody was capable of detecting ectopically expressed SUV420H2.  
It was also important to demonstrate that the SUV420H2 antibody could 
detect endogenous levels of SUV420H2. In the absence of several distinct 
SUV420H2 antibodies, an RNA interference approach was utilized to evaluate 
specificity. To this end, whole cell extracts were prepared from low passage IMR90 
cells infected with variable amounts of shControl or shSUV420H2 lentiviruses. The 
whole cell extracts were fractionated by SDS-PAGE, transferred to a PVDF 
membrane and Western blotted with the SUV420H2 antibody. A prominent band 
that migrated just above the 52 kDa molecular weight marker was detected (Figure 
4.7b). While the band remained unchanged across the shControl lanes, the 
shSUV420H2-infected cells exhibited markedly lower levels of expression. In fact, 
the cells that received the maximal amount of the shSUV420H2 lentivirus displayed 
the lowest expression of the putative SUV420H2 band. Because the band of interest 
migrated at the predicted molecular weight for SUV420H2 and underwent a 
reduction in expression following shSUV420H2 gene silencing, it was reasonable to 
conclude that the band represented endogenous SUV420H2. Based on this 
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evaluation, the SUV420H2 antibody could be used to accurately assess SUV420H2 
expression in proliferating and senescent cells. 
To evaluate SUV420H2 protein expression, whole cell extracts prepared from 
low passage (PD22) proliferating and high passage (PD85) senescent IMR90 cells 
were fractionated by SDS-PAGE and transferred to PVDF membrane for subsequent 
Western blot analysis. In parallel, whole cell extracts from control-infected 
proliferating and H-RASG12V-infected senescent IMR90 cells were also 
fractionated and immobilized to PVDF. The PVDF membrane was Western blotted 
with antibodies against SUV420H2 and GAPDH and quantified using the Image J 
software (Figure 4.8). A modest increase in SUV420H2 expression was observed in 
the PD85 replicative senescent cells relative to the PD22 proliferating cells, 
following normalization for GAPDH expression (Figure 4.8a & b). In contrast, 
SUV420H2 expression levels underwent a modest decrease in the H-RASG12V-
infected senescent cells relative to control-infected cells, following normalization for 
GAPDH expression (Figure 4.8c & d). Although SUV420H2 levels appear to 
undergo subtle changes in expression in RS and OIS, respectively, the findings do 
not provide any conclusive evidence to suggest that altered SUV420H2 expression is 
solely responsible for the maintenance of H4K20me3 levels in senescent IMR90 
cells. In OIS cells this is particularly unlikely to be the case, as H4K20me3 levels are 
maintained even in a context of reduced SUV420H2 expression. Consequently, 
whether H4K20me3 levels are maintained in senescent cells through a SUV420H2-
dependent mechanism remains to be tested using loss-of-function approaches. 
 
4.3 Discussion 
 In addition to the proliferation arrest and secretory phenotypes, senescent 
cells may also be characterized by a dynamic and extensively remodelled chromatin 
landscape. One of the more striking observations related to the chromatin state of 
senescent cells is that the cells undergo a loss of histone content. Importantly, despite 
the reduction of global histone levels, some histones are retained within the 
chromatin of senescent cells. Such is the case for histones that contain the 
H4K20me3 posttranslational modification, as levels of this mark remain identical in 
proliferating and senescent cells, when normalized per cell or to lamin A/C. The 
apparent stabilization of H4K20me3 is particularly intriguing as it occurs in both the 
contexts of RS and OIS, suggesting it might be a universal feature of the chromatin 
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of senescent cells. The observation that H4K20me3 level per cell is sustained for 
weeks following the onset of senescence is also of significance, possibly indicating 
that the modification plays a role in the long-term implementation of the senescence 
program. 
 Although the global level of H4K20me3 remains unaltered per senescent cell, 
the nuclear localization of the modification changes considerably as cells undergo 
senescence. In normal proliferating IMR90 cells, H4K20me3 exhibits a diffuse and 
even nuclear distribution as revealed by immunofluorescence staining. In striking 
contrast, replicative and oncogene-induced senescent cells display a pattern of 
H4K20me3 staining characterized by the formation of discrete nuclear foci. Several 
additional key nuclear proteins, including PML, 53BP1 and γ-H2AX, also form 
prominent foci during senescence, but surprisingly do not co-localize with 
H4K20me3. However, H4K20me3 does co-localize with SAHF in senescent IMR90 
cells, implying that the mark might help to facilitate the extensive chromatin 
remodelling that occurs as cells senesce. Given the proposed contribution of SAHF 
to the transcriptional silencing of proliferation genes, H4K20me3 might indirectly 
mediate the gene regulatory aspects of the senescence program (Narita et al., 2003; 
Zhang et al., 2007). 
 While the current findings provide convincing evidence that total H4K20me3 
levels remain unaltered in individual senescent cells, the data fail to provide clear 
insight into how abundance of the mark is maintained. One possibility is that 
nucleosomes containing the H4K20me3 modification are preferentially protected 
from removal during senescence. Alternatively, H4K20me3-containing nucleosomes 
might actually comprise a fraction of the histones that are lost during senescence, but 
the mark is maintained at steady state levels through the concomitant activity of an 
H4K20-specific histone methyltransferase acting upon the remaining nucleosomes. 
By either model, Western blotting analysis of H4K20me3 in proliferating and 
senescent cells and normalized for cell number would presumably reveal equivalent 
levels of the modification.  
The histone methyltransferase SUV420H2 has been reported to deposit the 
majority of H4K20me3 across the genome (Schotta et al., 2008). Similar to global 
H4K20me3 levels, SUV420H2 expression is only modestly altered in RS and OIS 
cells. This could imply that basal expression of SUV420H2 is sufficient to maintain 
H4K20me3 at appropriate levels following removal of H4K20me3-modified histones 
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during senescence. This also assumes that SUV420H2 is the primary histone 
methyltransferase for H4K20me3 in IMR90 cells, which remains to be formally 
tested through loss-of-function experiments. In contrast, the data could imply that 
H4K20me3 is simply not lost from senescent cells, thus no significant change in 
SUV420H2 expression is required. 
Another possibility that is not formally addressed in the present study is that 
H4K20me3 is maintained in senescent cells through a SUV420H2-independent 
mechanism. For example, H4K20me3 might be deposited by a different histone 
methyltransferase. To this end, several additional histone methyltransferases 
including NSD1, SMYD3 and SMYD5 have been reported to confer histone H4 
lysine 20 trimethylation either in vitro or in vivo (Rayasam et al., 2003; Foreman et 
al., 2011; Stender et al., 2012). Alternatively, H4K20me3 levels might be maintained 
in senescent cells through the inhibition of a specific histone lysine demethylase. The 
enzyme PHF2 was recently reported to demethylate H4K20me3 at the promoters of 
pro-inflammatory genes in macrophages (Stender et al., 2012). Although PHF2 
expression levels do not change by microarray in either RS or OIS (data not shown), 
it is possible that PHF2 undergoes enzymatic inhibition in senescent IMR90 cells. 
Although not tested in the present study, inhibition of PHF2 remains a potential 
mechanistic explanation for the stabilization of H4K20me3 during senescence.  
 Regardless, the question of whether H4K20me3 is simply retained at existing 
sites of deposition during senescence or is actively deposited to different 
nucleosomes following senescence-associated histone loss, is an important 
consideration. Possessing the ability to delineate between these two potential 
scenarios could provide valuable insight regarding the function of H4K20me3 during 
senescence. Probably the most effective way to address the question would be to 
obtain detailed genome-wide profiles of H4K20me3 occupancy in proliferating and 
senescent cells, respectively. Recent advancements in high-throughput sequencing 
technologies currently enable the rapid and accurate determination of nucleic acid 
sequence. Therefore, in order to better define the genomic distribution of H4K20me3 
in proliferating and senescent cells, chromatin immunoprecipitation of H4K20me3 
coupled to high-throughput sequencing will be employed and analyzed in the 
subsequent chapter. 
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Chapter 5. Mapping H4K20me3 Distribution in Senescence 
 
5.1 Rationale 
 Senescent cells are governed by a defined program of altered gene expression 
that culminates in the establishment of a stable proliferation arrest and secretory 
phenotype. Considerable evidence supports a model in which the senescence 
program is regulated at least in part by directed chromatin remodeling. However, 
despite widespread changes in chromatin structure, not all features of the epigenome 
undergo alteration during senescence. For example, total abundance of the 
H4K20me3 histone modification remains identical between proliferating and 
senescent cells. Even more remarkable, this maintenance of H4K20me3 levels occurs 
within the context of a profound reduction of total histone content from senescent 
cells, suggesting that H4K20me3 might be selectively retained at some regions of the 
genome or otherwise redistributed in senescent cells. To this end, chromatin 
immunoprecipitation followed by high-throughput sequencing (ChIP-Seq) can 
generate high-resolution profiles of the genomic distribution of specific histone 
modifications. By comparing the genome-wide localization of H4K20me3 in 
proliferating and senescent cells, it might be possible to gain insight into the 
modification’s contribution to chromatin remodeling and ultimately the senescence 
program. Therefore, I set out to map the genomic localization of H4K20me3 in 
senescent cells by ChIP-Seq and then compare distribution of the mark to other 




5.2.1 Optimization of ChIP-Seq Conditions 
 Over the last decade, considerable advancements in next-generation 
sequencing technologies have enabled the acquisition of genome-wide sequence data 
in a timely, accurate and cost-effective manner. Thus, as the sequencing technology 
has become more accessible, it has facilitated numerous important discoveries 
pertaining to chromatin structure, regulation and function. A valuable extension of 
next-generation sequencing has been to combine it with chromatin 
immunoprecipitation (i.e., ChIP-Seq) in order to obtain a detailed description of the 
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epigenetic landscape for a given cellular context (Barski et al., 2007; Wang et al., 
2008). To this end, I was interested in utilizing a ChIP-Seq approach to map the 
genome-wide distribution of the H4K20me3 histone modification in proliferating 
and senescent IMR90 cells. 
 However, in order to generate meaningful and reproducible data, ChIP-Seq 
can require considerable methodological optimization. To this end, the success of a 
ChIP-Seq experiment can be dictated by myriad factors including parameters for 
chromatin preparation, abundance of the ChIP target, ability to immunoprecipitate 
the target, antibody specificity and the selection of relevant controls (Kidder et al., 
2011). Another important consideration is the model system being used, as it may 
necessitate the optimization of additional parameters. Consequently, before 
proceeding with a wide-scale study of H4K20me3 in proliferating and senescent 
IMR90 cells, I first opted to systematically evaluate and optimize several of the key 
factors discussed above.  
 Because many of the downstream steps of the ChIP procedure are contingent 
upon efficient fragmentation of chromatin, it was first necessary to determine 
empirically the optimal conditions to achieve this. Chromatin fragmentation can be 
accomplished by multiple methods including sonication for cross-linked chromatin 
or nuclease digestion for native, unfixed chromatin. A standard ChIP protocol that 
relies on formaldehyde cross-linking and sonication-mediated fragmentation of 
chromatin was selected for the studies. Sonication of cross-linked chromatin occurs 
in a stochastic manner but can be influenced by several factors including cell density 
and the amplitude and duration of sonication. To determine optimal sonication 
conditions, a defined number of cross-linked IMR90 cells were resuspended in 
nuclear lysis buffer, divided evenly into multiple microcentrifuge tubes and 
subjected to water bath sonication for variable amounts of time at a fixed amplitude. 
As expected, chromatin fragmentation efficiency increased in a time-dependent 
manner, with optimal sonication occurring between 20 and 25 minutes (Figure 5.1). 
Excessive sonication can detrimentally affect ChIP target integrity, so a standard 
sonication time of 22.5 minutes was utilized for all subsequent experiments. 
 The ability to efficiently bind and immunoprecipitate an intended chromatin 
target is another requisite step of the ChIP procedure. Having previously assessed the 
binding specificity of a panel of H4K20me3 antibodies using the MODified Histone 
Peptide Array, the antibodies were subsequently evaluated for ability to 
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immunoprecipitate H4K20me3 from cross-linked chromatin preparations. Based on 
the prior specificity assessment, H4K20me3 rabbit antibodies supplied by Millipore 
(04-079), Cell Signaling Technology (5737), Abcam (ab9053) and Active Motif 
(39180) were selected for testing by ChIP. Sonicated cross-linked IMR90 chromatin 
solutions were subjected to immunoprecipitation with 2 or 10 µg of the Abcam and 
Cell Signaling Technology H4K20me3 antibodies, 10 µg of a total histone H4 
antibody (Millipore, 05-858), and 2 or 10 µg of a negative control rabbit IgG 
antibody (Sigma, M7023).  
 Following ChIP, bound chromatin and antibodies were eluted from the beads 
by boiling in SDS sample buffer, fractionated by SDS-PAGE and immobilized to a 
PVDF membrane. The membrane was subsequently Western blotted for histone H4 
and ChIP efficiency was estimated by the amount of total histone H4 
immunoprecipitated by the H4K20me3 antibodies compared to the histone H4 ChIP 
and input lanes (Figure 5.2a). While the negative control antibody (lanes 1 and 2) 
failed to immunoprecipitate any detectable histone H4, both the Abcam (lanes 3 and 
4) and Cell Signaling Technology (lanes 5 and 6) antibodies precipitated amounts of 
histone H4 comparable to the total histone H4 ChIP (lane 7). Use of an anti-rabbit 
IgG-HRP conjugated secondary antibody for the Western blot also enabled 
visualization of the ChIP antibody heavy and light chains and confirmed that equal 
amounts of the respective antibodies were used for each ChIP reaction. 
 In addition to testing the Abcam and Cell Signaling Technology H4K20me3 
antibodies by ChIP, rabbit antibodies produced by Millipore (04-079) and Active 
Motif (39180) were subjected to evaluation. Chromatin eluted from the Millipore and 
Active Motif H4K20me3 ChIP reactions was assessed by Western blot analysis of 
total histone H4 and compared to the previously validated Abcam antibody. Whereas 
even 10 µg of the Active Motif antibody was insufficient to precipitate any 
detectable histone H4 (Figure 5.2b, lane 5), the Millipore antibody (lane 3) 
precipitated a moderate amount of histone H4, but not as much as the Abcam 
antibody (lane 2). Utilization of an anti-rabbit IgG-HRP conjugated secondary 
antibody for the Western blot again facilitated detection of the ChIP antibody heavy 
and light chains, ensuring that equivalent amounts of the ChIP antibodies were used 
for each reaction. Based on the composite results of the two ChIP antibody 
evaluation experiments, three separate antibodies were found capable of 
immunoprecipitating H4K20me3 from cross-linked chromatin preparations. 
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However, because the Millipore and Cell Signaling Technology H4K20me3 
antibodies both demonstrated higher specificity than the Abcam antibody in the 
peptide array evaluation, these two antibodies were selected for use in all subsequent 
H4K20me3 ChIP experiments. 
 Although the relative specificities of histone modification antibodies can be 
effectively evaluated in vitro using a method such as the MODified Histone Peptide 
Array, it is important to recognize that all antibodies can exhibit a certain degree of 
nonspecific binding. Nonspecific antibody binding in the context of ChIP can be 
exacerbated by a variety of factors including antibody concentration, ChIP buffer 
composition and the stringency of wash conditions. Having previously ascertained 
that the Millipore and Cell Signaling Technology H4K20me3 antibodies were both 
highly specific and capable of immunoprecipitating cross-linked chromatin, the next 
step was to determine which ChIP conditions would permit sufficient H4K20me3 
pull-down while minimizing antibody cross-reactivity. To this end, a series of 
H4K20me3 ChIP reactions were set up to simultaneously evaluate the parameters of 
antibody concentration, ChIP buffer composition and wash stringency. 
  Most standard ChIP protocols suggest the inclusion of SDS in the ChIP lysis 
buffer as it helps facilitate fragmentation of chromatin during sonication. However, 
excessive SDS concentration can be detrimental to the subsequent antibody binding 
steps of ChIP. In order to determine the optimal SDS concentration for H4K20me3 
ChIP, chromatin was prepared from cross-linked IMR90 cells in lysis buffer 
containing 1% SDS and diluted to a final SDS concentration of either 0.25% or 
0.1%. The respective chromatin solutions were then subjected to 
immunoprecipitation using either 2 or 10 µg of the Millipore H4K20me3 antibody 
(04-079) or 10 µg of control rabbit IgG. Following immunoprecipitation, each ChIP 
reaction was washed either in accordance with the standard protocol or with an 
additional stringent wash buffer comprised of 10 mM Tris, 250 mM LiCl, 1 mM 
EDTA, 1% NP-40, 1% deoxycholic acid. The ChIP reactions were then boiled in 
SDS sample buffer, fractionated by SDS-PAGE, immobilized to a PVDF membrane 
and assessed by Western blotting of H4K20me3. 
 As expected, the control rabbit IgG ChIP failed to precipitate H4K20me3 
(Figure 5.3, lane 9), while the H4K20me3 ChIP reactions conducted under differing 
conditions produced variable amounts of H4K20me3 (lanes 1-8). The combined use 
of ChIP lysis buffer containing 0.25% SDS and 2 µg of H4K20me3 antibody was 
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insufficient to precipitate detectable levels of H4K20me3, irrespective of the 
inclusion or exclusion of the stringent LiCl wash (lanes 1 and 2). By reducing the 
SDS concentration to 0.1%, 2 µg of H4K20me3 became sufficient to precipitate low 
but detectable levels of H4K20me3 in either the presence or absence of the LiCl 
wash step (lanes 4 and 6). By increasing the amount of H4K20me3 antibody to 10 
µg, the ChIP reactions yielded considerably more H4K20me3 as assessed by 
Western blotting. The condition that facilitated the most robust precipitation of 
H4K20me3 was the combination of lysis buffer containing 0.1% SDS and 10 µg of 
H4K20me3 antibody (lanes 7 and 8). Under all conditions, the inclusion of the LiCl 
wash step did not appear to adversely affect the overall ChIP yield as determined by 
Western blotting for H4K20me3. As a result, the high stringency LiCl wash step was 
incorporated into all subsequent ChIP experiments. 
 
5.2.2 ChIP-Seq of H4K20me3 in Proliferating and Senescent Cells 
 Based on the series of experiments discussed above, I determined that the 
following conditions were optimal for ChIP of H4K20me3 from cross-linked IMR90 
cells: 22.5 minutes of sonication, dilution of chromatin solutions to 0.1% SDS, 
utilization of 6 µg of antibody per ChIP reaction and inclusion of the LiCl wash step. 
I arbitrarily selected 6 µg of antibody per ChIP as it represented the average of the 
two antibody amounts I had tested. Using these parameters, cross-linked, sonicated 
chromatin solutions isolated from proliferating (PD32) and replicative senescent 
(PD86) IMR90 cells were subjected to immunoprecipitation with 6 µg of control 
rabbit IgG, histone H4 antibody (Millipore, 05-858) or H4K20me3 antibody 
(Millipore, 04-079). For each ChIP reaction, 500 µg of chromatin protein, as 
determined by the Bradford assay, was utilized. Following overnight incubation with 
primary antibodies and beads, the ChIP reactions were washed, eluted, subjected to 
reverse cross-linking and purified by phenol-chloroform extraction. The purified 
ChIP DNA was subsequently quantified using the Qubit fluorometer (Invitrogen), of 
which 10 ng DNA was utilized to generate ChIP-Seq libraries according to the 
standard Illumina protocol. Prepared libraries underwent quality control analysis 
using the Agilent 2100 Bioanalyzer. The libraries were then hybridized to an 
Illumina flow cell for cluster generation, and subjected to single read sequencing on 
the Illumina Genome Analyzer IIx (GAIIx) by the Beatson Institute for Cancer 
Research’s Molecular Technology Services personnel. 
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Sequence (read) lengths of 75 basepairs for the first experiment and 76 
basepairs for the second experiment were extracted from the GAIIx as FASTQ files 
and inspected for quality as described in Chapter 2 (Materials and Methods). The 
resulting reads were then aligned to the human genome (assembly NCBI36/hg18) 
using the Bowtie alignment tool and the settings described in Chapter 2. It is 
important to note that Tony McBryan, our laboratory computational biologist, 
performed all of the sequence alignment and subsequent analysis. Any sequences 
that failed to align or align to more than one site in the genome were excluded from 
subsequent analyses. Because the standard ChIP-Seq library preparation protocol 
utilizes a PCR amplification step, preferential amplification of certain sequences can 
occur. PCR clonality is a particularly relevant issue when generating ChIP-Seq 
libraries from samples with a low ChIP yield, as low yield often corresponds with 
low sample complexity. In this context, an individual DNA fragment may undergo 
excessive amplification and become overrepresented in the sequencing run, reducing 
the specificity of the experiment. This can create bias in the process of identifying 
regions of the genome that are enriched for a particular chromatin modification. In 
order to account for this, any multiple identical reads were also excluded from the 
subsequent analyses.  
As summarized in Table 5.1, the first ChIP-Seq experiment generated 
between 28 and 42 million total reads for the DNA inputs and histone H4 and 
H4K20me3 ChIP reactions. After removing reads that failed to align uniquely to the 
human genome and multiple identical reads, between 7 and 33 million uniquely 
alignable reads remained (Table 5.1). For the PD32 input and histone H4 ChIP 
samples respectively, 24,478,131 (63%) and 25,455,213 (66%) of the total reads 
remained after filtering, whereas for the PD32 H4K20me3 ChIP sample only 
14,319,405 (36%) of the total reads were uniquely alignable sequences. Likewise, 
20,520,747 (71%) and 31,894,106 (76%) of the total reads from the PD86 input and 
histone H4 ChIP samples were uniquely alignable, while only 7,941,385 (20%) of 
the PD86 H4K20me3 ChIP reads remained after filtering. Although initially 
surprising, many of the PD32 and PD86 H4K20me3 ChIP reads were likely excluded 
by filtering because they represented repetitive regions of the genome, including 
pericentromeres and telomeres (Mravinac et al., 2009, Ernst & Kellis, 2010). 
Consequently, these repetitive sequences would not be aligned as unique regions of 
the genome. 
	   139	  
	   140	  
 There is some debate as to whether reads that align to multiple genomic 
locations should be excluded from downstream analysis. The advantage of removing 
multiple alignments is that it improves the specificity of the analysis, by ensuring 
that the remaining reads align to single, unambiguous genomic sites. The 
disadvantage of removing multiple alignments is that it can create bias and decrease 
the sensitivity of the experiment, as certain genomic classes such as DNA repeats 
might be excluded from analysis due to the inherently repetitive nature of the 
sequences. Ultimately, the decision to include or exclude multiple alignments comes 
down to a trade-off between specificity and sensitivity and is largely dictated by the 
nature of the experiment. For example, for a ChIP-Seq experiment conducted on a 
chromatin modification reported to associate with repetitive elements, it might be 
beneficial to perform the analysis two ways, both including and excluding multiple 
alignments. 
 Before performing any comprehensive analysis of the first H4K20me3 ChIP-
Seq data, a second experiment was conducted. Whereas the first set of H4K20me3 
ChIPs were performed using equal amounts of chromatin protein from proliferating 
and senescent cells, the second experiment was carried out using equal amounts of 
chromatin DNA. Because senescent cells can contain more protein per cell than 
proliferating cells, by using equal amounts of protein for each ChIP reaction, I might 
unintentionally utilize fewer senescent cells per ChIP. DNA content is arguably less 
variable between proliferating and senescent cells and was therefore used to ensure 
that the ChIP reactions utilized equivalent numbers of proliferating or senescent 
cells. As before, solutions of sonicated chromatin from proliferating (PD32) or 
replicative senescent (PD86) IMR90 cells were subjected to immunoprecipitation 
with 6 µg of control rabbit IgG or histone H4 antibody (Millipore, 05-858). 
However, for this second experiment, a different H4K20me3 antibody (Cell 
Signaling Technology, 5737) was used. The second H4K20me3 was utilized in order 
to confirm the specificity of any observed regions of H4K20me3 localization. 
Therefore, any H4K20me3-containing regions that appeared with both antibodies 
likely represented genuine regions of enrichment for the modification. Aside from 
the differences just described, the second H4K20me3 ChIP-Seq experiment was 
conducted in the same manner as the first experiment. The resulting ChIP DNA 
samples were used to generate libraries and sequenced as before using the Illumina 
GAIIx. 
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 The reads obtained from the second ChIP-Seq experiment were similarly 
aligned to the human genome using the Bowtie alignment tool. All reads that failed 
to align to a unique region of the genome and any identical reads were filtered from 
the data. Comparable to the first ChIP-Seq experiment, the second experiment 
yielded between 33 and 39 million reads per input or ChIP sample (Table 5.2). 
However, after considering the alignment requirements discussed above, between 7 
and 29 million uniquely alignable, non-redundant reads per sample remained (Table 
5.2). Similar to the first experiment, 23,638,627 (62%) and 24,221,792 (66%) of the 
PD32 input and histone H4 ChIP total reads, respectively, aligned uniquely to the 
genome, while only 7,824,101 (24%) of the total reads from the PD32 H4K20me3 
ChIP aligned uniquely to the genome. For the PD86 input and histone H4 ChIP 
samples, 25,474,711 (68%) and 29,646,203 (75%) of the total reads, respectively, 
aligned uniquely to the human genome. In contrast, only 12,222,896 (34%) of the 
PD86 H4K20me3 ChIP total reads aligned uniquely. Although both the PD32 and 
PD86 H4K20me3 ChIP samples from the second experiment exhibited considerably 
lower degrees of sequence alignment, the observation was consistent with the first 
experiment. Again, the majority of the PD32 and PD86 H4K20me3 ChIP reads failed 
to align to unique regions of the genome presumably because they corresponded to 
repetitive genomic loci. 
 
5.2.3 Senescent Cells Contain Regions of H4K20me3 Enrichment 
Having obtained H4K20me3 ChIP-Seq data from proliferating and replicative 
senescent IMR90 cells using two separate H4K20me3 antibodies, it was next 
important to determine whether the modification occupied identical or unique 
locations in the respective cell states. Because net abundance of the H4K20me3 
modification was comparable in proliferating and senescent cells, two scenarios were 
possible. Either H4K20me3 distribution remained identical in proliferating and 
senescent cells, or the profile of the modification was altered in senescent cells, 
being lost from one region and deposited at another, such that the absolute levels of 
the mark remained constant. Using the respective ChIP-Seq datasets, it was possible 
to distinguish between the two scenarios. To this end, it was first necessary to 
identify regions of H4K20me3 enrichment in proliferating and senescent cells.  
 In order to accomplish this, the uniquely aligned H4K20me3 reads were 
compared to the uniquely aligned histone H4 reads using SICER (version 1.1). 
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SICER is a tool used to identify regions of significant enrichment for specific 
chromatin modifications, including histone marks, by defining clusters of sequencing 
reads that are unlikely to occur at a given location due to chance (Zang et al., 2009). 
SICER was specifically selected for the analysis as it performs optimally for 
modifications that occur diffusely across the genome. As described in detail in 
Chapter 2 (Materials and Methods), SICER works by computing the likelihood that 
an accumulation of chromatin modification ChIP reads (e.g., H4K20me3) occurs 
specifically within a defined region, rather than occurring in the region in a 
stochastic manner. For each region, SICER was used to evaluate the H4K20me3 
reads relative to the total histone H4 ChIP reads, in order to reduce the likelihood 
that the H4K20me3 reads accumulated due to regional variation in chromatin 
solubility. Based on the SICER analysis, statistically significant clusters (i.e., 
domains) of H4K20me3 reads were identified in the PD32 and PD86 samples. 
Following the identification of H4K20me3 domains in the PD32 and PD86 
samples using SICER, the respective datasets were compared using the DiffBind 
Bioconductor package in order to determine regions of differential H4K20me3 
enrichment between the PD86 and PD32 samples. In total, DiffBind identified 
10,786 domains of H4K20me3 differential abundance between the PD32 and PD86 
samples. Remarkably, the PD86 sample from experiment 1 contained differentially 
enriched H4K20me3 domains spanning 87,878,460 bp or 3.0% of genome, while the 
PD86 sample from experiment 2 contained H4K20me3 domains covering 
75,658,200 bp or 2.6% of the genome.  
The 10,786 domains of H4K20me3 differential enrichment were 
subsequently displayed as a cluster diagram (Figure 5.4a) using the R version 2.15.1 
hclust function from the fastcluster library, as described in Chapter 2 (Materials and 
Methods). Each row in the cluster diagram represents one of the 10,786 differentially 
enriched domains. It is important to note that the color intensity of each domain 
reflects the level of H4K20me3 enrichment over histone H4 (after normalization for 
library size) for each replicate, rather than the level of H4K20me3 differential 
enrichment between the PD86 and PD32 samples. As revealed in Figure 5.4a, the 
PD86 samples displayed numerous H4K20me3 domains that were either not present 
in the PD32 samples or present at a considerably lower abundance. Remarkably, the 
distribution of these differentially enriched H4K20me3 domains was strikingly 
similar between the PD86 samples from both experiments. Importantly, this 
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indicated that both the Millipore and Cell Signaling Technology H4K20me3 
antibodies immunoprecipitated chromatin from comparable regions of the genome. 
In this way, the data provided supporting evidence that the individual H4K20me3 
antibodies were highly specific to the modification and added confidence in 
interpreting the distribution of H4K20me3 in senescent cells. 
To provide additional insight into the genomic distribution of the 
SICER/DiffBind defined regions of H4K20me3 enrichment, the domains identified 
in Figure 5.4a were plotted as a chromosome ideogram (Figure 5.4b). As evident in 
the ideogram, regions of PD86-specific H4K20me3 differential enrichment were 
present across all chromosomes. Although some chromosomes exhibited regions 
devoid of H4K20me3 enrichment, the mark was distributed widely across the 
genome and occasionally present as larger blocks of enrichment (e.g., chromosome 
19). 
 In order to better characterize the distribution of H4K20me3 in senescent 
cells, the regions of PD86-specific H4K20me3 differential enrichment identified in 
Figure 5.4a were compared to defined features of the human genome. To accomplish 
this, the coordinates of the H4K20me3 differentially enriched domains were assessed 
for overlap with a panel of well-defined genomic features. The 10,786 H4K20me3 
domains were clustered by hierarchical clustering, using the R 2.15.1 hclust function 
from the fastcluster library. As described in Chapter 2 (Materials and Methods), each 
differential domain was treated as a k-dimensional vector, for which each entry 
within the vector was either the presence or absence of a genomic feature of interest. 
The domains were then clustered both row and column-wise using Euclidian distance 
as the distance metric and the complete linkage function. The data were then 
reordered to conform to the clustering analysis and plotted using the R heatmap.2 
function in the gplots library (Figure 5.5a). Each row represents one of the 10,786 
H4K20me3 differentially enriched domains and each column reflects a specific 
genomic feature. It is important to note that because each feature was scored for 
either presence or absence of overlap with H4K20me3, this analysis did not provide 
any ranking based on the level of H4K20me3 differential enrichment.  
 As presented in Figure 5.5a, the domains of H4K20me3 differential 
enrichment coincided with a variety of genomic features, including long terminal 
repeats (LTR), intergenic regions, late replicating regions (Late), regions that 
become DNA hypomethylated in senescent cells (Hypo), lamina-associated domains 
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(LAD), short interspersed elements (SINE) and long interspersed elements (LINE). 
The late replicating regions were defined by the work of Hellman and colleagues 
(Aran et al., 2011). Regions of DNA hypomethylation were based on recent work 
from Peter Adams’ laboratory (Cruickshanks et al., submitted). Likewise, the lamina-
associated domains were defined by work from Shelley Berger’s laboratory (Shah et 
al., submitted). Finally, considerably more of the senescence-specific H4K20me3 
domains mapped to intergenic regions of the genome than to genes. This was not 
surprising however, as protein-coding genes comprise approximately only 1.5% of 
the human genome (Venter et al., 2001; International Human Genome Sequencing 
Consortium, 2004). 
 Several of the genomic features identified in Figure 5.5a as containing 
H4K20me3 enrichment in senescent cells, represented interspersed DNA repeats 
(e.g., LTRs, SINEs and LINEs). Although H4K20me3 was previously identified at 
another class of DNA repeats, the tandem satellite repeats, fewer of the senescence-
specific H4K20me3 domains appeared to occur at satellite sequences (Sat) in our 
analysis (Ernst & Kellis, 2010). This is may be partially explained by the fact that 
satellite repeats only account for approximately 3% of the human genome, whereas 
LTR retrotransposons (9%), SINES (15%) and LINES (21%) comprise a 
considerably larger proportion of the genome (Treangen & Salzberg, 2012). It is also 
important to point out that some of the H4K20me3 reads which might have aligned 
to DNA repeats were presumably removed from the analysis due to our intentional 
exclusion of sequences that could not be aligned to singly unique locations in the 
genome.  
 It is important to note that each of the genomic features included in the 
clustering analysis in Figure 5.5a comprised different proportions of the genome. 
Consequently, it was formally possible that some of the overlap between the 
H4K20me3 domains and individual genomic features might be attributed to the 
frequency that a specific feature occurred throughout the genome. To address this, 
the genomic coordinates of the H4K20me3 differentially enriched regions and 
defined genomic features were compared and the number of basepairs present in both 
datasets was calculated as a percentage of the total number of basepairs for each 
individual feature. For each genomic feature, a random overlap percentage was also 
calculated, which involved random distribution of the feature across the genome and 
the calculation of the overlap between this random feature and the H4K20me3 
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differentially enriched signal. The random distribution was carried out 1000 times 
and the mean percentage overlap was utilized. The data were then expressed as the 
fold enrichment of the observed H4K20me3 percentage overlap over the random 
percentage overlap for each genomic feature, and displayed graphically in Figure 
5.5b. P-values were calculated by observing the frequency that the random overlap 
was greater than or equal to the observed overlap. 
 Based on this analysis, three genomic features exhibited significant 
H4K20me3 enrichment over random chance: LTRs, satellite repeats and ZNF genes 
(Figure 5.5b). Approximately 3-fold enrichment over random chance was observed 
for H4K20me3 at both LTRs and satellites, with a p-value below the limit of 
detection. Likewise, 5-fold enrichment over random chance was observed for 
H4K20me3 at ZNF genes, with a p-value similarly below the limit of detection. 
Importantly, these data are largely consistent with a previous genome-wide study that 
reported marked enrichment of H4K20me3 at satellite DNA and ZNF genes in 
human CD4+ T cells (Barski et al., 2007). However, Barski and colleagues failed to 
observe significant H4K20me3 enrichment at LTRs, which may be attributed to one 
of several factors. First, it is possible that H4K20me3 enrichment varies between cell 
types, as the study by Barski and colleagues utilized T cells while the present study 
was conducted using IMR90 cells. Second, H4K20me3 enrichment may only occur 
at LTRs in senescent cells, as the enrichment at LTRs was only observed for the 
senescence-specific domains of H4K20me3 differential enrichment. Finally, the 
discrepancy between the study by Barski and colleagues and the present analysis 
may reflect differences in H4K20me3 antibody quality. Whereas the data from the 
report by Barski and colleagues was generated using the Abcam (ab9053) 
H4K20me3 antibody, the present study was conducted using Millipore (04-079) and 
Cell Signaling Technology (5737) antibodies, which I have previously demonstrated 
to exhibit higher specificity than the Abcam (ab9053) antibody (see Figure 4.1). 
Regardless of any discrepancies with the previous literature, the current data indicate 
that H4K20me3 is significantly enriched at LTRs, satellites and ZNF genes in 
senescent IMR90 cells.  
Based on the analysis presented in Figure 5.5, domains of statistically 
significant H4K20me3 enrichment coincided with several features of 
heterochromatin and repetitive DNA in the PD86 senescence cells. In order to 
validate the observed overlap between H4K20me3 and these features, it was 
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important to examine the H4K20me3 enriched domains within the genomic context. 
To this end, all uniquely alignable reads from the input DNA, histone H4 ChIP and 
H4K20me3 ChIP samples were assembled as individual bigWig tracks and uploaded 
to the UCSC Genome Browser for visualization. The SICER/DiffBind defined 
domains of H4K20me3 differential enrichment identified in Figure 5.4a were 
included as a parallel track in the Genome Browser viewer. Using the RepeatMasker 
tool, a program that identifies regions of low complexity DNA and interspersed 
repeats throughout the genome, a track showing domains of repetitive DNA and 
potential heterochromatin was also included in the viewer. As evident in Figure 5.6b, 
several domains of H4K20me3 differential enrichment exhibited distinct overlap 
with LTRs within an 85 kb region of chromosome 5 (5q31.3). Although occasional 
minor overlap between H4K20me3 and LINEs or SINEs was also apparent, the 
majority of the overlap occurred between H4K20me3 and LTRs. While LTRs are not 
exclusive to heterochromatic domains, this class of repeats is frequently associated 
with heterochromatin and was therefore considered a feature of heterochromatin for 
the present analysis (Cordaux & Batzer, 2009). It is important to note that alignment 
of the H4K20me3 differentially enriched domains to two of the most prominent 
examples of heterochromatin (e.g., centromeres and telomeres) was not possible, as 
these sequences are omitted from the current version of the UCSC Genome Browser. 
 In order to provide a less biased interrogation of the ChIP-Seq data, I next 
wished to examine the distribution of H4K20me3 across the broader genomic 
context. To this end, input DNA, histone H4 ChIP and H4K20me3 ChIP samples 
were again assembled as individual bigWig tracks and visualized using the UCSC 
Genome Browser. Whereas the previously discussed analysis was based on 
H4K20me3 differential enrichment, utilizing the Genome Browser enabled 
simultaneous viewing of each PD32 and PD86 sample from the two ChIP-Seq 
experiments. After viewing the input, histone H4 ChIP and H4K20me3 ChIP tracks 
aligned to each chromosome, chromosome 19 was selected as it contained discrete 
regions of marked H4K20me3 enrichment in the senescent samples (Figure 5.7b). As 
indicated by the schematic chromosomal ideogram displayed in Figure 5.7a, the 
tracks represented in Figure 5.7b spanned the entire length of chromosome 19 
(p13.3-q13.34).  
 Importantly, based on each of the input and ChIP tracks in Figure 5.7b, no 
regions appeared obviously devoid of reads, suggesting that sufficient sequencing 
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coverage had been achieved. However, a better and less ambiguous indicator of 
sequencing coverage is reflected in the total number of reads obtained for each ChIP-
Seq replicate. As recommended in the current guidelines of the ENCODE and 
modENCODE consortia, 10 million uniquely alignable reads per replicate is 
considered to provide sufficient sequencing coverage for binding factors and 
modifications that localize to specific positions across the genome, while 20 million 
uniquely alignable reads per replicate is considered adequate for chromatin 
modifications with a broad genomic distribution (Landt et al., 2012). As summarized 
in Tables 5.1 and 5.2, each input and histone H4 ChIP sample yielded in excess of 20 
million uniquely alignable reads, suggesting sufficient coverage. The H4K20me3 
ChIP samples ranged from 7.8-14 million reads per replicate, which is on the low 
end for a broadly distributed histone modification, but within an acceptable range for 
a localized modification. H4K20me3 is not a broadly distributed modification, as it 
only occupies approximately 2-3% of all histone H4 molecules present in chromatin 
and predominantly localizes to defined genomic regions including certain DNA 
repeats and ZNF genes (Pesavento et al., 2008; Ernst & Kellis, 2010). Consequently, 
the current H4K20me3 ChIP samples likely provide sufficient sequencing coverage. 
 As presented in Figure 5.7b, all of the input and histone H4 tracks for the 
PD32 proliferating and PD86 senescent cells exhibited a predominantly even 
distribution across chromosome 19, with very few regions of variability. This was 
important as it signified that there were unlikely any regions exhibiting solubility 
bias. For example, if multiple tracks had displayed identical regions lacking reads, it 
might have been formally possible that those particular genomic coordinates were 
resistant to solubilization during the ChIP process. Fortunately, this did not appear to 
be the case. Both of the PD32 H4K20me3 tracks contained some regions of subtle 
H4K20me3 enrichment over background, with slightly higher levels of enrichment 
observed in the track from the first experiment (PD32 H4K20me3 v1). Interspersed 
regions of H4K20me3 enrichment over background were even more apparent in both 
of the PD86 H4K20me3 tracks, again with higher numbers of clustered H4K20me3 
reads in the track from the first experiment (PD86 H4K20me3 v1). Domains of 
H4K20me3 enrichment in the PD86 cells relative to the PD32 cells were identified 
using SICER and DiffBind and represented graphically as a track of black bars 
plotted along the bottom of the Genome Browser window. Remarkably, both of the 
PD86 H4K20me3 tracks exhibited an extensive cluster of H4K20me3 enrichment 
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spanning nearly 5 megabases and located within the 19p12 locus (Figure 5.7b, 
indicated by the orange box). Similar clusters of robust H4K20me3 enrichment were 
also present at several additional regions of chromosome 19. 
 Several regions located within the p13.11-p12 locus of chromosome 19 
displayed high levels of H4K20me3 enrichment in the PD86 replicates. 
Consequently, this region was selected for visualization at a higher resolution. While 
no enrichment was observed in this 4.4 Mb region for the PD32 and PD86 input and 
histone H4 ChIP samples, marked H4K20me3 enrichment (ranging from 2- to 5-fold 
over background) was present in both PD86 replicates (Figure 5.8b). Domains of 
H4K20me3 enrichment in the PD86 versus PD32 replicates were confirmed using 
SICER and DiffBind and plotted graphically as a track of black bars along the 
bottom of the Genome Browser window. Surprisingly, whereas the initial 
comparison of PD86-specific H4K20me3 enrichment to defined genomic features 
indicated that H4K20me3 frequently resided within intergenic regions (Figure 5.5), 
the H4K20me3 enrichment observed in the PD86 replicates with the 19p13.11-p12 
locus seemingly occurred at a genic region (Figure 5.8b). Intriguingly, although 
numerous genes were present within this locus, much of the H4K20me3 enrichment 
appeared to localize to a specific cluster of ZNF genes. 
 Given that the PD86 replicates exhibited considerable H4K20me3 enrichment 
across multiple regions of chromosome 19 and appeared to localize to genes, it was 
important to inspect these regions at a higher resolution. To accomplish this, a 97-
kilobase region of chromosome 19 containing PD86-specific H4K20me3 enrichment 
was selected for visualization using the UCSC Genome Browser (Figure 5.9). At this 
resolution, three distinct genes (ZNF563, ZNF442, ZNF799) were visible and each 
displayed a PD86-specific accumulation of H4K20me3 reads within the gene body, 
as evident in the bigWig tracks and black SICER/DiffBind bars (Figure 5.9b). 
Although some of the H4K20me3 reads occurred within the intergenic regions 
adjacent to the genes, for each gene the most abundant accumulation of H4K20me3 
reads existed within the gene body, particularly toward the 3’ end. This strongly 
suggests that the domains of H4K20me3 enrichment in the PD86 samples likely 
originate within the gene bodies and extend into the adjacent intergenic regions, 
rather than the inverse. In order to explore this further, I next decided to evaluate the 
genomic distribution of H4K20me3 enrichment in the PD86 senescent cells with 
respect to genes. 
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5.2.4 H4K20me3 Does Not Correlate with Transcriptional Changes 
Given that the senescence program is regulated in part through a 
characteristic set of transcriptional changes, it was important to determine whether 
H4K20me3 was significantly enriched at specific genes in the PD86 senescent cells. 
As an extension, it was equally relevant to ask whether there was a correlation 
between H4K20me3 enrichment at genes and altered expression of those genes. To 
address this, the H4K20me3 ChIP data were directly compared to the replicative 
senescence gene expression data obtained from the Affymetrix Human Genome 
U133 Plus 2.0 microarrays.  
In order to visualize any potential correlation between H4K20me3 
distribution in senescent cells and gene expression, a scatter plot was generated 
(Figure 5.10a). Each individual data point represented an individual gene from the 
array with the relative expression levels of the genes (log of the fold change of 
senescent versus proliferating) plotted along the x-axis and relative H4K20me3 ChIP 
Difference plotted along the y-axis. As described in Chapter 2 (Materials and 
Methods), H4K20me3 ChIP Difference is defined as the senescent (PD86) 
H4K20me3 ChIP signal minus the proliferating (PD32) H4K20me3 ChIP signal. The 
respective PD32 and PD86 H4K20me3 ChIP signals were first determined by 
measuring the number of H4K20me3 reads (extended to 150 bp) within the promoter 
region of each gene, normalized by the library size, with the corresponding histone 
H4 library subtracted following similar normalization. For this analysis, the gene 
promoter was broadly defined as the gene body plus 5 kb upstream and 1 kb 
downstream of the gene body. 
 The majority of genes localized to the center of the plot indicating that those 
genes had neither undergone a change in expression in senescent cells nor contained 
different levels of the histone H4K20me3 modification in the proliferating and 
senescent states (Figure 5.10a). While there was a modest shift left along the x-axis 
for some genes, indicating reduced expression in PD86 senescent cells, these genes 
clustered around the zero point of the y-axis, revealing no relative H4K20me3 
enrichment was present at those genes. Likewise, although some genes contained 
relatively high enrichment of H4K20me3 in the PD86 senescent cells, these genes 
remained essentially unchanged at the level of expression and clustered around the 
zero point of the x-axis. Thus, gain or loss of H4K20me3 at genes does not appear to 
be tightly linked to activation or repression of gene expression in senescent cells. 
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Interestingly, a subset of genes showed marked enrichment of H4K20me3 but did 
not change expression between proliferating and senescent cells. It is possible that if 
more stringent criteria were applied in defining gene promoters then the results might 
exhibit a different pattern. For example, if gene promoters were more conservatively 
defined as the TSS +/- 1 kb, it is possible that a stronger correlation between 
H4K20me3 abundance and gene expression might emerge. Although this analysis 
was not performed for the present study, it could be useful in evaluating a potential 
role for H4K20me3 in the regulation of gene expression in senescent cells. 
To investigate the relationship between H4K20me3 and gene expression in 
senescent cells further, all of the genes from the replicative senescence microarray 
dataset were categorized into one of three classes: those that were upregulated in 
senescence, those that were downregulated in senescence and those that remained 
unchanged. As before, the expression changes were considered significant if the fold 
difference between proliferating and senescent cells exceeded 1.5 fold (or less than -
1.5 fold) and the BH-FDR adjusted p-value was less than 0.05. Using these lists of 
genes, composite gene profiles were generated for each of the three groups. 
To generate composite gene profiles, the gene body for each gene from the 
respective lists was divided into forty equally sized compartments and then queried 
for H4K20me3 ChIP Difference within each compartment. This enabled comparison 
of H4K20me3 distribution along genes while accounting for variations in gene 
length. Gene body was defined as any sequence that occurred between the 
transcription start site (TSS) and transcription end site (TES) of each gene. In 
addition, 5 kb of sequence up- and downstream of the gene body was also included 
in the analysis. Upon assembly of the three composite genes (e.g., upregulated, 
downregulated and unchanged), the compartments within each composite gene were 
interrogated for the level of H4K20me3 ChIP Difference. As with the analysis in 
Figure 5.10a, H4K20me3 ChIP Difference was defined as senescent (PD86) 
H4K20me3 ChIP signal (normalized for library size and histone H4 signal) minus 
the proliferating (PD32) H4K20me3 ChIP signal (normalized for library size and 
histone H4 signal). Mean H4K20me3 ChIP Difference was calculated within each 
compartment of the respective composite genes and plotted graphically. 
As displayed in Figure 5.10b, the composite gene profiles of H4K20me3 
distribution across the upregulated and downregulated genes were essentially 
identical, with modest levels of H4K20me3 present around the TSS and TES, 
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respectively. The fact that H4K20me3 abundance was comparable at both the 
upregulated and downregulated genes again confirmed that no obvious functional 
relationship existed between the histone mark and expression of those genes. 
Interestingly, as in the previous analysis, the set of genes that remained unchanged 
between proliferating and senescent cells exhibited the highest average levels of 
H4K20me3 ChIP Difference. Although data from only the first ChIP-Seq experiment 
were presented here, the composite gene profiles were nearly identical for the second 
experiment. 
 One potential caveat to the interpretation of the composite gene profiles 
presented in Figure 5.10b is that not every gene from the microarray overlapped with 
a domain of H4K20me3 enrichment. Because the composite gene profiles represent 
the mean H4K20me3 ChIP Difference within the respective gene categories and 
there are likely numerous genes within each category devoid of H4K20me3 signal, 
the plots potentially underestimate the distribution of the mark. For example, if the 
composite gene profiles were generated for only those genes which contained 
overlap with SICER/DiffBind defined domains of H4K20me3 enrichment, the 
profiles would likely provide a better representation of H4K20me3 distribution 
across the three categories of genes in senescent cells. This approach would 
undoubtedly increase the overall mean H4K20me3 enrichment observed for the 
respective profiles, with the greatest increase likely occurring in the profile of the 
unchanged genes (based on Figure 5.10a). However, it is difficult to predict whether 
specific features of the composite gene profiles, such as the observed peaks at the 
TSS and TES, would become even more evident using only genes that overlap with 
the SICER/DiffBind defined H4K20me3 domains. 
 It should also be noted that the H4K20me3 peaks present at the TSS of the 
composite gene profiles in Figure 5.10b were surprising. This was particularly 
unexpected for the profile of upregulated genes, as it has been widely reported that 
the TSS of active genes is ordinarily largely devoid of nucleosomes (Ozsolak et al., 
2007; Schones et al., 2008). As discussed earlier, the H4K20me3 ChIP Difference 
calculation involves subtraction of PD32 H4K20me3 reads (after normalization to 
histone H4 reads and library size) from PD86 H4K20me3 reads (after normalization 
to histone H4 reads and library size). Consequently, any signal observed for 
H4K20me3 at a histone H4-depleted TSS might be interpreted as a domain of 
H4K20me3 enrichment after normalization for histone H4. For this reason, 
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normalization to the respective DNA input samples might reduce any bias generated 
as a consequence of the histone H4-depleted regions. Although the present analyses 
were performed using normalization to histone H4, it might be useful to separately 
normalize to input DNA in order to determine whether H4K20me3 was indeed 
enriched at the TSS of genes in senescent cells. 
 
5.2.5 H4K20me3 is Enriched at ZNF Genes in Senescent Cells 
 Although the presence of H4K20me3 in senescent cells did not appear to 
overtly impact gene expression, it was still important to assess whether the 
modification was enriched at any specific classes of genes. Significantly, as revealed 
by the hierarchical clustering analysis (Figure 5.5) and visualized by the UCSC 
Genome Browser bigWig tracks (Figures 5.7, 5.8 and 5.9), replicative senescent 
IMR90 cells displayed considerable H4K20me3 enrichment at several distinct 
clusters of ZNF genes. In order to obtain a more definitive picture of the extent to 
which H4K20me3 was specifically enriched at ZNF genes, a composite gene 
approach was again employed to compare H4K20me3 enrichment at ZNF genes 
versus non-ZNF genes. In order to keep this analysis comparable with the previous 
comparisons of H4K20me3 enrichment and gene expression, only genes contained 
on the Affymetrix Human Genome U133 Plus 2.0 were included. In this case, 
composite genes were generated for two categories of genes: ZNF genes (of which 
there were 547) and all other non-ZNF genes (of which there were 18,056).  
 The composite genes were subsequently interrogated for H4K20me3 
enrichment in the PD32 proliferating and PD86 senescent ChIP datasets, 
respectively. It is critical to note that in this case, regions of significant H4K20me3 
enrichment were defined in the PD32 and PD86 samples by comparing H4K20me3 
reads to the corresponding histone H4 reads from the same ChIP sample. In the 
PD32 proliferating cells, relatively low levels of H4K20me3 enrichment were 
observed across the ZNF and non-ZNF composite genes, with only modest 
H4K20me3 enrichment present around the TSS of the ZNF genes (Figure 5.11a). In 
the PD86 senescent cells, low levels of H4K20me3 abundance were similarly 
observed for the non-ZNF genes (Figure 5.11b). In contrast, the PD86 cells exhibited 
significantly higher levels of H4K20me3 across the entire ZNF composite gene, with 
considerable enrichment noted at the TSS and increasingly toward the TES. This 
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data strongly suggests that in senescent cells, H4K20me3 is specifically enriched at 
ZNF finger genes, relative to all other genes. 
 It is important to note that the current ChIP-seq methodology does not 
provide a truly quantitative measure between samples, but rather a semi-quantitative 
measure. While the present analysis can detect differences in the distribution of a 
given histone modification between samples, it does not provide absolute levels of 
the modification for the respective samples. Although we did not utilize spike-in 
controls in the present ChIP-seq experiments, such an approach might provide a 
method for improving the quantitative capability of the analysis. By incorporating a 
fixed amount of known DNA into each ChIP sample prior to the library preparation, 
it is subsequently possible to determine the amount of the spike-in control that is 
recovered for each library after sequencing and to utilize the percentage of recovered 
spike-in control to provide a weighting normalization factor for the respective 
samples. However, one potential caveat of utilizing a spike-in control is that it might 
alter the complexity of the library sample and potentially be subjected to preferential 
amplification, thus providing an inaccurate measure of the spike-in recovery. In this 
case, the PCR amplification efficiency of the known spike-in DNA and sample DNA 
could not be assumed to be equivalent, ultimately compromising the accuracy of the 
normalization factor. Despite this caveat, spike-in controls provide a valid approach 
toward developing a more quantitative ChIP-seq assay and should be considered for 
future experiments. 
 In order to provide a more quantitative assessment of the apparent enrichment 
of H4K20me3 at ZNF genes in senescent cells, it was necessary to calculate the 
frequency with which the modification was present at ZNF genes relative to all other 
non-ZNF genes. To accomplish this, ZNF genes and non-ZNF genes were evaluated 
for H4K20me3 enrichment at the individual base pair level. To this end, the 
coordinates of H4K20me3 enrichment over histone H4 in PD32 and PD86 cells, 
respectively, were compared at the coordinates of ZNF and non-ZNF genes and the 
percentage of gene base pairs that were occupied by H4K20me3 was calculated. For 
each condition (i.e., PD32 ZNF genes, PD32 non-ZNF genes, PD86 ZNF genes, 
PD86 non-ZNF genes) the percentage of base pairs that was likely to overlap due to 
chance was also calculated. In both the PD32 and PD86 cells, H4K20me3 
overlapped with a higher percentage of ZNF gene base pairs than non-ZNF gene 
base pairs, with as much as 14% of all ZNF gene base pairs overlapping with 
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H4K20me3 in the PD86 senescent cells (Figure 5.12). Importantly, in both the PD32 
and PD86 cells, the observed percentage of ZNF gene base pairs overlapping with 
H4K20me3 exceeded that which might have occurred due to random chance. 
 
5.3 Discussion 
 By mapping the genome-wide distribution of a specific histone modification, 
it is possible to gain significant insight regarding the mark’s contribution to the 
broader chromatin landscape of the system being studied. Given the dynamic 
chromatin changes that take place as cells undergo senescence, I set out to further 
characterize the senescent chromatin state and investigate its role in mediating the 
senescence program. To this end, I first endeavored to map the genomic distribution 
of H4K20me3, a histone modification that I had previously demonstrated is 
selectively retained in senescent cells despite a net reduction of total histone content. 
In order to accomplish this, I opted to utilize a ChIP-sequencing based methodology, 
as it could facilitate the rapid acquisition of robust genome-wide sequence data. 
 Despite significant advances in sequencing technologies, conducting ChIP-
Seq experiments is not a trivial technical undertaking and typically requires 
considerable optimization. As such, great effort was made toward optimizing several 
of the key ChIP parameters including choice of antibody, sonication time, antibody 
concentration, chromatin dilution and wash stringency. Following optimization, 
immunoprecipitation of histone H4 and H4K20me3 was successfully performed on 
cross-linked chromatin isolated from proliferating and replicative senescent IMR90 
cells. Because antibody cross-reactivity is always a concern with any 
immunological-based assay, the ChIP experiments were performed with two 
independent H4K20me3 antibodies. 
Analysis of the H4K20me3 ChIP-Seq data revealed a markedly altered 
distribution of H4K20me3 in replicative senescent cells, relative to proliferating 
cells. Utilizing SICER and DiffBind, 10,786 domains of senescence-specific 
H4K20me3 differential enrichment were identified. Comparison of these domains to 
a panel of well-characterized genomic features showed that a large proportion of the 
H4K20me3-rich domains coincided with various classes of DNA repeats (e.g., LTRs 
and satellite DNA). Importantly, H4K20me3 enrichment has also been previously 
reported at regions of repetitive DNA, including satellite repeats (Ernst & Kellis, 
2010). Although sequencing reads corresponding to DNA repeats can be difficult to 
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align uniquely to the human genome and are often excluded from downstream 
analyses, the inexact and variable composition of DNA repeats allows for some reads 
to be aligned in an unambiguous manner (Treangen & Salzberg, 2012). 
 It should be noted that to identify the domains of H4K20me3 differential 
enrichment, the default settings were utilized for both SICER and DiffBind, as 
described in Chapter 2 (Materials and Methods). Ideally, by increasing the stringency 
of the settings it might be possible to improve the accuracy of the H4K20me3 
domain calling, while minimizing the false discovery rate. In the present study, the 
true false discovery rate was not determined, as this would require validation using 
an independent method such as quantitative PCR performed across hundreds of 
regions from different positions in the FDR ranking. However, there are several lines 
of evidence to suggest that SICER/DiffBind defined accurate domains of H4K20me3 
enrichment. First, the domains that exhibited the most statistically significant 
H4K20me3 enrichment coincided with satellite repeats and ZNF genes, two genomic 
features that have previously been reported to contain H4K20me3 (Barski et al., 
2007). In addition, the 10,786 H4K20me3 domains identified by SICER/DiffBind 
were essentially identical across two separate experiments, performed using 
independent H4K20me3 antibodies and under different conditions (e.g., 
normalization to protein in experiment 1, normalization to DNA in experiment 2). 
Taken together, this provides compelling evidence to suggest that SICER/DiffBind 
defined accurate domains of H4K20me3 enrichment in senescent cells. 
 In addition to DNA repeats, H4K20me3 was also present to a lesser degree 
within genic regions in senescent cells. Because senescence is regulated through a 
program of well-defined transcriptional changes, it was important to determine 
whether enrichment of H4K20me3 influenced gene expression in senescent cells. 
However, no clear correlation between the presence of H4K20me3 and changes in 
gene expression was observed. This was surprising, as H4K20me3 has previously 
been reported to contribute toward the establishment of a repressive chromatin state 
in a variety of contexts. For example, in humans, inactive female X chromosomes are 
highly enriched for H4K20me3 and additional epigenetic marks of heterochromatin 
(Chadwick & Willard, 2004). High levels of H4K20me3 have also been observed at 
imprinting control regions, presumably contributing to monoallelic gene silencing 
(Henckel et al., 2009; McEwen & Ferguson-Smith, 2010). Likewise, a role for 
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H4K20me3 in the repression of specific genes has been reported (Donati et al., 2008; 
Gurtner et al., 2008a; Kwon et al., 2010; Ma et al., 2011; Stender et al., 2012).  
 Although no direct functional impact on gene expression was observed for 
H4K20me3, the modification was highly enriched at numerous ZNF genes in 
senescent cells. In fact, 59% of all ZNF genes exhibited some H4K20me3 
enrichment in senescent cells, whereas only 26% of non-ZNF genes contained 
H4K20me3 overlap. Enrichment of H4K20me3 at ZNF genes has also been 
previously reported for human CD4+ T cells (Barski et al., 2007; Ernst & Kellis, 
2010). In the absence of any overt role for H4K20me3 in the regulation of gene 
expression in senescent cells, it is likely that enrichment of H4K20me3 at ZNF genes 
serves some other functional or structural purpose. 
 The H4K20me3 modification is an intriguing component of the senescent 
chromatin landscape. As I demonstrated previously, the histone mark is 
preferentially retained in senescent cells, despite an overall reduction of histone 
levels. Building on that observation, I have now shown that H4K20me3 is enriched 
in senescent cells at distinct regions of the genome, including DNA repeats and the 
ZNF genes. Although the present analyses do not suggest a direct role for 
H4K20me3 in the regulation of gene expression, it is entirely plausible that the 
modification facilitates some other aspect of senescence. To this end, I next set out to 
investigate whether H4K20me3 contributes functionally to arguably the most 
important feature of the senescence program: the induction and maintenance of a 
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Chapter 6. Functional Dissection of H4K20me3 
  
6.1 Rationale 
As established earlier, the chromatin of senescent cells undergoes profound 
remodeling, characterized in part by a progressive loss of the core histones. 
However, as evidenced by the H4K20me3 histone modification, it is apparent that 
not all modified histones behave uniformly during senescence. In replicative 
senescent cells, levels of histone H4K20me3 remained stable despite a net loss of 
global histone content. Likewise, in cells induced to senescence by the expression of 
oncogenic H-RASG12V, H4K20me3 levels remained stable. These findings provide 
compelling evidence that histone H4 proteins containing trimethylation of lysine 20 
are preferentially retained as cells undergo senescence and suggest that this specific 
histone modification might serve a crucial function in the senescence program. To 
understand this function, I next set out to manipulate the level of H4K20me3 and 




6.2.1 Technical Approaches for Depleting H4K20me3 
 One of the most effective ways to decipher the molecular function of a 
protein is to eliminate or reduce its expression and assess any resulting phenotypic 
changes. To reduce the abundance of an individual histone modification it is first 
necessary to reduce or eliminate expression of the specific enzyme responsible for 
the modification. To this end, shRNA-mediated gene silencing can provide an 
efficient tool for attenuating the expression of a given protein target. The H4K20me3 
modification is primarily deposited in vivo by the histone methyltransferase 
SUV420H2. Therefore, in an effort to evaluate the functional contribution of 
H4K20me3 to the senescence program, I set out to deplete IMR90 cells of 
SUV420H2 using a lentiviral shRNA approach. 
 To accomplish this, a complete set of SUV420H2 shRNA clones contained 
within the pLKO.1 lentiviral expression vector was obtained. Control and 
SUV420H2 shRNA constructs were transfected into 293T packaging cells, which 
were used to produce infectious lentiviral particles. The resulting control and 
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shSUV420H2 lentiviruses were purified by centrifugation and applied to low passage 
IMR90 cells. The shRNA-infected cells were drug selected and used to prepare 
whole cell extracts four days after infection. The cell extracts were then fractionated 
by SDS-PAGE, immobilized to PVDF membranes and subjected to Western blot 
analysis to assess the efficiency of the SUV420H2 knockdown. Of the five 
SUV420H2 shRNAs tested, three hairpins efficiently reduced SUV420H2 expression 
(Figure 6.1). However, although both shSUV420H2 #1 and shSUV420H2 #5 
depleted SUV420H2, infection with either virus resulted in considerable cell death 
(data not shown). Additional SUV420H2 shRNA clones encoded within the pRS 
retroviral expression vector were also tested for knockdown, but none of the five 
constructs yielded efficient silencing (data not shown).   
It is formally possible that the cell death observed following infection with 
the shSUV420H2 #1 and shSUV420H2 #5 viruses was a consequence of low 
infection efficiency, although unlikely as both hairpins markedly reduced 
SUV420H2 expression. It is also unlikely that a puromycin concentration of 1 µg/ml 
was too high, as I previously determined that this dose is sufficient to kill uninfected 
cells within two to three days, but well tolerated by positively infected IMR90 cells 
(data not shown). Although drug selection can exacerbate the stress associated with 
viral infection, it simultaneously provides a critical control by ensuring that each 
target cell has undergone viral transduction. This is particularly important when 
screening shRNAs for efficient depletion, as without drug selection, low infection 
efficiencies could be misinterpreted as suboptimal knockdown. Consequently, only 
the shSUV420H2 #4 construct remained a viable option for reducing SUV420H2 
expression. 
In order to evaluate whether reduction of H4K20me3 levels would have a 
functional impact on the senescence program, it was first necessary to establish 
stable SUV420H2 knockdown cells. Having previously determined that the 
shSUV420H2 #4 hairpin could effectively reduce SUV420H2, low passage IMR90 
cells were infected with either shControl or shSUV420H2 #4 lentiviruses and 
subjected to drug selection. As before, both the control and shSUV420H2 cells 
survived drug selection and exhibited morphological features comparable to 
uninfected IMR90 cells. In order to generate a sufficient number of cells, the 
respective lines were expanded in culture and maintained under puromycin selection. 
However, by seven days after infection, most of the shSUV420H2 cells exhibited an 
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irregular morphology and began to die (Figure 6.2). Most of the control-infected 
cells continued to survive. Drug selection of IMR90 cells with puromycin typically 
occurs with rapid kinetics, as all of the uninfected, drug-selected IMR90 cells died 
within 3 days of treatment. As such, the cell death observed in the shSUV420H2 
cells after seven days in culture was likely unrelated to drug selection and was either 
reflective of a SUV420H2 knock down phenotype or an off-target effect of RNA 
interference. In the absence of an additional viable SUV420H2 hairpin, it was 
impossible to distinguish between these two possibilities.  
Because the establishment of viable SUV420H2-depleted cells was not 
initially feasible, an alternative strategy to downregulate the modification was 
developed. In many cases, ectopic expression of a specific mutant form of a protein 
may serve as a dominant negative by antagonizing the function of the endogenous 
wild-type protein. Functionally, SUV420H2 contains two major domains: a 120 
amino acid N-terminal SET domain that catalyzes trimethylation of histone H4 at 
lysine 20 and an 88 amino acid C-terminal domain that is required for recruitment to 
heterochromatin (Schotta et al., 2004; Souza et al., 2009). In fact, ectopic expression 
of a SUV420H2 mutant comprised solely of the 88 amino acid heterochromatin 
recruitment domain is sufficient to target the construct to heterochromatic regions of 
the genome (Souza et al., 2009). To exploit this for use as a potential dominant 
negative, an N-terminal truncation mutant of SUV420H2 lacking amino acids 1-280 
of the wild-type protein, but still retaining the C-terminal heterochromatin 
recruitment domain, was cloned into the pBABE retroviral vector along with an N-
terminal MYC-tag (pBABE-puro-MYC-SUV420H2 281-462). As a control, a 
construct encoding MYC-tagged, full-length SUV420H2 was also cloned into 
pBABE (pBABE-puro-MYC-SUV420H2 1-462) (Figure 6.3a). 
 In order to address whether SUV420H2 281-462 could function as a 
dominant negative, early passage IMR90 cells were stably infected with a control 
retrovirus or retroviruses encoding either full length MYC-SUV420H2 1-462 or the 
MYC-SUV420H2 281-462 truncation mutant, subjected to drug selection and 
maintained in culture. The three cell lines survived drug selection, exhibited normal 
IMR90 morphology and continued to proliferate. Although no overt morphological 
or proliferation alterations were observed, it was first important to confirm that both 
the wildtype and mutant SUV420H2 constructs were expressed adequately and 
localized to the cell nucleus as expected. To this end, each cell line was seeded onto 
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glass coverslips and subjected to indirect immunofluorescence staining to detect 
expression of the MYC-tagged SUV420H2 constructs as well as the H4K20me3 
modification. As anticipated, only a negligible level of background MYC-tag 
staining was present in the control-infected cells (Figure 6.3b). The control-infected 
cells also possessed a diffuse nuclear staining pattern for H4K20me3, consistent with 
that of uninfected, early passage IMR90 cells. In contrast, both the MYC-SUV420H2 
1-462 and MYC-SUV420H2 281-462 overexpressing cell lines exhibited marked 
MYC-tag nuclear staining patterns, containing punctate foci of high signal intensity. 
The MYC-SUV420H2 1-462 cells showed a similar pattern for H4K20me3, with an 
overall higher nuclear intensity than the control cells and regions of brightly staining 
H4K20me3 foci. Intriguingly, in the MYC-SUV420H2 1-462 cells there also 
appeared to be a high degree of spatial co-localization between the MYC-
SUV420H2 1-462 foci and H4K20me3 foci. Although not proven definitively, it is 
possible that the intensely staining MYC-SUV420H2 1-462 foci reflect recruitment 
of the enzyme to defined heterochromatic regions of the genome.  
Conversely, the MYC-SUV420H2 281-462 overexpressing cells showed a 
different H4K20me3 staining pattern. Although both the MYC-SUV420H2 1-462 
and 281-462 cells contained high levels of ectopic enzyme expression including 
discrete nuclear foci, the H4K20me3 staining intensity in the MYC-SUV420H2 281-
462 cells remained comparable to that of the control cells and lacked discernible foci 
(Figure 6.3b). This suggests that as predicted, in cells overexpressing MYC-
SUV420H2 281-462, the mutant SUV420H2 enzyme is capable of being recruited to 
defined genomic loci, but incapable of catalyzing the H4K20me3 modification due to 
absence of the SET domain. Despite this, overexpression of MYC-SUV420H2 281-
462 apparently failed to serve a dominant negative function, as the cells retained 
basal levels of H4K20me3 staining in this assay. It is important to note that while 
immunofluorescence can provide some insight regarding the relative abundance of 
the H4K20me3 modification, the assay is inherently non-quantitative and can be 
artificially influenced by differences in epitope conformation or exposure. 
To account for this caveat, whole cell extracts were prepared from control, 
MYC-SUV420H2 1-462 and MYC-SUV420H2 281-462 cells, fractionated by SDS-
PAGE and immobilized to PVDF membranes. The membranes were then assayed by 
Western blot to assess expression of the ectopic enzymes and the H4K20me3 
modification. Consistent with the immunofluorescence data, Western blot analysis 
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using an antibody raised against the MYC tag revealed equivalent and robust 
expression of MYC-SUV420H2 1-462 and MYC-SUV420H2 281-462 in the 
respective cell lines, and no expression in control cells (Figure 6.4). Also similar to 
the immunofluorescence findings, the MYC-SUV420H2 1-462 cells contained 
elevated levels of the H4K20me3 modification compared to control cells. In contrast, 
cells expressing the mutant MYC-SUV420H2 281-462 exhibited low H4K20me3 
levels identical to the basal levels observed in the control cells. A longer exposure of 
the H4K20me3 Western blot confirmed that although H4K20me3 levels were 
generally low in the MYC-SUV420H2 281-462 cells, there was no additional 
reduction of the modification relative to control cells. As a result, the MYC-
SUV420H2 281-462 construct does not function in a dominant negative capacity and 
cannot be utilized to modulate levels of the H4K20me3 modification.  
There are several potential explanations that may account for the inability of 
the MYC-SUV420H2 281-462 construct to function as a dominant negative. First, 
while both the immunofluorescence and Western blot assays revealed robust 
expression of the MYC-SUV420H2 281-462 mutant, it is formally possible that the 
ectopic protein levels were not sufficient to displace or compete with the endogenous 
wild-type SUV420H2 protein. To this end, neither assay provided any information 
about the capacity to bind chromatin or the enzymatic activity of endogenous wild-
type SUV420H2 in the presence of ectopic MYC-SUV420H2 281-462. 
Alternatively, truncated MYC-SUV420H2 281-462, although capable of recruitment 
to heterochromatin, might not retain enough of the full-length protein to compete 
with other SUV420H2 binding partners. For example, proteins might bind to the SET 
domain or other N-terminal regions of SUV420H2 to facilitate catalysis of the 
H4K20me3 modification. Because MYC-SUV420H2 281-462 lacks 280 N-terminal 
amino acids, the mutant might be unable to efficiently titrate binding partners away 
from the endogenous enzyme. One way of addressing this would be to introduce a 
single point mutation within the catalytic SET domain of SUV420H2 that would 
attenuate histone methyltransferase activity but retain all other functions of the wild-
type protein. Finally, it is possible that some degree functional redundancy exists 
between SUV420H1 and SUV420H2. In this context, even a true dominant negative 
of SUV420H2 might be insufficient to fully abolish H4K20me3 genome-wide, as 
SUV420H1 could maintain basal levels of the modification.  
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Regardless of the reason for the failure of the dominant negative mutant, to 
this point I have been unable to devise a strategy to suppress abundance of the 
H4K20me3 mark in viable cells. In fact, based on the results from shRNA knock 
down, it is a formal possibility that suppression of H4K20me3 is incompatible with 
cell viability.  
 
6.2.2 MYC-SUV420H2 Cells Proliferate Despite Elevated H4K20me3 
As an alternative approach to functionally assess how H4K20me3 might 
contribute to the various features of the senescence program, I decided to develop a 
model system in which H4K20me3 levels could be elevated efficiently. To 
accomplish this, an additional retroviral plasmid directing the expression of N-
terminally MYC-tagged SUV420H1 was generated in pBABE-puro by standard 
molecular biology procedures. A construct encoding full-length SUV420H2 was 
described earlier. Early passage IMR90 cells were stably infected with control 
retrovirus or a retrovirus encoding either N-terminally MYC-tagged SUV420H1 or 
SUV420H2. The infected cells were maintained under drug selection and monitored 
microscopically for viability and overall morphologic appearance. Fourteen days 
after infection, whole cell extracts were prepared from the cells, subjected to 
fractionation by SDS-PAGE and Western blotted to confirm expression of MYC-
SUV420H1 and MYC-SUV420H2 (Figure 6.5a). As anticipated, both MYC-
SUV420H1 and MYC-SUV420H2 were expressed to comparable levels and 
migrated at expected apparent molecular weights of 120 and 52 kDa, respectively.  
Whole cell extracts were additionally assayed by Western blot for markers of 
active cell proliferation and senescence (Figure 6.5a). Cyclin A, a key regulator of 
the cell cycle that binds to cyclin-dependent kinase 2 (CDK2) and promotes S phase 
progression, can be utilized as an indicator of cell proliferation. Both MYC-
SUV420H1 and MYC-SUV420H2 infected cells exhibited cyclin A expression 
levels comparable to that of the control cells, suggesting similar levels of 
proliferation among the respective cell populations. In contrast, cells infected in 
parallel with a retroviral construct encoding H-RASG12V showed a marked 
reduction in cyclin A expression, indicating a considerable decrease in the number of 
proliferating cells in the population, as expected in association with H-RASG12V-
induced senescence. 
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The tumor suppressor protein p16INK4a blocks cell cycle progression 
through inhibition of cyclin D/CDK4 and CDK6 activity, and is commonly used as a 
senescence biomarker (Alcorta et al., 1996; Serrano et al., 1997). In order to further 
evaluate the proliferative status of the MYC-SUV420H1 and MYC-SUV420H2 
overexpressing cells, the lysates were Western blotted for p16INK4a. Whereas H-
RASG12V infected cells showed a robust increase in p16INK4a expression linked to 
induction of senescence, the control, MYC-SUV420H1 and MYC-SUV420H2 cells 
maintained minimal levels of expression (Figure 6.5a).  
Consistent with continued expression of cyclin A and failure to upregulate 
p16INK4a, MYC-SUV420H1 and MYC-SUV420H2 over-expressing cells showed 
no proliferative impairment compared to control infected cells, as judged by cell 
counting and cumulative population doublings. Collectively these data affirm that 
cells ectopically expressing SUV420H1 or SUV420H2 are viable, maintain 
proliferative capacity in the short-term and do not undergo immediate senescence. 
Before SUV420H1 or SUV420H2 overexpression could be considered a 
relevant model with which to dissect the functional contribution of H4K20me3 to 
senescence, it was essential to confirm that the H4K20me3 histone modification was 
appropriately modulated in the cells. Whole cell extracts obtained from control, 
MYC-SUV420H1, MYC-SUV420H2 and H-RASG12V-infected cells were titrated 
such that an equal amount of histone H4 from each sample was fractionated by SDS-
PAGE. The blots were subsequently probed with antibodies to detect total histone 
H4 as well as the H4K20me1, H4K20me2 and H4K20me3 modifications of histone 
H4 (Figure 6.5b). While H4K20me3 levels were markedly elevated in H-RASG12V-
infected senescent cells, an even more robust increase of lysine 20 trimethylation 
was observed upon SUV420H1 and SUV420H2 overexpression, with the highest 
levels occurring in the MYC-SUV420H2 cells. Although H4K20me2 levels 
remained largely unaffected in all of the cell lines, a marked decrease in the 
H4K20me1 modification was also noted in the MYC-SUV420H2 cells. 
To further characterize the MYC-SUV420H1 and MYC-SUV420H2 cells, 
the localization patterns of the MYC-tagged SUV420H enzymes and H4K20me3 
modification were evaluated by indirect immunofluorescence microscopy. Control, 
MYC-SUV420H1 and MYC-SUV420H2 cells were stained with DAPI and 
antibodies to detect the MYC tag and H4K20me3. Control cells exhibited an even 
nuclear DAPI staining pattern, no staining with the MYC tag antibody and a diffuse 
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granular nuclear pattern for H4K20me3 (Figure 6.6). MYC-SUV420H1 cells 
contained an even DAPI staining pattern and strong yet largely diffuse nuclear 
signals for both the MYC-tagged SUV420H1 and H4K20me3. In contrast, the MYC-
SUV420H2 cells were characterized by a generally even nuclear DAPI pattern with 
some subtle foci present and intense punctate staining patterns for both the MYC-
tagged SUV420H2 enzyme and the H4K20me3 modification. As evident in the 
merged image, a high degree of co-localization occurred between the ectopically 
expressed SUV420H2 and H4K20me3 in the MYC-SUV420H2 cells, suggesting that 
either SUV420H2 remains at sites where the histone mark has been deposited or the 
modification undergoes rapid turnover and the enzyme co-localizes to the newly 
deposited mark.  
Although not investigated here, it is formally possible that the subtle DAPI-
rich foci present in the MYC-SUV420H2 cells might represent SAHF-like 
heterochromatic structures. Functional roles for SAHF in reinforcing senescence by 
silencing proliferation-promoting genes and dampening the DNA damage response 
have been proposed (Narita et al., 2003; Di Micco et al., 2011). However, it is 
unlikely that the DAPI-rich foci in the MYC-SUV420H2 cells reflect the formation 
of bona fide SAHF, as the cells failed to exhibit any overt proliferation defect or 
express the senescence biomarker p16INK4a (Figure 6.5, panel A). Whether the 
MYC-SUV420H2 cells exhibit an altered DNA damage response, another putative 
function of SAHF, has not been evaluated in the present study but could prove useful 
in the subsequent characterization of these cells. Consequently, based on the present 
data it is not possible to conclude whether the subtle DAPI foci in the MYC-
SUV420H2 cells reflect true SAHF formation. 
Alternatively, the MYC-SUV420H2 cell DAPI foci might coincide with 
centromeric or telomeric constitutive heterochromatin. To this end, the potential co-
localization of the MYC-SUV420H2 DAPI foci with domains of constitutive 
heterochromatin could be evaluated using immunofluorescence staining for defined 
heterochromatin features (e.g., H3K9me3, HP1 proteins) (Richards & Elgin, 2002). 
Finally, in order to further delineate the specific nature of the DAPI foci in the MYC-
SUV420H2 cells, fluorescence in situ hybridization (FISH) could be performed 
utilizing centromere and telomere-specific probes. Likewise, the DAPI-rich foci 
could be assayed for co-localization with centromeres and telomeres through 
immunofluorescence staining with antibodies to detect either centromere-specific 
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(e.g., CENPA) or telomere-specific (e.g., TRF2) proteins (Palmer et al., 1987; 
Smogorzewska et al., 2000). Although not conducted as part of the present study, 
these additional data might enhance the characterization of the MYC-SUV420H2 
cells as a model system.  
Regardless, based on the combined Western blot and immunofluorescence 
analyses of the MYC-SUV420H1 and MYC-SUV420H2 cells, both lines were 
capable of increasing levels of the H4K20me3 modification and could therefore be 
utilized as appropriate model systems. Although both of the overexpressing cell lines 
elevated H4K20me3 abundance well above the basal levels observed in control cells, 
the MYC-SUV420H2 cells consistently yielded the highest levels of H4K20me3. 
Additionally, the apparent differences in H4K20me3 localization patterns in the 
MYC-SUV420H1 and MYC-SUV420H2 cell lines might indicate that while 
SUV420H1 appears capable of catalyzing H4K20me3 uniformly across the genome, 
SUV420H2 might deposit the modification at specifically defined genomic regions. 
 
6.2.3 SUV420H2 Overexpression Accelerates Senescence Onset   
Since the relative abundance of H4K20me3 is increased in senescent cells 
compared to total histone H4, I set out to determine whether elevated levels of 
H4K20me3 exert an effect on cellular senescence. In order to address this, control, 
MYC-SUV420H1 and MYC-SUV420H2 cells were exposed to either of two well-
defined triggers of senescence in vitro, prolonged passage in culture or ectopic 
expression of an activated oncogene, and evaluated for effects on senescence. 
To evaluate what effect an elevated level of H4K20me3 would have on 
cellular lifespan, early passage IMR90 cells were stably infected with a control 
retrovirus or viruses encoding either MYC-SUV420H1 or MYC-SUV420H2. 
Positively infected cells were maintained under drug selection and subjected to serial 
passage in culture. At every passage, the cells were counted and the number of 
population doublings calculated using the following equation: [log(number of cells 
counted) − log(number of cells plated)] / log(2). Importantly, and consistent with 
previous short-term experiments, the control, MYC-SUV420H1 and MYC-
SUV420H2 cells exhibited nearly identical population doubling times for 
approximately the first 70 days in culture (Figure 6.7). This confirms that elevation 
of H4K20me3 is not acutely stressful or toxic to the cells. However, beginning 
around 80 days in culture, a noticeable slowing of population doubling time was 
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observed in the MYC-SUV420H2 cells, while the control and MYC-SUV420H2 
continued to divide at comparable rates. MYC-SUV420H2 cells reached a 
proliferative plateau at 86 days, ultimately manifesting in a four cumulative 
population doublings advanced onset of senescence in the MYC-SUV420H2 cells 
compared to the control and MYC-SUV420H1 cells. These data indicate that while a 
high level of the H4K20me3 modification is not sufficient to drive an immediate cell 
cycle exit, increased abundance of the mark does accelerate proliferation arrest in the 
context of replicative senescence. 
Next, I asked whether a SUV420H2 mediated increase in H4K20me3 could 
elicit a similar effect on senescence induced by an activated oncogene. To this end, 
early passage control, MYC-SUV420H1 and MYC-SUV420H2 cells were infected 
with either a control retrovirus or a virus encoding oncogenic H-RASG12V and 
assayed for expression of SA β-gal, a marker of senescence, 14 days after infection. 
Importantly, in the absence of H-RASG12V, neither the MYC-SUV420H1 nor 
MYC-SUV420H2 showed elevated SA β-gal, supporting the previous conclusion 
that elevated H4K20me3 does not inappropriately stress the cells. In contrast, nearly 
all of the H-RASG12V-infected control, MYC-SUV420H1 and MYC-SUV420H2 
cells stained positively for SA β-gal activity (Figure 6.8). The MYC-SUV420H2 + 
H-RASG12V cells revealed a subtle yet consistently higher SA β-gal staining 
intensity compared to SUV420H1 + H-RASG12V and control + H-RASG12V, 
possibly reflecting an increased lysosomal compartment in the cells, an enhanced 
senescence or a combination thereof. Importantly, it is unlikely that the observed 
differences in SA β-gal activity among the H-RASG12V-infected control, MYC-
SUV420H1 and MYC-SUV420H2 cells were due to variations in the multiplicity of 
infection (MOI), as the respective cell lines were all infected with equal volumes of 
the same H-RASG12V viral stock. Similarly, no cell death was noted following 
puromycin selection of the H-RASG12V-infected control, MYC-SUV420H1 and 
MYC-SUV420H2 cells, indicating a sufficient and comparable MOI for each of the 
respective infections. 
To better characterize the senescence program, whole cell extracts prepared 
from the same cells were fractionated by SDS-PAGE and probed for markers of 
proliferation and senescence. As anticipated, both MYC-SUV420H1 and MYC-
SUV420H2 were expressed abundantly in the respective cell lines, resulting in a 
robust elevation of H4K20me3 levels in the MYC-SUV420H2 cells and a more 
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modest increase in the MYC-SUV420H1 cells (Figure 6.9). Consistent with previous 
findings, both total histone H4 and lamin B1 levels dropped precipitously in all three 
of the H-RASG12V-infected cell lines. Cyclin A expression and pRB 
phosphorylation (judged by the slower mobility of the hyperphosphorylated form), 
two biochemical indices of cell proliferation, were also reduced significantly in all of 
the H-RASG12V infected cells. However, longer exposures of the cyclin A and pRB 
Western blots revealed marked differences in the degree to which these proteins were 
regulated in the H-RASG12V expressing cells, with and without MYC-SUV420H2. 
Although low but detectable levels of cyclin A and phosphorylated pRB were 
observed in the H-RASG12V + control or MYC-SUV420H1 cells, cyclin A was 
essentially undetectable and pRB almost entirely in the unphosphorylated form in the 
H-RASG12V + MYC-SUV420H2 cells (Figure 6.9). Likewise, while p16INK4a 
induction occurred in all three H-RASG12V infected cell lines, absolute levels were 
slightly higher in the MYC-SUV420H2 cells. 
To summarize, in both the replicative and oncogene-induced models of 
senescence, the MYC-SUV420H2 cells consistently exhibited either an accelerated 
onset or enhanced senescence compared to the control or MYC-SUV420H1 cells. 
This accelerated or enhanced senescence in the MYC-SUV420H2 cells was evident 
through multiple parameters, including the precise measurement of population 
doublings prior to replicative senescence, a reduction in proliferation indicators (i.e. 
cyclin A expression, pRB phosphorylation) and the induction of senescence markers 
(i.e. SA β-gal activity, p16INK4a expression). Importantly, elevated H4K20me3 
levels mediated by SUV420H2 overexpression, but not SUV420H1 overexpression, 
appears to be critical for driving the accelerated senescent phenotype. However, it is 
difficult to distinguish whether this is due to the fact that H4K20me3 is increased to 
higher levels in the MYC-SUV420H2 cells than in the MYC-SUV420H1 cells, or 
whether the two enzymes deposit the H4K20me3 modification at different regions of 
the genome, thus exerting variable effects, or perhaps another non-histone substrate 
of SUV420H2. Regardless, collectively, these data support the hypothesis that 
although a high level of H4K20me3 is not sufficient to induce frank and immediate 
cell senescence, the modification does promote the onset of senescence in response 
to detrimental factors, including telomere attrition or an activated oncogene. 
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6.2.4 SUV420H2 Protects Against Senescence Escape 
 Although the MYC-SUV420H2 cells exhibited an enhanced senescent 
phenotype upon exposure to H-RASG12V compared to H-RASG12V-infected 
control or MYC-SUV420H1 cells, the experiment relied on assessment of 
senescence at a fixed endpoint and failed to provide insight regarding the kinetics of 
the proliferation arrest. To compare the kinetics of entry into senescence, control and 
MYC-SUV420H2 cells were infected with control or H-RASG12V retroviruses and 
assayed by Western blot for senescence markers at regular intervals post infection. 
As expected, high levels of ectopic MYC-SUV420H2 and the resulting H4K20me3 
modification were maintained for the duration of the timecourse (Figure 6.10). H-
RASG12V was expressed at high levels in both the control and MYC-SUV420H2 
cells and also sustained for the entire length of the experiment. As described 
previously, a marked reduction of total histone H4 was observed by day 5 of H-
RASG12V exposure in both the control and MYC-SUV420H2 cells and continued to 
progress as the timecourse proceeded. By day 10 of H-RASG12V infection, histone 
levels were depleted to comparable levels in both the control and MYC-SUV420H2 
cell lines. However, by the 15-day H-RASG12V timepoint, histone H4 levels 
appeared to rebound in the control cells, but not in the MYC-SUV420H2 cells. Also 
by 5 days of H-RASG12V exposure, both the control and MYC-SUV420H2 cells 
exhibited a considerable reduction in cyclin A expression and p16INK4a induction, 
consistent with cell cycle exit and the onset of senescence. Similar to the histone H4 
kinetics, in the H-RASG12V-infected control cells but not the MYC-SUV420H2 
cells, cyclin A levels began to increase around the 15-day timepoint. This partial 
restoration of proliferation in the H-RASG12V-infected control cells was also 
accompanied by a decrease in p16INK4a expression. Together, these results indicate 
that the control cells infected with H-RASG12V had partially bypassed or escaped 
the senescence-associated proliferation arrest, whereas the MYC-SUV420H2 cells 
appeared to maintain the senescent state. 
The concept that some cells are capable of either escaping or bypassing the 
H-RASG12V-induced senescence arrest in vitro has been previously documented 
(Kohsaka et al., 2011). Consistent with this, a subset of the control cells infected with 
H-RASG12V appeared to resume proliferation approximately 15 days after infection. 
In contrast, H-RASG12V infected MYC-SUV420H2 cells appeared to maintain a 
more stable proliferation arrest. In order to track the progression of the H-RASG12V 
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infected control and MYC-SUV420H2 cell lines, the cells were maintained in culture 
under continuous drug selection and observed frequently under the microscope. 
Thirty days after infection, bright field microscopic images of the respective plates 
were obtained and the cells were stained with crystal violet (N-
hexamethylpararosaniline), a basic dye that binds DNA and other negatively charged 
cellular components, enabling visual quantification of the cells (Gillies et al., 1986).  
As revealed in the bright field images, both the H-RASG12V-infected control 
and MYC-SUV420H2 plates contained a mixture of cells exhibiting either a 
classically-senescent, large, flattened morphology or concentrated in densely packed 
colonies of spindly apparently proliferative cells (Figure 6.11a). However, the 
densely packed colonies were more apparent in the H-RASG12V-infected control 
cells, compared to the H-RASG12V-infected MYC-SUV420H2 cells. Crystal violet 
staining confirmed that colony formation in the control cells infected with H-
RASG12V vastly exceeded that of the H-RASG12V + MYC-SUV420H2 cells, with 
the control cells nearly filling the culture dish (Figure 6.11b). Importantly, the H-
RASG12V + MYC-SUV420H2 cells did not lose viability, but persisted as viable 
cells with a classic senescent morphology (Figure 6.11a). Thus, the H-RASG12V-
infected control cells managed to overcome the senescence proliferation arrest with 
relatively high frequency, whereas expression of MYC-SUV420H2 and the 
corresponding elevation of H4K20me3 levels appeared to restrict the degree to 
which H-RASG12V-infected cells could bypass senescence. Consequently, the data 
suggest that H4K20me3 might play an important role in the senescence program by 
enhancing the stability of the proliferation arrest.  
 
6.3 Discussion 
 In contrast to the widespread chromatin remodeling that occurs during cell 
senescence, the H4K20me3 histone modification reflects a relatively stable 
component of the epigenetic landscape. Remarkably, the absolute levels of 
H4K20me3 remain seemingly unaffected in the contexts of replicative and 
oncogene-induced senescence, respectively. Even more compelling, the apparent 
stability of H4K20me3 levels during senescence occurs despite a profound reduction 
of overall histone content. Based on this, it was reasonable to hypothesize that the 
H4K20me3 modification might serve a specific and critical function within the 
senescence program. In order to test this hypothesis, it became essential to develop 
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model systems in which H4K20me3 levels could be effectively altered. To this end, 
approaches were employed to either reduce or enhance endogenous levels of 
H4K20me3 and interrogate whether modulation of the histone mark was sufficient to 
affect specific features of the senescence program. 
 Efforts to reduce or completely abrogate H4K20me3 levels by either shRNA-
mediated knockdown of SUV420H2 or through utilization of a dominant negative 
strategy were largely unsuccessful. Primarily, an inability to obtain multiple short 
hairpins capable of reducing SUV420H2 while maintaining cell viability posed a 
considerable technical challenge. One formal possibility is that IMR90 cells are 
unable to tolerate reduced levels of the H4K20me3 modification and consequently 
undergo cell death. However, in the absence of multiple active SUV420H2 hairpins, 
it is not possible to determine whether the observed cell death is an on-target or off-
target phenotype. Efficient silencing of SUV420H2 in human cells has been 
previously reported (Kapoor-Vazirani et al., 2011). While the study by Kapoor-
Vazirani and colleagues demonstrated successful knockdown of SUV420H2 in 
human MDA-MB-231 cells, only a single SUV420H2 hairpin was utilized and the 
authors failed to include convincing data that global H4K20me3 levels were reduced. 
Additionally, in contrast to primary IMR90 cells, MDA-MB-231 cells are a 
transformed breast cancer cell line, which may partially account for the ability of 
MDA-MB-231 cells to tolerate reduced H4K20me3 levels. Future experiments with 
additional shRNAs will address this issue in IMR90 cells.  
 Despite the limited success of efforts to reduce H4K20me3 levels in IMR90 
cells, considerable information was obtained from the complimentary SUV420H2 
overexpression approach. Infection of IMR90 cells with a retrovirus encoding MYC-
tagged SUV420H2 resulted in overexpression of the enzyme and a robust increase in 
the H4K20me3 histone modification. Although elevated levels of H4K20me3 alone 
did not directly induce senescence, high abundance of the modification did accelerate 
the onset of replicative senescence and produced an enhanced senescence phenotype 
following infection with H-RASG12V. Specifically, MYC-SUV420H2 cells 
displayed higher levels of p16INK4a expression and lower cyclin A expression than 
control cells upon induction of senescence, suggesting an enhancement of the 
senescence proliferation arrest in the MYC-SUV420H2 cells. 
 High levels of H4K20me3 also appeared to reinforce the stability of the 
senescence proliferation arrest induced by the expression of a constitutively active 
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H-RAS allele. In fact, unlike H-RASG12V-infected control cells, the H-RASG12V-
infected MYC-SUV420H2 cells were largely resistant to escape of oncogene-
induced senescence. This was a compelling finding as it implied that H4K20me3 
might be preferentially retained in senescent cells in order to maintain a chromatin 
state conducive to permanent proliferation arrest. In this manner, retention of 
H4K20me3 by oncogene-induced senescent cells in vivo would prohibit cells from 
re-entering the cell cycle, thus decreasing the likelihood of cellular transformation 
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Chapter 7. Discussion 
 
7.1 Summary of Findings 
Cell senescence is an important biological state that limits the replicative 
capacity of impaired or damaged cells through a network of programmed processes. 
As a result, senescence provides a potent barrier to tumorigenesis and contributes to 
other physiological processes such as aging and wound healing. In addition to a 
variety of well characterized morphological and biochemical changes, senescent cells 
exhibit profound changes to chromatin structure. Specifically, the formation of 
facultative heterochromatin has been proposed to play an important role in mediating 
several aspects of senescence, including the repression of proliferation genes and 
limiting the DNA damage response. Therefore, I set out to further investigate how 
chromatin structure influences senescence, by asking whether the heterochromatic 
histone modification H4K20me3 contributes to the various features of the senescence 
program. 
In order to investigate the relationship between chromatin structure and 
senescence, I first established and validated two in vitro models of cell senescence. 
To this end, I established replicative senescent cells by subjecting primary human 
diploid IMR90 fibroblasts to prolonged passage in culture. Separately, I established 
an oncogene-induced senescence model by infecting IMR90 cells with a retrovirus 
encoding oncogenic H-RASG12V. Using common molecular markers of senescence, 
including proliferation arrest, p16INK4a induction and SA β-gal activity, I was able 
to confirm that the respective models generated senescent cells. I subsequently 
generated gene expression profiles for the respective senescence models and defined 
a common gene signature of senescence that included cell cycle genes, regulators of 
mitosis and genes involved in DNA damage signaling. 
Having established and validated models of replicative and oncogene-induced 
senescence, I next set out to characterize the H4K20me3 histone modification in 
proliferating and senescent cells, as the mark has implications for both cancer and 
aging. Remarkably, although global histone levels decreased in senescent versus 
proliferating cells, H4K20me3 abundance remained unaltered. As a result, senescent 
cells contain a higher ratio of H4K20me3 to total histone H4 than proliferating cells. 
It is important to note that whereas relative H4K20me3 levels were determined by 
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Western blotting, quantitative mass spectrometry is commonly accepted as the gold-
standard method for the accurate determination of histone posttranslational 
modification abundance (Britton et al., 2011). Importantly, recent work from Scott 
Lowe’s laboratory utilizing mass spectrometry to quantify histone modifications 
confirmed that H4K20me3 levels are indeed maintained/elevated in H-RASG12V-
induced senescent cells (Chicas et al., 2012). 
Although the absolute abundance of H4K20me3 did not change during 
senescence, senescent cells displayed a considerably different nuclear distribution of 
the mark compared to proliferating cells. Proliferating cells typically exhibited a 
diffuse nuclear staining pattern for H4K20me3, while senescent cells invariably 
contained distinct nuclear H4K20me3 foci. The senescence-specific foci did not co-
localize with several other well-characterized nuclear foci, including PML, 53BP1 
and γ-H2AX. In contrast, the H4K20me3 foci in senescent cells did co-localize with 
SAHF. Given the apparent stabilization of H4K20me3 abundance and presence of 
the mark at SAHF, I investigated whether these phenotypes were caused by altered 
expression of SUV420H2, the enzyme responsible for the majority of H4K20me3 
deposition. However, no change in SUV420H2 mRNA or protein expression was 
observed in senescent cells. 
 In order to evaluate whether the H4K20me3 modification might influence 
other features of the senescent chromatin landscape, I mapped the genome-wide 
distribution of H4K20me3 in proliferating and senescent cells using ChIP-Seq. 
Importantly, I performed the ChIP-Seq experiments with two independent 
H4K20me3 antibodies, which allowed for differentiation between specific antibody 
binding and non-specific binding. Marked H4K20me3 enrichment was noted in 
senescent cells with both antibodies. The regions of H4K20me3 enrichment were 
subsequently compared to defined features of the human genome. Regions of 
senescence-specific H4K20me3 enrichment coincided with intergenic regions, 
various classes of DNA repeats (e.g., LTRs, LINES, SINES) and regions of 
senescence-specific DNA hypomethylation. 
 Although the majority of H4K20me3 enrichment occurred at intergenic 
regions in senescent cells, some overlap with genes was evident. To investigate a 
potential role for H4K20me3 in the regulation of gene expression in senescent cells, 
regions of H4K20me3 enrichment were compared to the replicative senescence 
microarray data. The presence of H4K20me3 largely failed to correlate with gene 
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expression changes in senescent cells, suggesting that the mark does not contribute to 
the regulation of genes in senescence. However, significant enrichment of 
H4K20me3 was observed at numerous ZNF genes that were arranged in distinct 
genomic clusters. In addition, the enrichment of H4K20me3 at ZNF genes was far 
more prominent in senescent cells, with highest levels of the mark observed toward 
the 3’ ends of gene bodies. 
 In light of the observations that H4K20me3 is maintained in senescent cells 
and distributed to specific genomic regions, I next set out to ask whether the mark 
contributed to the defining feature of senescence: stable proliferation arrest. To 
accomplish this, I attempted to modulate levels of H4K20me3 and test whether the 
mark was required for permanent cell cycle exit. Due to technical limitations I was 
unsuccessful in reducing H4K20me3 levels either through shRNA-mediated knock 
down of SUV420H2 or through ectopic expression of a potential SUV420H2 
dominant negative construct. In contrast, ectopic expression of MYC-tagged 
SUV420H2 markedly increased H4K20me3 levels, but did not immediately yield 
any overt phenotype. However, following prolonged passage in culture, ectopic 
expression of MYC-SUV420H2 maintained elevated H4K20me3 levels and resulted 
in a moderate acceleration of senescence compared to control cells. Similarly, 
ectopic expression of MYC-SUV420H2 appeared to enhance entry into H-
RASG12V-induced senescence. Most remarkably, whereas MYC-SUV420H2 
overexpressing cells infected with H-RASG12V maintained a permanent 
proliferation arrest, control cells infected with H-RASG12V were able to escape the 
senescence arrest and resume proliferation. 
 The H4K20me3 modification is an important epigenetic mark involved in 
maintaining the structure and function of heterochromatin. Here, I have presented 
several key findings that demonstrate H4K20me3 is selectively retained in senescent 
cells despite global histone loss, is enriched in senescent cells at DNA repeats and 
ZNF genes, and helps facilitate the senescence proliferation arrest. Although these 
observations strongly support a contributory role for H4K20me3 to the senescence 
program, there are several limitations to the study, which will be subsequently 
discussed in detail. Despite the limitations, the current body of work contains 
compelling data to suggest that H4K20me3 plays an integral role in shaping 
chromatin structure in senescent cells. Thus, I will subsequently explore some of the 
important implications that the present study has for our understanding of 
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H4K20me3 regulation and the relationship between H4K20me3, senescence and 
cancer. 
 
7.2 Limitations of the Study 
 
7.2.1 Loss-of-Function Experiments 
Potentially the most significant caveat of the present work is the lack of loss-
of-function data. Consequently, one outstanding and critical question that remains to 
be addressed is whether the H4K20me3 modification is required for cell senescence 
to occur. In essence, are cells deficient for H4K20me3 still capable of undergoing 
senescence? This is an important question as the answer could reveal whether 
selective retention of H4K20me3 in senescent cells is an inconsequential passive 
event or whether the mark is retained in order to serve a specific function as part of 
the senescence program. Additionally, it could provide novel insight into how 
higher-order chromatin structure might suppress tumorigenesis by limiting the 
proliferative capacity of damaged cells. 
  As discussed in Chapter 6, the most significant obstacle to addressing 
whether H4K20me3 is required for senescence was obtaining viable cells in which 
the modification was sufficiently reduced. Although it is formally possible that 
reduction of H4K20me3 levels might adversely impact cell viability, there is some 
evidence that depletion of the mark can be achieved in human cells (Kapoor-Vazirani 
et al., 2011). Therefore, in order to efficiently reduce global levels of H4K20me3, 
several experimental approaches could be utilized. First, the selection and testing of 
additional SUV420H2 shRNAs might enable the identification of short hairpin 
sequences capable of effectively reducing SUV420H2 and H4K20me3 levels, while 
maintaining cell viability. Additional shRNAs targeting SUV420H2 have been 
developed as part of the Broad Institute’s RNAi Consortium TRC2 phase 
(http://www.broadinstitute.org/rnai/trc) and are now commercially available. It is 
possible that these new shRNA constructs might facilitate efficient depletion of 
H4K20me3 from IMR90 cells. 
 In the absence of two or more shRNAs that effectively target SUV420H2, it 
is difficult to differentiate between actual phenotypes and potential off-target effects 
of RNA interference. In addition, viral infection, the most commonly employed 
method of delivering shRNAs to primary target cells, can incur a further set of 
	   197	  
complications. One way to distinguish between the phenotypic effects of shRNA 
knockdown and the potentially cytotoxic effects associated with viral introduction of 
the construct is to utilize an inducible shRNA system (Meerbrey et al., 2011). 
Inducible shRNA systems enable the initial establishment of stably infected cells and 
subsequent control over when RNA interference is initiated. By utilizing this 
strategy, it is possible to temporally separate any phenotypic changes from infection-
related complications. Inducible lentiviral shRNA constructs are commercially 
available and might provide an effective method of modulating H4K20me3 in 
IMR90 cells. 
 An alternative technical approach to conducting loss-of-function studies in 
vitro is to utilize cells isolated from genetically modified knockout mice. To this end, 
Suv420h2-/- mice have been successfully generated and characterized by Thomas 
Jenuwein’s laboratory (Schotta et al., 2008). Produced by germline disruption of 
floxed Suv420h2 alleles, the mice are viable, do not express SUV420H2 protein and 
are largely depleted of H4K20me3. Primary mouse embryonic fibroblasts (pMEFs) 
isolated from genetically modified mice provide an important tool for studying loss-
of-function. Importantly, pMEFS isolated from Suv420h2-/- mice remain viable and 
exhibit marked H4K20me3 depletion (Schotta et al., 2008). Consequently, the 
Suv420h2-/- pMEFs might provide an alternative and useful tool for evaluating 
H4K20me3 function in cell senescence. 
 Before initiating loss-of-function studies using the Suv420h2-/- pMEFs, it is 
important to consider several potential caveats. To this end, there are several 
limitations to utilizing mouse cells as a surrogate model for studying senescence. 
First, in human fibroblasts, inactivation of both the p53 and pRB pathways is 
required in order to abolish senescence (Shay et al., 1991; Bond et al., 1999; Hahn et 
al., 2002). In contrast, inactivation of either the p53 pathway or pRB along with p107 
and p130 is sufficient to abolish senescence in mouse fibroblasts (Harvey et al., 
1993; Sage et al., 2000; Dannenberg et al., 2000). This underscores a potentially 
fundamental difference in how cell senescence is established in humans and mice, 
respectively.  
Second, most proliferating human cells lack telomerase and undergo telomere 
attrition due to repeated rounds of DNA replication. Ultimately, telomeres reach a 
critically short length, which produces a DNA damage signal and induces replicative 
senescence (d'Adda di Fagagna et al., 2003). In contrast, most mouse somatic cells 
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express telomerase and consequently maintain lengthy telomeres (Kipling, 1997). As 
a result, telomere attrition is not a characteristic cause of senescence in mice, 
illustrating another important difference between human and mouse senescence 
(Parrinello et al., 2003). The difference between human and mouse telomeres also 
has implications for H4K20me3 loss-of-function experiments, as H4K20me3 has 
been reported to play a crucial role in the maintenance and function of telomeres 
(Benetti et al., 2007). 
Despite the inherent limitations of utilizing either shRNA mediated gene 
silencing or Suv420h2-/- pMEFs to conduct loss-of-function experiments, both 
approaches provide ways of investigating the role of H4K20me3 in cell senescence. 
For this reason, I would implement both strategies in order to adequately address the 
question of whether H4K20me3 is required for senescence. In fact, the use of 
multiple technical approaches and models can potentially enhance the significance of 
a finding, by demonstrating that the given phenomenon is a conserved feature of 
senescence in multiple species and cell types. Alternatively, using different methods 
might reveal species or cell type-specific features of the senescence program. Either 
way, the methods discussed above reflect complimentary and viable strategies for 
deciphering the role of H4K20me3 in cell senescence. 
 
7.2.2 H4K20me3 and Senescence In Vivo 
 A second limitation of the present work is the lack of experiments evaluating 
H4K20me3 in the context of senescence in vivo. The data presented in this study 
convincingly demonstrate that H4K20me3 abundance increases relative to total 
histone H4 content in replicative and oncogene-induced senescent cells, compared to 
proliferating cells. Thus, senescent cells appear to selectively retain H4K20me3 
despite a decrease of bulk histone content. Although the data are robust, reproducible 
and consistent across two separate models of senescence, the experiments were only 
conducted in primary human cells in vitro. Thus, it is difficult to conclude whether 
selective retention of H4K20me3 is a bona fide hallmark of cell senescence, or rather 
a feature of senescence in vitro. 
 Despite this limitation to the interpretation of the data, there is some evidence 
of H4K20me3 retention/elevation in an in vivo context. Significantly elevated levels 
of H4K20me3 were observed in the livers of 450-day-old aged rats compared to the 
livers of 30-day-old young rats (Sarg et al., 2002). Although senescent cells have 
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been shown to accumulate with age in many mammalian tissues, Sarg and colleagues 
did not explicitly describe the presence of senescent cells in the livers of the 450-
day-old rats. Therefore, the elevated levels of H4K20me3 observed in the livers of 
aged rats might have resulted from the presence of old, but not necessarily senescent, 
cells. 
 Over the last decade, there has been a growing interest in understanding how 
cell senescence contributes to both normal and pathophysiological processes in vivo. 
As a result, the presence of senescent cells has been described in a variety of in vivo 
contexts. Increased numbers of senescent cells have been detected in various aged 
mammalian tissues including human skin and liver, primate skin and mouse dermis, 
liver, spleen, lung and gut epithelium (Dimri et al., 1995; Paradis et al., 2001; Herbig 
et al, 2006; Jeyapalan et al., 2007; Wang et al., 2009). Accumulation of senescent 
cells has also been reported in numerous premalignant lesions including benign 
melanocytic nevi, early-stage thyroid tumors, dermal neurofibroma, pancreatic 
intraepithelial neoplasia, prostate intraepithelial neoplasia, lung adenoma, colon 
adenoma and lymphoma (Michaloglou et al., 2005; Gray-Schopfer et al., 2006; 
Vizioli et al., 2011; Courtois-Cox et al., 2006; Morton et al., 2010; Caldwell et al., 
2012; Chen et al., 2005; Acosta et al., 2008; Collado et al., 2005; Bartkova et al., 
2006; Fujita et al., 2009; Kuilman et al., 2008; Braig et al., 2005). 
 Importantly, many of the molecular markers that define senescent cells in 
vitro, including SA β-gal activity, p16INK4a induction and SASP, have also been 
observed extensively in senescent cells in vivo (Dimri et al., 1995; Michaloglou et 
al., 2005; Coppé et al., 2008). Thus, these markers reflect genuine features of the 
senescence program, and are not simply contextual artifacts of investigating 
senescence in vitro or in vivo, respectively. Whether the selective retention of the 
H4K20me3 modification similarly reflects a conserved feature of the senescence 
program remains to be seen. From a technical perspective, determining whether 
senescent cells exhibit retention or elevation of the H4K20me3 mark in vivo should 
be relatively straightforward. Given the extensive H4K20me3 antibody evaluation 
that I performed for this study, employing an immunological-based assay such as 
immunohistochemistry to detect H4K20me3 in vivo would be a reasonable approach. 
Finally, based on the current finding that elevated levels of H4K20me3 serve to 
reinforce the senescence proliferation arrest induced by oncogenic H-RAS, 
evaluating H4K20me3 in the senescent cells of pre-malignant lesions might reveal a 
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novel tumor suppressive function for the modification. To this end, it might be most 
appropriate to investigate H4K20me3 in the context of pancreatic intraepithelial 
neoplasia (PanIN), a pre-malignant lesion that often arises from aberrant RAS 
activation and has been reported to harbor senescent cells (Morton et al., 2010). 
 
7.3 Implications of the Study 
 
7.3.1 Regulation of H4K20me3 
The H4K20me3 histone modification is a repressive epigenetic mark that has 
important implications for aging, senescence and cancer. As demonstrated in the 
present study, H4K20me3 is selectively retained in replicative and oncogene-induced 
senescent cells, despite a net loss of bulk histone content. Additionally, ectopic 
expression of SUV420H2 in IMR90 cells conferred high levels of H4K20me3 and 
reinforced the H-RASG12V-induced proliferation arrest. Consequently, this raises 
the important mechanistic question of how H4K20me3 is regulated in senescent 
cells. 
One possibility is that H4K20me3 levels are simply maintained in senescent 
cells through the basal activity of the SUV420H2 histone methyltransferase. Indeed, 
SUV420H2 is responsible for the majority of H4K20me3 deposition in vivo (Schotta 
et al., 2008). In the present study, SUV420H2 mRNA and protein levels remained 
unaltered in senescent cells, supporting a possible role for the enzyme in stabilizing 
levels of the mark during senescence. Alternatively, it is possible that H4K20me3 
might be regulated through the activity of a different histone methyltransferase in 
senescent cells. One potential candidate is SUV420H1, an enzyme that primarily 
deposits the H4K20me2 mark, but also retains the ability to trimethylate H4K20 in 
some contexts (Schotta et al., 2008; Tsang et al., 2010). In fact, in the current study, 
ectopic expression of SUV420H1 increased H4K20me3 abundance, but not to the 
same magnitude as SUV420H2. 
There is emerging evidence that additional enzymes can deposit the 
H4K20me3 modification in a variety of contexts. The nuclear receptor-binding SET 
domain-containing protein (NSD1) has been reported to methylate H4K20 in vitro 
(Rayasam et al., 2003). Genetic disruption of NSD1 in humans results in Sotos 
syndrome, an autosomal dominant disorder characterized by tall stature, distinctive 
facial features, macrocephaly, cognitive disabilities and an increased risk of 
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developing tumors (Lapunzina, 2005; Tatton-Brown & Rahman, 2007). Remarkably, 
lymphoblastoid cell lines isolated from Sotos syndrome patients exhibited markedly 
reduced levels of H4K20me3, suggesting a role for NSD1 in the trimethylation of 
H4K20 (Berdasco et al., 2009). 
Recently, several members of the SET and MYND domain (SMYD) family 
of proteins were shown to play a role in H4K20me3 regulation. To this end, it was 
reported that SMYD3 exhibits histone methyltransferase activity in vitro and 
preferentially trimethylates H4K20 in reconstituted chromatin (Foreman et al., 2011). 
Another SMYD family member, SMYD5, in cooperation with the NCoR corepressor 
complex, trimethylates H4K20 and silences pro-inflammatory genes in primary 
mouse macrophages (Stender et al., 2012). Stender and colleagues also showed that 
upon lipopolysaccharide (LPS)-mediated activation of toll-like receptor 4 (TLR4), 
PHF2 is recruited by an NF-κB-dependent mechanism to the promoters of pro-
inflammatory genes, where it demethylates H4K20me3. Whether any of these 
histone methyltransferases contribute to the regulation H4K20me3 in senescent cells 
remains to be tested. 
Another potential mechanism by which H4K20me3 abundance could be 
maintained in senescent cells might be through the inhibition of an H4K20me3-
specific histone demethylase. However, to date, no genome-wide demethylase has 
been identified for H4K20me3. Although the histone lysine demethylase JMJD2A 
has been shown to bind H4K20me3 with high affinity in vitro, it has not been 
reported to demethylate the mark (Huang et al., 2006; Lee et al., 2008; Ozboyaci et 
al., 2011). While PHF2 has been identified as a putative H4K20me3 demethylase, it 
is possible that the enzyme only functions in a local context (e.g., at pro-
inflammatory genes) and does not impact H4K20me3 on a global scale. Thus, the 
hypothesis that H4K20me3 is retained in senescent cells through inhibition of a 
specific histone demethylase remains a formal possibility, but one that is challenging 
to test.  
Finally, it is formally possible that the H4K20me3 retention in senescent cells 
occurs independently of active methylation or inhibition of demethylation. For 
example, H4K20me3 stabilization might involve the interaction of other chromatin 
binding proteins. To this end, technical approaches such as quantitative interaction 
proteomics might enable identification of novel binding partners involved in the 
regulation of H4K20me3 (Wysocka, 2006; Vermeulen et al., 2010). Thus, although 
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additional work is required in order to fully elucidate how H4K20me3 is maintained 
in senescent cells, the findings might ultimately inform our current understanding of 
the relationship between chromatin, senescence and cancer. 
 
7.3.2 H4K20me3 and Cancer 
 Despite the dynamic nature of chromatin during senescence, net abundance 
of the H4K20me3 modification remains remarkably stable between proliferating and 
senescent cells. Additionally, genome-wide mapping of H4K20me3 distribution 
revealed senescence-specific enrichment of the mark at ZNF gene clusters, DNA 
repeats (e.g., LTRs, LINES and SINES) and regions of the genome that become 
DNA hypomethylated during senescence. However, the most compelling finding of 
the current study was the observation that high levels of H4K20me3, resulting from 
ectopic expression of MYC-SUV420H2, was sufficient to suppress escape from H-
RASG12V-induced senescence in vitro. In fact, this result has important implications 
for not only how H4K20me3 impacts the senescence program, but also how the mark 
might contribute to tumor suppression. 
Epigenetic factors undoubtedly play a significant role in the maintenance and 
regulation of chromatin. Consequently, epigenetic dysregulation is frequently 
associated with a variety of pathological processes, including human cancers (Jones 
& Baylin, 2007). Although considerable attention has been directed toward 
understanding how altered patterns of DNA methylation impact the initiation and 
promotion of cancer, an important role for histone modifications in these processes is 
also emerging (Sharma et al., 2010). Supporting this concept is the striking 
observation that the H4K16ac and H4K20me3 modifications are frequently lost from 
a variety of human cancer cell lines and primary tumors (Fraga et al, 2005). Equally 
compelling, as Fraga and colleagues noted, was the fact that loss of these two marks 
frequently coincided with DNA hypomethylation at regions of repetitive DNA (e.g., 
satellite 2). 
 Subsequent reports have provided additional evidence that loss of H4K20me3 
is indeed a common epigenetic feature of cancer. One study of breast cancer showed 
that compared to non-malignant MCF-10-2A breast epithelial cells, the MDA-MB-
231 and MDA-MB-231(S30) malignant breast cancer cell lines exhibited global 
DNA hypomethylation, marked reduction of H4K20me3 and decreased expression of 
the H4K20 histone methyltransferase SUV420H2 (Tryndyak et al., 2006). In the 
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same study, MCF-7 cells, a less invasive cell line that represents an earlier stage of 
breast cancer, also displayed H4K20me3 loss, but to a lesser extent. Utilizing a rat 
model of estradiol‐17b (E2)‐induced mammary carcinogenesis, the same group 
subsequently reported a decrease of global DNA methylation, LINE‐1 
hypomethylation and loss of the H3K9me3 and H4K20me3 marks in hyperplastic 
mammary tissue (Kovalchuk et al., 2007). Significantly, the observed epigenetic 
changes preceded the development of full mammary carcinoma by approximately six 
weeks. 
 Evaluation of H4K20me3 abundance in tumors also provides important 
clinical prognostic insight. In a comparison of 50 lung squamous cell carcinomas and 
50 lung adenocarcinomas to normal lung tissue, the tumors frequently displayed 
H4K5/H4K8 hyperacetylation, H4K12/H4K16 hypoacetylation, loss of H4K20me3 
and reduced SUV420H2 expression (Van Den Broeck et al., 2008). Although 
H4K20me3 loss was generally less frequent in the adenocarcinoma samples, a 
subgroup of stage I adenocarcinoma patients with reduced H4K20me3 exhibited a 
significantly lower rate of survival. In a separate study of 880 characterized human 
breast carcinomas, tumors of the poorest prognostic subgroups (e.g., basal 
carcinomas, HER-2-positive tumors) displayed moderate to low H4K20me3 levels 
(Elsheikh et al., 2009). Finally, in a study of bladder cancer, H4K20me3 levels 
decreased across the clinical spectrum, with highest levels noted in normal 
urothelium, and progressively lower levels observed in non-muscle-invasive bladder 
cancer (NMIBC), muscle-invasive bladder cancer (MIBC) and bladder cancer 
metastases (METS) (Schneider et al., 2011). Remarkably, the METS exhibited lower 
levels of H4K20me3 than the primary tumors.  
 Given the evident correlation between H4K20me3 loss and cancer, several 
critical questions arise. First, is loss of the H4K20me3 mark a driver or consequence 
of cancer initiation and progression? Evidence from several of the studies discussed 
above suggests that loss of H4K20me3 is an early event, often beginning in less 
malignant stages and decreasing progressively with increased tumor grade and 
severity. If H4K20me3 loss is indeed a mechanistic driver of cancer, it implies that 
proper maintenance of H4K20me3 levels in the cell might provide a barrier against 
tumorigenesis. In fact, this model is broadly consistent with two important 
characteristics of cell senescence: (1) senescent cells selectively retain high levels of 
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the H4K20me3 mark and (2) senescence is a potent tumor suppressor mechanism. In 
this manner, one novel way that senescence might block cancer initiation is through 
the maintained stability of H4K20me3. If so, what is the mechanism by which 
H4K20me3 reinforces the tumor suppressive properties of senescence?  
Revisiting the senescence-specific H4K20me3 mapping data might provide 
some critical insight toward addressing this mechanistic question. In senescent cells, 
H4K20me3 is seemingly abundant at a variety of DNA repeats including LTRs, 
LINES, SINES and DNA satellites (e.g., satellite 2). Based on recent data from Peter 
Adams’ laboratory, some of these same regions also become DNA hypomethylated 
in replicative senescent IMR90 cells (Cruickshanks et al., submitted). Thus, in 
senescent cells, DNA methylation and H4K20me3 are clearly separable epigenetic 
marks. As noted earlier, Fraga and colleagues established that loss of H4K20me3 is 
commonly associated with hypomethylation of repetitive DNA sequences in human 
cancer (Fraga et al, 2005). In view of this, it is formally possible that loss of 
H4K20me3 from hypomethylated DNA repeats allows cancer initiation and 
progression, whereas the presence of H4K20me3 at hypomethylated DNA repeats in 
senescent cells might maintain the barrier to tumorigenesis. 
If this is the case, it raises an important follow-up question: how might the 
presence of H4K20me3 at hypomethylated DNA repeats suppress cancer initiation? 
One possibility is that H4K20me3 prevents aberrant recombination events at regions 
of hypomethylated repetitive DNA. Loss of DNA methylation at repetitive regions 
(e.g., LINES, satellite 2) is associated with derepression of repeats, increased rates of 
insertional mutagenesis, genomic instability and cancer (Wong et al., 2001; Schulz et 
al., 2002; Howard et al., 2008). H4K20me3 is enriched in senescent cells at many of 
these regions, including LINES and satellite 2 repeats, suggesting that the mark 
might play a role in maintaining proper heterochromatin structure, particularly in the 
context of DNA methylation. Although this argument is largely correlative, a direct 
role for H4K20me3 in suppressing recombination at DNA repeats has been reported. 
Work from Maria Blasco’s group demonstrated that Suv420h2-/- pMEFs exhibit 
marked loss of H4K20me3 at telomeres and subtelomeres, resulting in telomere 
elongation and a higher frequency of telomere recombination (Benetti et al., 2007). 
Importantly, the authors noted that telomere recombination occurred independent of 
any subtelomeric DNA methylation changes, suggesting that H4K20me3 alone might 
be responsible for suppressing recombination at telomeric repeats. 
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Finally, marked enrichment of H4K20me3 was also observed at ZNF gene 
clusters in senescent cells. ZNF genes comprise one of the largest gene families in 
the human genome, including the Krüppel associated box (KRAB) domain-
containing ZNF (KRAB-ZNF) genes, a subgroup of approximately 800 loci that are 
arranged in large familial clusters (Shannon et al., 2003). Although H4K20me3 was 
generally not enriched at many genes in senescent cells, specific and marked 
enrichment was observed at KRAB-ZNF gene clusters. Additional reports have 
confirmed the presence of several other heterochromatic marks at ZNF genes. The 
heterochromatic protein HP1b (CBX1) is highly enriched at the 3’ ends of KRAB-
ZNF genes (Vogel et al., 2006). In a separate study, significant enrichment of 
another repressive epigenetic mark, H3K9me3, was observed at the 3’ exons of ZNF 
genes, but did not correlate with gene expression (Blahnik et al., 2011). In both 
studies, the authors proposed that the presence of heterochromatic histone 
modifications and associated proteins might stabilize chromatin at KRAB-ZNF gene 
clusters and prevent inappropriate recombination. Thus, the striking enrichment of 
H4K20me3 at KRAB-ZNF genes in senescent cells might similarly suppress 
recombination at these loci. 
Based on these published observations and the findings of this study, I 
propose a model of H4K20me3 function in senescence in which H4K20me3 prevents 
tumorigenesis in response to various triggers, by preventing recombination at DNA 
repeats and ZNF genes, thus maintaining genomic integrity (Figure 7.1). In this 
manner, retention of the H4K20me3 mark might compensate for the wide-scale 
chromatin changes that occur in senescent cells including DNA hypomethylation, 
shortened telomeres or damage resulting from DNA hyper-replication. Accordingly, 
cells that initiate the senescence program and retain adequate levels of H4K20me3 
might maintain genomic stability and successfully establish a permanent 
proliferation arrest. In contrast, if H4K20me3 is lost from DNA repeats and ZNF 
genes, these regions might become predisposed to a higher frequency of 
recombination and mutational insertions, consequently driving cancer initiation and 
progression. Indeed, recent data indicate that in cancer, regions of the genome that 
normally exhibit enrichment of H4K20me3 and other repressive marks, contain the 
highest rates of mutation, as evidenced by high single nucleotide variant (SNV) 
densities (Schuster-Böckler & Lehner, 2012). Thus, H4K20me3 represents an 
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important epigenetic feature of the senescence program that likely stabilizes the 
genome, prevents recombination and mutation and suppresses tumorigenesis. 
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